|
|
·|û¡G¥ý¶i10000164 µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
|
ÃÒ¥æ©Ò«¤j°T®§¤½§i (6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Öã¡C 1.¨Æ¹êµo¥Í¤é:103/07/21 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«öpµe¶i¦æ(¥ç§Y¬ü°êFDA®Öã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅçpµe)¡C 6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©xû«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C (2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C
¶}ª©·|û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/21 ¤U¤È 10:00:30²Ä 669 ½g¦^À³
|
ºô¸ô¤W¦³ÃöDAAÃĪ«¦³µL¯Ê¥¢°Q½×¤§2016¦~¤å³¹¡A¨Ñºô¤Í°Ñ¦Ò¡G(¥»Ä³ÃD °¶¤j¤j³Ì±M·~¡A¥i°Ñ¦Ò¨ä¬ÛÃö¤¶²Ð) ¤@¡B¦W¶F¸ÑÄÀ¡G C «¬¨xª¢(Hepatitis C) ª½±µ§@¥Î§Ü¯f¬rÃĪ«(Direct-acting antiviral agent , DAA) C «¬¨xª¢¯f¬r(hepatitis C virus, HCV) §K¥Î¤zÂZ¯ÀÀøªk(Interferon-free treatment) ªø®Ä¤zÂZ¯À(pegylated interferon) ¹p¤Ú«ÂªL (ribavirin) «ùÄò¯f¬r¾Ç¤ÏÀ³ (sustained virological response,SVR)¡G ¥ç§Y¦bªvÀøµ²§ô24 ¶g«á¡A ¦å¤¤¤´°»´ú¤£¨ìC «¬¨xª¢¯f¬r5¡A ¦Ó¥Ø«e¤]«ØijªvÀøµ²§ô12 ¶g«á¡A ¦å¤¤Y¤´´ú¤£¨ì¯f¬r¡A §Y¥i§P©w¹F¨ìSVR¡C ¤G¡B¬ÛÃö¤å³¹ (¤@)Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (04¡B2016) (¤G)Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV( 05¡B2016) (¤T)Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma (06¡B2016) (¥|)Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals(06¡B2016) (New direct-acting antivirals are able to eradicate HCV infection in over 90% of patients with advanced liver disease. Unfortunately, the occurrence of liver cancer is not reduced in effectively treated cirrhotic patients. In addition, patients previously treated for HCC have still a high risk of tumour recurrence in the short term, despite DAA treatment.)¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/9/21 ¤U¤È 09:16:55²Ä 668 ½g¦^À³
|
¤£ºÞ¦n¤£¦n ·sÃĤ£¥Î¥h·QÁȤj³° ¸ò¦L«×¤Hªº¿ú ·í0´N¬O¤F |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/21 ¤U¤È 09:12:54²Ä 667 ½g¦^À³
|
èè§Ñ°O¸É¥R... °£¤F¬£®æ»«ªº°Æ§@¥ÎÀ³¸Ó¸òpagasys ¤@¼Ë(¦ôp³Ì°ª¥u¯à¥´¨ì 180 ug ¦Ó¤w)¡A°Æ§@¥Î¤j©óÃĵتºP1101¤§¥~ ¥¦¤]¬O¥²¶·¤@©P¤@°w .... µLªk¹³P1101¤@¼Ë ¨â©P¤@°w ¬Æ¦Ü¤@¦~«á ¤@Ó¤ë¤@°w |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/21 ¤U¤È 09:04:26²Ä 666 ½g¦^À³
|
ÃĵؤzÂZ¯À(P1101) VS ¯\®æ¦è¬I(Pegasys) (°Ñ·Ó2016/06/08¡B®É³ø°OªÌ³¢ÂE¼z¥x¥_³ø¾É) ¤@¡BºC©ÊC«¬¨xª¢¯f¬r°ò¦]«¬²Ä2«¬ ¾Ú¦b¥x¤jÂå°|¡B¥x¥_ºaÁ`¡BªL¤fªø©°µ¥¦U¤jÂå°|¶i¦æªºÁ{§É¤G´Á¸ÕÅç¼Æ¾Ú¤ÀªRÅã¥Ü¡A°w¹ïºC©ÊC«¬¨xª¢¯f¬r°ò¦]«¬²Ä2«¬ ¯f±w¡A¨C¤G¶gª`®g¤@¦¸P1101(360£gg)¡A«ùÄò©ÊÀø®Ä (SVR24)»P¹ï·Ó²Õ¯\®æ¦è¬I(Pegasys)¨C¶gª`®g¤@¦¸(180£gg)¬Û·í¡A°Æ§@¥Î§ó§C¡C ¤G¡BºC©ÊC«¬¨xª¢¯f¬r°ò¦]«¬²Ä1«¬ °w¹ïºC©ÊC«¬¨xª¢¯f¬r°ò¦]«¬²Ä1«¬¯f±w¡A¨C¶gª`®g¤@¦¸P1101(270£gg)¡A«ùÄò©ÊÀø®Ä(SVR 24)¬Æ¦ÜÀu©ó¹ï·Ó²Õ¯\®æ¦è¬I(180£gg)¡A°Æ§@¥Î¤]§ó¤Ö¡C ¤T¡Bµ²½×¡G (¤@)C«¬¨xª¢¯f¬r°ò¦]«¬²Ä2«¬¡G 1¡BÀø®Ä¡GÃĵؤzÂZ¯À(P1101)»P¯\®æ¦è¬I(Pegasys)¬Û·í¡C 2¡B°Æ§@¥Î¡GÃĵؤzÂZ¯À(P1101)§ó§C¡C (¤G)C«¬¨xª¢¯f¬r°ò¦]«¬²Ä2«¬¡G 1¡BÀø®Ä¡GÃĵؤzÂZ¯À(P1101)Àu©ó¯\®æ¦è¬I(Pegasys)¡C 2¡B°Æ§@¥Î¡GÃĵؤzÂZ¯À(P1101)¤]§ó¤Ö¡C |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/21 ¤U¤È 08:45:50²Ä 665 ½g¦^À³
|
¦U¦ì©ñ¤ß ·Hªù¯SÄ_ªº¬£¯S»«¡A·íªì¬O¬°¤F§Æ±æ¥i¥H¸ò¶i¤fªº pagasys ·m¹Ü¤¤°ê¤j³°BC¨x¥«³õ³o¤@¶ô ¥¦ªºPEG±µªk¤£¦P¡A©Ò¥H¥iºâ¬O¦Û¥D²£Åv¡A¦ý¯Â«×¨ä¹ê¸òpegasys®t¤£¦h¦Ó¤w(¾Ú¤F¸Ñ¬O 8 Ó®p¡A¤£¹³p1101 ¥u¦³¤@Ó¡A¦³°µ ¥\½Òªºª¾¹D§Ú¦bÁ¿¬Æ»ò)¡A¨Ã¨S¦³Àu©ópagasys¡A¤£¨¬¬°Äß |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/9/21 ¤U¤È 07:57:46²Ä 664 ½g¦^À³
|
¤WÂd¦Ü¤µÀ³¸Ó¬O²Ä¤@¦¸¬Ý¨ì100±i¥H¤Wªº¦¨¥æ³æ¶q¡A«Ü¿³¾Ä ´Á«Ý¨S¬Ý¹Lªº«G¬õ¿O Ó¤H¬O¬Ý¦n12¤ëªºASH meeting ªº·Ï¤õ! ¥[ªo¡ã |
|
|
·|û¡G¥ý¶i10000164 µoªí®É¶¡:2016/9/21 ¤U¤È 05:13:57²Ä 663 ½g¦^À³
|
PharmaEssentia¡]6446.TWO¡^ ¦b±Ò°Ê¶R¤J/°ª·ÀI¡G·s«¬¤zÂZ¯À»s¾¯ ƒÞTP NT $ 230 - §Ú̺¦¸¦b¶R¡]1H¡^PharmaEssentia¡]PEC¡^»P·s¥x¹ô$ 230ªº¥Ø¼Ð»ù¡C PECªººXÄ¥ÃĪ«¡ABESREMi¡]P1101¡^¡A»E¤A¤G¾J¤Æ¬O¤@ºØ·sªº°t¤è ¤zÂZ¯À¬O¤ñÄvª§§ó¯Âºéªº°t¤è¡A²£¥Í¤Ö±o¦hsideeffects ¨Ã´î¤Ö¥Î¶qÀW²v¡C§Ú̪º¼ÖÆ[¬Ýªkªº«e´£¬O P1101¦b¼Ú·ù©M¬ü°ê¥«³õªº¦¨¥\±À¥X¬°²Ä¤@FDA§å㪺²Ä¤@Ó¦æ ªvÀø¯u©Ê¬õ²ÓM¼W¦h¯g¡]PV¡^¡C§ÚÌÁÙ¹wp§ó¼sªxªº±Ä¥ÎP1101ªº ¨ä¥LMPN¯e¯f©M¨xª¢¡A¥H¶i¤@¨B´£¤É¨äªø´Á¼Wªø¼ç¤O¡C ƒÞPV¡G¥¼º¡¨¬ªºÂåÀø»Ý¨D - P1101³Ìªì±N¥Ø¼Ð1stline¥ú¥ñ«ü¥Ü ªvÀø¡A¨ä¦ôp¨ã¦³100,000±wªÌ±w¯f¤W ¥§¡¤ô¥¡C¦b¬ü°ê©M¼Ú¬w¨âÓ¥«³õ©M¼ç¦b¥«³õ¶W¹L US $ 100»õ¡C P1101¡A»P©t¨àÃÄ¡A¦¨«~Ph3ªº¼f§P¤¤¦¯©M16 MAA´£¥æ²{¦b«Ü¥i¯à¦b2017¦~¦~ªì¡A¨ä¦¸¬OBLA´£¥æµ¹¬ü°êFDA 25¦~«á¡C¹ï©óMPN¾AÀ³¯g¯Ê¥FÀø®ÄªºªvÀøÀ³ ´£°ª·í§½ªº¶É¦V§åã¡A¦b§Ú̪ºÆ[ÂI¡C©M....¬Û¤ñ Incyte¤½¥qªºJakafi¡A°ß¤@FDA¥u¹ï²Ä¤G½uªvÀøÃĪ«§åã¥ú¥ñµM¦Ó¡A ¹ï©óPEC¯f¤H¦À±N³Q¤T¿¤j¡C Incyte¤½¥q²£¥Íªº¦¬¤J ¬ü°ê¬ü°ê$ 154»õªº¥«È$ 940mn¦b2H15-1H16¡C ƒÞ¨xª¢¡G¨È¬w¥«³õ¤zÂZ¯À§Q°ò - PEC¤]¦b¶i¦æPh3ªº ¼f§PHCVºË·Ç¨È¬w¥«³õ¡C¾¨ºÞDAAªº¥i¥Î©Ê¡A¾ÉP¤F ¨âÓ²{¦³ªº¤zÂZ¯ÀªvÀø¡]¬£Ã¹ªY©M¨Ø¼Ö¯à¡^¡A¤]¦³®ø¤` ¹ï©ó¤þ¨xªvÀøªº¾÷·|¤´µM¤zÂZ¯À¥Ñ©ó¬Û·í§C ªvÀø¦¨¥»©M¯f¤HªºÀu¶V®Ä¤O¡]> 80¢Hªº¤ÏÀ³²v¡^ °ò¦]«¬2©M»PIL28B CC°ò¦]«¬¡A¨ä¤¤²±¦æ¦b¨È¬w°ê®a¡C ƒÞ·ÀI - 1¡^¥¼Àò±o§åã¦b¼Ú¬w©M¬ü°ê¥ú¥ñ«ü¥Ü·| «Â¯ÙPEC³Ì¤jªº¼ç¦b¦¬¤J¨Ó·½; 2¡^ªº§ó¥þ±ªº«OÀI«O»Ù ¦bÁú°ê©M¥xÆW¥«³õ¦N§Q¼w¤fªAªvÀøÃĪ«±N´î¤Öªº§l¤Þ¤O BESREMi§@¬°´À¥N¡A§ó«K©yªºªvÀø¡C |
|
|
·|û¡Gªü³Ç10139080 µoªí®É¶¡:2016/9/21 ¤U¤È 04:46:31²Ä 662 ½g¦^À³
|
Àò§Q¤S¶}©lÂॿ¤F😃😃😃 Ä~Äò«O«ù¡K¡K¡K¡K®¥¶PµØ¤Í |
|
|
·|û¡Glinrongyua10142888 µoªí®É¶¡:2016/9/21 ¤U¤È 04:10:11²Ä 661 ½g¦^À³
|
«e´X¤Ñ¬Ý¨ì¤@«h·s»D, ½Ðª¾±¡ªº¤j¤jcomment¤@¤U ¤£ª¾¹ï©óP1101¥¼¨Ó¦b¤j³°¥«³õªºµo®i·|¤£·|¦³¼vÅT? ¤¤国º个拥¦³¦Û¥Dª¾识产权国产长®Ä¤zÊð¯À¡§¬£®æ宾¡¨¤W¥« 2016¦~09¤ë19¤é 21:51¡@来·½¡G¤¤国·s闻ÊI ¡@¡@¤¤·sÊIºÖ¦{9¤ë19¤é电 (龙±Ó)ºÖ«Ø¬Ù¹«~药«~监·þºÞ²z§½19¤é³q报¡A¥ÑºÖ«Ø¬Ù药«~¥ø业¬ã发ªº¥Íª«¨î«~1类·s药¡§¬£®æ宾¡¨(»E¤A¤G¾J¤zÊð¯À£\2bª`®g²G)¥¿¦¡获±o国®a¹«~药«~监·þºÞ²z总§½§åã¡A¨ú±o药«~ª`册§å¥ó©M·s药证书¡C ¡@¡@¯f¬r©Ê¨xª¢¬O¤¤国当«e³Ì为¬ð¥Xªº¤½¦@卫¥Í问题¤§¤@¡CÕuºÖ«Ø¬Ù¹«~药«~监·þºÞ²z§½¦³关负责¤Hªí¥Ü¡A¡§¬£®æ宾¡¨ªº临§ÉÓì应¯g为临§É»Ý¨D¥¨¤jªº¯f¬r©Ê¨xª¢¡A¨t¤¤国º个¤W¥«ªº长®Ä¤zÊð¯À¡A¥´¯}¤F国¥~¦P类¨î«~ªº垄断¡A¶ñ补¤F国内ªÅ¥Õ¡C¡§¬£®æ宾¡¨ªº¦¨¥\¤W¥«¡A¥i为ÆΤj¨x¯f±wªÌ´£¨Ñ°ª©Êɲ¤ñªº药ª«¡A³yºÖÆΤj¨x¯f±wªÌ¡C ¡@¡@该负责¤H还«ü¥X¡A¡§¬£®æ宾¡¨ªº¦¨¥\¤W¥«¡A预计将产¥Í¥¨¤jªº经济©MªÀ会®Ä¯q¡A¬OºÖ«Ø¬Ù·s药¦Û¥D创·sªº¨å«¬¦¨¥\S¨Ò¡A将对ºÖ«Ø¥Íª«医药发®i°_¨ì积Ì媺«P进§@¥Î¡C ¡@¡@资®Æ显¥Ü¡A¡§¬£®æ宾¡¨¨tû÷门¯Sûҥͪ«¦³¤½¥q¬ã发ªº1类¥Íª«¨î«~·s药¡A¨ã¦³§¹¥þ¦Û¥Dª¾识产权¡A¨ä专属ªº40kDY«¬»E¤A¤G¾J×饰§Þ术拥¦³¥þ²y专§Q¡A¤]¬O国®a¹«~药«~监·þºÞ²z总§½2016¦~§å㪺²Ä¤@个国产¥Íª«¨î«~创·s药¡C ¡@¡@û÷门¯Sûҥͪ«¦³¤½¥q°Æ总经²z陈¤è©M¤¶绍¡A¡§¬£®æ宾¡¨¤_2002¦~¥ß项¡A2007¦~´£¥æ临§É¥Ó请¡A2009¦~¨ú±o临§É§å¥ó¡A2013¦~´£¥æ¤W¥«¥Ó请¡A¦Ü2016¦~获§å¡A¬ã发历µ{长达14¦~¡C ¡@¡@陈¤è©M说¡A¡§¬£®æ宾¡¨¤W¥«¦Z将¥´¯}国¥~产«~ªº垄断¡A为国内¯f¬r©Ê¨xª¢±wªÌ´£¨Ñ§ó¨ã©Êɲ¤ñªºªv疗产«~¡C ¡@¡@Õu©ÜÅS¡A2016¦~9¤ë13¤é¡A¡§¬£®æ宾¡¨GMP认证¥¿¦¡¤WÊI¤½¥Ü¡A预计2016¦~10¤ë¥i获±oGMP证书¦}¥¿¦¡§ë产¡A¤_2016¦~¦~内实现药«~销°â¡C(§¹) |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/21 ¤U¤È 03:55:31²Ä 660 ½g¦^À³
|
¥~¸ê¤j¶R310±i¡C§ë«H¶R175±i¡C ÃĵØÃÄ¡A¥[ªo¡C |
|
|
·|û¡Gaa18188810142040 µoªí®É¶¡:2016/9/21 ¤U¤È 02:40:35²Ä 659 ½g¦^À³
|
¤Q¤ë¥÷§Y±N¨Ñ§G ¼Æ¾Ú ®¥³ß16¦h ¥´©³¨S³Q¬~¥XªºµØ¤Í ¼Æ¾Ú¦]¸Ó¬O«D±`§¹¬ü ©Ò¥H¶}©l¦³¶R½L±þ¶i §O¦]µu½uÀò§Q¦Ó³Q¬~¥X ªø´ÁªºÀò§Q ¤~¬O²¢¬üªº ¹³§Ú¸êª÷¤£°÷ªº Á~¤ô±Ú ³£¬O¤@ÂIÂIªº¶R¹sªÑ ·í°µ¦s¿ú ´N¬O¬Û«HÃĵجO¶¡¦n¤½¥q |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/21 ¤U¤È 12:27:06²Ä 658 ½g¦^À³
|
µ¥«Ý«G¿O¡I |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/21 ¤U¤È 12:18:24²Ä 657 ½g¦^À³
|
·PÁÂAlan¤jªº¥Î¤ß! |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/21 ¤U¤È 12:11:06²Ä 656 ½g¦^À³
|
·PÁÂAlan¤j´£¨Ñªº°T®§¡Aºô¯¸¸ê®Æ¦³ÃöÃĵØÃĬÛÃö¸ê®Æ¡A¯u¬O¤ÓÂ×´I¤F¡C ¥\¼wµL¶q¡A·P®¦¡C |
|
|
·|û¡GAlan Liu10136094 µoªí®É¶¡:2016/9/21 ¤W¤È 11:57:52²Ä 655 ½g¦^À³
|
¥Ñ©ó¥²´IºôµLªk¤W¶Çªí®æ¤Î¹ÏÀɪº¨î, °w¹ï Dr.Srdan Verstovsek µoªí Development of long acting interferon as new therapy for PV(and ET) ¨ä§¹¾ã¤º®e¾ã²z, ½Ð¦U¦ì§ë¸ê«e½ú«e©¹¤Uz³sµ²ÂǦ¹§@¬°ÃĵØÃħë¸ê»ùȧPÂ_ªº°Ñ¦Ò¡C Mobile01- (6446) ÃĵØÂåÃĪº§ë¸ê»ùȤÎÄ@´º www.mobile01.com/topicdetail.php?f=291&t=4919602&p=2 |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/21 ¤W¤È 10:47:47²Ä 654 ½g¦^À³
|
¨CÓ»ù¦ì³£°±¹y¤@¤U¦A±a¶q¦Y±¼ ³oÓ¾Þ½L¤â«Ü¼F®` |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/21 ¤W¤È 09:58:02²Ä 653 ½g¦^À³
|
§ë«H¤Ñ¤Ñ¶R,¥[¤W¦Ñ®v¤£Â_³Û¶i ¤UÓ¤ën¤½§G¼Æ¾Ú ±N¨Ó¯Ç¤J¤j¼¯¦¨¥÷ªÑ¥~¸ê¶Õ¥²¥[½X... |
|
|
·|û¡G¥v±Z¯S10142964 µoªí®É¶¡:2016/9/20 ¤U¤È 10:54:15²Ä 652 ½g¦^À³
|
1.¥Ø«e·sÃĪѧë¸ê®ðª^±q¥»¹Ú¤ñÂಾ¨ì¥¼¨ÓÀò§Q¼Æ¦r¸û¬°©ú½TªºÓªÑ:¦p´¼Àº,ÃÄµØ 2.±q§Þ³N«ü¼Ð¬Ý,³o¨âÀɶgKD³£¤w¸g©¹¤W¤Ä¤F,ªi¬q¦æ±¡¥i´Á |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/20 ¤U¤È 05:04:21²Ä 651 ½g¦^À³
|
¤ÀªR®v±ÀÂËÃĵØÃÄ(6446) ¤ÀªR®v¬x¤@§¡¡G6446 ÃĵØÃÄ §ë«H¶R¶W¤O¹DÂX¤j¡AªÑ»ù¬Û¹ï§Ü¶^¡C(2016-09-18 00:01:57 ¸gÀÙ¤é³ø ¤å¡þ±i瀞¤å) ¤ÀªR®v¤ýºa¦°¡G6446 ÃĵØÃÄ ¾AÀ³¯g·sÃÄ ¶i¤J3´ÁÁ{§É.( 168²z°]ºô2016/9/20 ¤U¤È 12:49:00) (¥H¤W°Ñ¦Ò´N¦n¡A¤Å§@§ë¸ê¤§¨Ì¾Ú¡C) |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/19 ¤U¤È 05:12:18²Ä 650 ½g¦^À³
|
·PÁ¤pªL¤j´£¨Ñªºyoutube¸ê°T¡C(¤µ¦~8/26~27èÁ|¿ìªºUS MPN & MDS Congress¡A¨ä¤¤¤@³õ¥Ñ¬ü°ê¤zÂZ¯À¤§¤÷Dr. Richard T. SilverºtÁ¿ªº¥DÃDUpdate on long-acting interferons for MPN¡A¥i¥H°Ñ¦Ò¦¹Youtube¼v¤ù¡A¤º®e¦³´£¨ìAOP2014/P1101¡C) ^¤åÅ¥¤£À´¡A¥u¬Ý¨ìpowerpoint ¤º®e´£¨ì¡G So, Can we cure MPNS with pegylated interferons¡H µª®×¬°¡GYes ¥t¥~¡Ayoutube¸ê°T(µo§G¤é´Á¡G2015¦~9¤ë28¤é) Development of long acting interferon as new therapy for PV(and ET) ¥ÑSrdan Verstovsek and Heinz Gisslinger ¦@¦P±¾¦W¡ASrdan Verstovsek ¥DÁ¿¡C ¥ç¦³´£¤ÎAOP2014(P1101) ¤º®eºKn¡G Summary ¤@¡BIFN administered once every two weeks has low toxicity and induces high and sustained hematologic response ¤G¡BMajority of the patients experienced decrease of JAK2 allelic burden ¤T¡BDose of AOP2014 can be individually titrated from 50 to 540 ug every two weeks to achieve optimal response with acceptable toxicity |
|
|
·|û¡G¦n¹B10137114 µoªí®É¶¡:2016/9/19 ¤U¤È 01:16:04²Ä 649 ½g¦^À³
|
Hi ¤pªL¤j °¶¤j¤j¤j ÁÂÁ§AÌ´£¨Ñªº«n¸ê°T. |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/19 ¤U¤È 12:39:43²Ä 648 ½g¦^À³
|
±Ä¥Î¹ï¤ñ¦¡¡A¥²¶·¤ñ¥«±®Ö㪺ÃÄhydroxyureaÀu¨q¡A´N¥i¥Ó½ÐÃÄÃÒ¡A¦Ü©ó£¸½u©Î¤G½u¥ÎÃÄ¡A¼Ð¥Ü¤º®e¬°¦ó¡A´N¬Ý§AÀu¨q¨ìþ¸Ì¡C ¦p¤U¤å¤º®e:¹ï¤j³¡¤À¯f¤H¦³®Ä¡B¦w¥þ¡A¦Ó¥B¤ñhydroxyureaÀu¨q (safe and effective in the majority of patients and to be superior to hydroxyurea) http://www.aoporphan.com/nc/news-medien/startseite-detailseite/artikel/aop-orphan-pharmaceuticals-announces-progress-of-pivotal-phase-iii-trial-proud-pv-applying-ropeginterferon-alfa-2b-a-novel-long-acting-mono-pegylated-interferon-for-treatment-of-polycythemia-vera.html |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/19 ¤W¤È 11:58:51²Ä 647 ½g¦^À³
|
¦n¹B¤j¡A ¤G´Á¸ÕÅç½s¸¹: NCT01193699 clinicaltrials.gov/ct2/show/NCT01193699?term=P1101&rank=4 ¤G´Á¸ÕÅçµ²ªGµoªí©óBlood´Á¥Z: www.bloodjournal.org/content/early/2015/08/10/blood-2015-04-637280 www.bloodjournal.org/content/126/23/4056 ¤¤¤åªº¤G´Áµ²ªG«ÂI¥i¥H°Ñ¦Òªk»¡·|¸ê®Æp.22~p.26 mops.twse.com.tw/nas/STR/644620160620M001.pdf |
|
|
·|û¡G¦n¹B10137114 µoªí®É¶¡:2016/9/19 ¤W¤È 11:28:01²Ä 646 ½g¦^À³
|
¦U¦ì¤j¤j¦n, ¤p§Ìºa©¯¦³¾÷·|¶XªÑ»ù¥ý«e¦^ÀÉ,¥[¤JµØ¤Íªº¦æ¦C. ³s°²®É»{¯uª¦¤å¤F¸Ñ¨ìÃĵتº¼ç¤O»PÀu¶Õ, ¹ï©óÁ{§É¤T´Á¦³¤@¨Ç°ÝÃD,·Q³Â·Ð¤F¸Ñªº¤j¤j̨ó§U¸Ñ´b. ÁÂÁ PV¤T´Áªº¥Dn«ü¼Ð,¬O12Ó¤ë«á a. ¦å·»¤ñ<45% b. ¦å¤pªO<400 G/L c. ¥Õ¦å²ÓM<10 G/L d. µÊŦ¤j¤p¥¿±` ¦ý¬Oª¦¤å¨Ã¨S¦³§ä¨ì¬ÛÃöªº¥ý«e¤G´Á¼Æ¾Ú(¥i¯à¤å³¹¤Ó¦h²¨©¿¤F), ¤j³¡¤À»¡ªº³£¬O°Æ§@¥Î¤p,¥ÎÃÄÀW²v¥i¥H¨â©P¦Ü¤@Ó¤ë...µ¥, ¦]¬°¯EX¨Æ¥ó,²`©ÈÁ{§É¼Æ¾Ú¤½¥¬®É¬Y¶µ¼Æ¾Ú¥¼¹F¼Ð¼vÅT¨ì§P©wµ²ªG, YµØ¤Í̦³¬ÛÃö¼Æ¾Ú¸ê®Æªº³sµ²¥i¥H¤À¨É,·P¿E¤£ºÉ. EX: 4147¤]±N¤½¥¬Á{§É¤T´Á¼Æ¾Ú,¦ý¥Dnµ²ªG¦³¤§«e¤G´Á¼Æ¾Ú¦õÃÒ,§ë¸ê·ÀI©Ê¬Û¹ï¸û§C. ¯¬¦U¦ìÁȤj¿ú!! |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/19 ¤W¤È 10:44:09²Ä 645 ½g¦^À³
|
¤µ¦~8/26~27èÁ|¿ìªºUS MPN & MDS Congress¡A¨ä¤¤¤@³õ¥Ñ¬ü°ê¤zÂZ¯À¤§¤÷Dr. Richard T. SilverºtÁ¿ªº¥DÃDUpdate on long-acting interferons for MPN¡A¥i¥H°Ñ¦Ò¦¹Youtube¼v¤ù¡A¤º®e¦³´£¨ìAOP2014/P1101¡C www.youtube.com/watch?v=lp58hdmZTIE *Scientific Agenda imedex.com/us-myeloproliferative-neoplasms-myelodysplastic-syndromes/agenda.asp |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/16 ¤U¤È 08:03:08²Ä 644 ½g¦^À³
|
¸É¥RÃĵØÃĤ½¶}»¡©ú®Ñ¤§¤º®e¡G (¤@)PV¥Ó½ÐÃÄÃÒ¬ü°ê±ß¼Ú·ù1©u¡G(PV¦~©³¦V¼Ú·ù¥Ó½ÐÃÄÃÒ¡A2017¦~²Ä1©u¦V¬ü°ê¥Ó½ÐÃÄÃÒ) ¦]¬°Ãĵؤw³W¹º¥Î¼Ú·ùªº²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ窺¼Æ¾Ú¦A¥[³¡¥÷¼Æ¾Ú³ø§i³w¦V¬ü°êFDA ¥Ó½ÐÃÄÃÒ¡A±©¼Ú¬ü¤å¥ó®æ¦¡²¤¦³®t²§¡A»Ý¦³¤å®Ñ§@·~Âà´«¤Î¥i¯à¸É¥ó©Î°Q½×®É¶¡µ¥¦]¯À¼vÅT¡A¹wp¦V¬ü°êFDA ´£¥X¥Ó½ÐÃÄÃҮɶ¡·|²¤±ß©ó¼Ú¬w¤@©u¡C (¤G) ºC©Ê°©Åè©Ê¥Õ¦å¯f(CML)±ÂÅvAOP AOP ¤½¥q¦¨¥ß©ó85 ¦~¡A¤½¥qÁ`³¡¦ì©ó¶ø¦a§Qºû¤]¯Ç¡A¬°¼Ú¬wª¾¦Wªº©t¨àÃÄ ¶}µo¤½¥q¡A¥Ø«e¥þ²y¦³12 Ó¾ÚÂI¤À¥¬©ó10 Ó°ê®a¡Aû¤u¤H¼Æ¬ù150 ¤H¡A¦~Àç·~ÃB¬ù7,500 ¸U¼Ú¤¸¡A¥H´£¨Ñ¿©±w¨u¨£¯e¯f¯f¤HÓÅé¤ÆªvÀø¬°©v¦®¡AAOP ¤½¥q±Mª`©ó¦å²G¾Ç¡B¸~½F¾Ç¡B¤ßŦ¯f¾Ç¡BªÍ¯f¾Ç¡B¯«¸g¯f¾Ç¡Bºë¯«¯f¾Ç¤Î¥NÁ©ʯe¯f»â°ì¡C¥Ñ©óAOP ¤½¥q»{¬°¤zÂZ¯À¥iÂåªv¦å²G¨u¨£¯e¯f¡A¦ý¦]¥Ø«e¥«±¤Wªº¤zÂZ¯À¤´¦³°ª°Æ§@¥Î¤Î®Ä´Á¹Lµuµ¥°ÝÃD©|«Ý§JªA¡A¬G¦bÃĵØÂåÃÄ98 ¦~°Ñ¥[¼Ú¬wÂå¾Ç¦~·|®É²£¥Í¦X§@¤§«´¾÷¡C¸Ó¤½¥q©ó98 ¦~¿W®a±ÂÅvAOP ¤½¥q©ó¼Ú¬w¦a°Ï¡B¤¤ªF¤Î«eĬÁp¿W¥ß°ê(CIS)¶i¦æ¥HP1101 ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g(PV)¡B¦å¤pªO¼W¦h¯g(ET)¤Î°©ÅèÅÖºû¯g(PMF)µ¥¯e¯f¤§Á{§É¸ÕÅç¤Î¥«³õ¶}µo¡A¨Ì±ÂÅv¦X¬ù(«´¬ù¦³®Ä´Á¶¡¬°30¦~)¡AAOP ¤½¥q¿W®a¾Ö¦³©ó«ez¦a°Ïªº¥«³õ¶}µo¤Î¦A±ÂÅv¤§Åv§Q¡A¦Ó¸Ó¤½¥q«h«O¯d¥Í²£»s³yÅv¤Î¥¼¨Ó¾P°âÅv§Qª÷¡CÂù¤è¨Ã©ó103 ¦~¼Wq¦X¬ù¤º®e¼W¥[P1101 ªvÀøºC©Ê°©Åè©Ê¥Õ¦å¯f(CML)¤§±ÂÅv¡C (¤T)¥Ó½Ð EAP(Expanded/Early Access Program)¡A¨ÏP1101 ¾P°â®É¶¡´£«e ¥»¤½¥q¤w©e°Uª¾¦W±M·~ÅU°Ý³W¹º¦VFDA ¥Ó½ÐEAP¡A¹w¦ô105 ¦~²Ä¥|©uFDA ®Öã«á¡AP1101 ¥i¦b¬ü°êFDA ®ÖãÃÄÃÒ¤§«e¡A¾P°âµ¹¨ä¥L³QÂå¥Í¶EÂ_¥i¨Ï¥ÎP1101ªvÀøªº¯f¤H¡A¼W¥[²£«~¾P°â¦¬¤J(°â»ù«D¥H²£«~¤W¥«»ù®æ¾P°â)¡A¹w¦ô¬ü°ê¦a°Ï¦]EAP ¦Ó¼W¥[ªº¯f¤H¬ù¹F450~750 ¤H¡A¥B·íP1101 ¨ú±oÃÄÃÒ«á¡A¨äEAP ÃÄ»ù±N¥i¥H²£«~¥¿¦¡¤W¥«ªº»ù®æ¾P°â¡A´£«eP1101 ªº¾P°â®É¶¡¡C (¥|)³]¥ß¬ü°ê¤l¤½¥q¡A«Ø¥ß¦Û¥D¦æ¾P¹Î¶¤ °£ÂǧUµ¦²¤¦X§@¦@¦P¦æ¾P¼Ò¦¡¥~¡A¥»¤½¥q¥Ø«e¤w¬£¾n±M¤H(¸ê²`³Bªø¯Å)Äw¹º¬ü °ê¦æ¾P±À¼s¤è®×¡A±N³v¨B«Ø¥ß²£«~¦æ¾P¾ÚÂI¡A¹wp©ó106 ¦~¦b¬ü°ê³]¥ß¤l¤½¥q¡A¬°P1101 ²£«~¤§ªø´Áµo®i°µ·Ç³Æ¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/15 ¤U¤È 04:19:33²Ä 643 ½g¦^À³
|
P1101 ¤ýªÌ¦a¦ì¤£¥i°Ê·n ¡¥§ÚÅ¥»¡°ê¤º¦³¥Í§Þ¤½¥q¶}µo¥X·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À¡AÀuÂI¬O°Æ§@¥Î·¥§C¡A¥B¤w¸g°µ¨ìÁ{§É¤T´Á¸ÕÅç¡A¦pªG¯uªº¬O³o¼Ë¡A§Ú°J¤ß´Á¬ß³o¼Ëªº²£«~¯à°÷¾¨§Ö¤W¥«¡A¦]¬°¤zÂZ¯À¦pªG°£«o°Æ§@¥Î¥B©ÔªøªvÀø®ÄªG¡A½T¹ê¬OªvÀø¬Æ¦Ü¹w¨¾¨xª¢«Ü¦nªºÃĪ«¡C¡¦ B¨x¤@©wn¥Î¤zÂZ¯À¡A³o¬O½T©wªº¡C °ê½Ã°|Ĭ«e©Òªø¤w¸gÂI¥XP1101¤~¬O¥¼¨Ó¤§§Æ±æ¡C C¨x©O? ¬O§_§¹¥þ¥Ñ¤fªAªºDAA¨ú¥N?¨C¤ÑªA¥ÎªºÃĪ«¥i¥H¨ú¥N¨â¬P´Á¥´¤@°wªº¤zÂZ¯À¡C ¥Ñ©ó¥i¥H¦³®Ä¹F¨ìSVRªº¤p¤À¤lÃĪ«¤@ª½¥X²{¡A¦Êªá»ô©ñ¡A¦n¹³³o¤@¨Ç¤p¤À¤lÃÄ´N¬O¸U¥@±Ï¬P¡C ¥Ñ©óè¤W¥«´X¦~¡A¤j®a³QSVR¹F¦¨²v¡A«GÄRªº¼Æ¦r©Ò°g´b¡A¦ý¸g¹L³o´X¦~¹êÃÒ¡A¤×¨ä¦¤@¨Ç®Ö㪺°ê®a¡A´N¥X²{¤£¦PªºÁnµ¡C¦p¤é¥»¡B¼Ú¬w¡B¬ü°ê¡C¥unºô¸ô·s»D¥´¡¨DAA SVR ¡§t±½èºÃªºÁn®ö¤w¸g¶W¶V¥¿±ªºÁnµ¡C ¥¼¨Ó¥ô¦ó³o¤@¨Ç¦P½è©Ê°ªªº¤fªA¤p¤À¤l¡¨±þ¼Ä¡¨ÃĪ«¡A¤@©wn°t¦X¨â©P¤@°w§K¬ÌÀøªk¤zÂZ¯À¡A¤~·|²£¥Í¤¬¸É¡A¤~¬O³Ì¨ÎªºªvÀø²Õ¦X¡CSovaldiµo©ú¤H¨Ó³X¤w»¡©ú¤@¤Á¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/15 ¤W¤È 09:12:04²Ä 642 ½g¦^À³
|
ªø®Ä¤zÂZ¯À ªvÀø¨xª¢§Q¾¹ ¡½Ä¬¯q¤¯ ¨x¯f¤@ª½¬OµØ¤Hªº°ê¯f¡A¦Ó¤j¦h¼Æªº¨x¯f³£¦]¡u¨xª¢¡v¦Ó°_¡A¨ä¤¤¡AB«¬¨xª¢§ó¬OµØ¤H¿©±wªº¨xª¢¡u³q¯f¡v¡AB¨x¤£¶ÈÃøªv¡AÁÙ®e©ö¤Þµo¨xµw¤Æ¡B¨xÀù¡An¦p¦ó¹w¨¾»PªvÀø¡A½T¹ê¬O¤j«v°Ý¡C 2000¦~«e«á¡A§Úµoªí¤F¤@½g½×¤å¡A±´°Q¦³¨ÇB«¬¨xª¢±wªÌ¨ü¨ìÃĪ«ªvÀø«á¡AÁöµM¦å²G¤¤ªº¯f¬r¶q¤w¸g¤U°¡A¦ý¬O¨Æ«á°lÂÜ«o¤´¿©±w¨xÀù¡C§Úªºµ²½×¬O¡AB¨x±wªÌ¨x²ÓM¤Wªº°ò¦]§Ç¦CPre-S2¬ðÅÜ®è¡A·|»s³y¯f¬r§Üì³J¥Õ¡A¦Ó³oÓ³J¥Õ´N¬O¾ÉPºtÅܦ¨¨xÀùªº¥û¤â¡C³o¤]¬O¬°¦óB«¬¨xª¢Ãø¥Hªv¡ªºì¦]¡C §Úªº¬ã¨sµoªí«á¦h¦~¡A¨Ã¥¼¨ü¨ì°ê»Ú¾Ç¬É«µø¡A¦ýªñ´Á¡A³oÓ¬ã¨s¤w¸g³QÃÒ¹ê¡A¥B¦¨¬°¾Ç¬Éªº¦@ÃÑ¡C¨ä¤¤¡A¤£¤Ö°ê¤ºÂå¬É±M®a¥]¬A¥x¤jÂå¾Ç°|°ª¹Å§»±Ð±Â»P°ª¶¯ªø©°³¯«Ø§»Âå®v¡A¤]³£°ò©ó³o¼Ëªº²z½×¡A¨Ã¥B¶i¤@¨Bµoªí·¥¬°ºëÅPªº½×¤å¡C ¶i¤@¨B»¡¡AB«¬¨xª¢¤§©Ò¥H·|¾ÉP¨xÀù¡A´N¦b¯f¬rªí±§Ü쪺¤@¬q°ò¦]§Ç¦CPre-S2¡A³o¬q§Ç¦CºÙ¬°¡uªí±§Üì¬ðÅÜ®è¡v¡CPre-S¬O¤@ºØ¦MÀI¦]¤l¡A¤@¥¹¥X²{¬ðÅܯʷl¡A·|²Ö¿n¦bt³d²ÓM¤ºª«½è¹B¿éªº¤º½èºô¡A¤Þ°_²ÓMÀ£¤O¡A¾ÉP¡u¤ò¬Á¼þ¨x²ÓM¡v¡C ³oÓ¡u¤ò¬Á¼þ¨x²ÓM¡v·|Åý¨xªºªí²{¥X²{¡u¤@Ì@¤@Ì@¡v¤£³W«hªº²Õ´¡A³o¨Ç²Õ´´N¬O¨xÀù§Î¦¨ªº«e¥ü¡F´«¨¥¤§¡A¦pªG¤£³B²zPre-S2°ò¦]¬ðÅܮ誺°ÝÃD¡A¥ú¥u¾a§Ü¯f¬rÃĪ«±þB¨x¯f¬r¡A¨ä¹êÁÙ¬O±Ë¥»³v¥½¡A³Ì«áÁÙ¬O·|¾ÉP¨xÀù¡C ¥xÆW¦³300¸U¦WB«¬¨xª¢±aìªÌ¡B¨C¦~¬ù¦³1¸U¤H¦º©ó¨xµw¤Æ¤Î¨xÀù¡A±aìªÌ¦pªG·P¬VB¨x¯f¬rªí±§Üìµo¥ÍPre-S°ò¦]¯Ê·l¡A¿©±w¨xÀùªº¾÷²v¸û¤@¯ë¤H°ª250¿¡C §Ú¦b°ê®a½Ã¥Í¬ã¨s°|®É¡A»P¦¨¥\¤j¾Ç¬ã¨s¶À·Å¶®±Ð±Â¹Î¶¤¦X§@¡A¶}µoPre-S°ò¦]¶EÂ_¸Õ¾¯¡A³Ìªñ¤w¸g§ÞÂ൹°ê¤º¥Í§Þ¤½¥q¡A¥Î©ó´ú¸ÕB«¬¨xª¢¯f¬r°ò¦]§Ç¦C¡C ¦ý¬Oª¾¹D¦p¦óÀË´ú¡A¤]nª¾¹D¦p¦óªvÀø¡C¹L¥h§Ü¯f¬rÃĪ«¡B¤zÂZ¯À¡]interferons¡AIFN¡^¤@ª½¬O¥D¬y¡FÁöµM¤zÂZ¯À¯à°÷¹F¨ìªvÀøªº®ÄªG¡A¦ý¬O¤zÂZ¯ÀÄY«ªº°Æ§@¥Î¡A¤j¦hÅý¨x¯f±wªÌ»D¤§¦âÅÜ¡A¤j¤j°§C±µ¨üªvÀøªº·NÄ@¡A¦AªÌ¡A§Ü¯f¬rÃĪ«»ù®æ©ù¶Q¡A¤j¦h¬O°·«O¤£Ä@µ¹¥Iªº·sÃÄ¡A³o¤]ÅýB¨x¯f±w±Á{§x¹Ò¡C ¬ü°êÂå¬Éªñ´Á¤w¸g§Î¦¨¤@Ó¦@ÃÑ¡A¨xª¢±wªÌªºªvÀø¡A¦h¥H¤zÂZ¯À¥[¤W§Ü¯f¬rÃĪ«ÂùºÞ»ô¤U¡A¥Ñ©ó®ÄªG¤£¿ù¡A©Ò¥H¤w¸g¦¨¬°¨xª¢±wªÌªº¥D¬yÀøªk¡C¦ü¥G¬O¥xÆWÂå¾Ç¬É¥i¥HÉÃ誺¦a¤è¡C §ÚÅ¥»¡°ê¤º¦³¥Í§Þ¤½¥q¶}µo¥X·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À¡AÀuÂI¬O°Æ§@¥Î·¥§C¡A¥B¤w¸g°µ¨ìÁ{§É¤T´Á¸ÕÅç¡A¦pªG¯uªº¬O³o¼Ë¡A§Ú°J¤ß´Á¬ß³o¼Ëªº²£«~¯à°÷¾¨§Ö¤W¥«¡A¦]¬°¤zÂZ¯À¦pªG°£«o°Æ§@¥Î¥B©ÔªøªvÀø®ÄªG¡A½T¹ê¬OªvÀø¬Æ¦Ü¹w¨¾¨xª¢«Ü¦nªºÃĪ«¡C ¦pªG·s¤@¥Nªø®Ä¤zÂZ¯À¯à¶¶§Q¤W¥«¡A¥Ñ©ó¤zÂZ¯À¦³®Ä¡B»ù·Gªº¯S©Ê¡A°·«O¸p©Î³\¥i¥H±N²£«~¯Ç¤Jµ¹¥I¡A¨Ã¥B«ØijÂåÀø³æ¦ì¯Ç¤J¼Ð·ÇÀøªk¡A¤]¥i·f°tPre-S°ò¦]¬ðÅÜ¿zÀ˸վ¯¨Ï¥Î¡A¶X¦¦b¨x¯f±wªÌ§Î¦¨¨xÀù«eªvÀø¡A¬Û«H¥i¤j¤j°§C°·«O¨x¯f¥ÎÃĪº¤ä¥X¡C ¥þ²y¨´¤µÁÙ¥¼¶}µo¥X¦³®Äªº§ÜB¨x¯f¬rÃÄ¡A¥¼¨ÓY¥H¿zÀËB«¬¨xª¢¯f¬rPre-S°ò¦]¡A¥h¿z¿ï§í¨îPre-S2¬ðÅܮ誺ÃĪ«¡A¥i±æ¦¨¬°¥þ²y·sÃĬãµo¡A¶i¦æ¨xÀù¹w¨¾»P¼Ð¹vªvÀø¤§¦ñÀH¦¡¶EÂ_¤u¨ã¡C¤£¹L¡A¦b¦¹¤§«e²{¦³ÃĪ«¦p¦ó¿ï¾Ü¡Aȱo¦³Ãö³æ¦ì«ä¦Ò¡C ¡]¥»¤å¥Ñ°ê½Ã°|«e¬Ì]©Ò©Òªø¡þ«n¥x¬ì§Þ¤j¾Ç¥Í§Þ¨tÁ¿®y±Ð±ÂĬ¯q¤¯¤fz¡^ |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/15 ¤W¤È 09:06:39²Ä 641 ½g¦^À³
|
¨s³ºþ¨ÇB¨x±aìªÌ·|´c¤Æ¬°¨xÀù¡H¾ú¸g¤T¤Q¦~Áæ¦Ó¤£±Ë¦a°lÂÜ¡A §ÜSARS^¶¯¡B¯eºÞ§½«e§½ªøĬ¯q¤¯¡A²×©ó¯}¸Ñ³oÁ¼¹Î¡A µª®×´N¦bpre-S°ò¦]¸Ì¡A¨Ã¶}µo¥X¥þ²y²Ä¤@´Ú¹w¨¾¨xÀùªº·sÃÄ¡C ÁÙ°O±o¶Ü¡HÃÀ¤H¦w¶vÀö¶È¤T¤Q¤@·³ªº¦~»´¥Í©R¦]¨xÀùÆJµM¹L¥@¡A¤Þ°_¦U¬É¿ò¾Ñ¤£±Ë¡A¦ý§ó¥O¤H¾_Å媺¬O¡A¥L±qµo²{¨xÀù´_µo¨ìÆJ³uªº¹Lµ{¡A¥u¦³µuµu¨â¬P´Á¡C ³o¬O¨xÀù¥O¤H®`©Èªº¦a¤è¡A¤@¥¹µo²{¤j¦h¬°¥½´Á¡A¦]¦¹¥[«ªvÀøªº§xÃø«×¡C¨ä¤¤¡AB«¬¨xª¢§ó¬O¨xÀùªºÀY¸¹±þ¤â¡A¥xÆWB«¬¨xª¢±aìªÌ°ª¹F¤T¦Ê¸U¤H¡A¦¨¬°¨xÀùªº¤£©w®É¬µ¼u¡C B«¬¨xª¢¯f¬r¨s³º¦p¦óÂà¤Æ¬°Àù¯g¡H¦p¦ó¯}Ãa¨x¥¿±`²ÓM¡H¦p¦ó«P¶i¨x²ÓM¤£¥¿±`¼W¥Í¡H²¨¥¤§¡A¨s³ºþ¨ÇB¨x±aìªÌ·|´c¤Æ¬°¨xÀù¡H³oÓ°ÝÃD¤@ª½¬OÂå¾Ç¥@¬ö¤§Á¼¡A°ê¤º¥~µL¼Æ±M®a¾ÇªÌ§ë¤J²¦¥Íºë¤O¡A«o¤@ª½¿ð¿ðµL¤H¯à¸Ñµª¡C «¤j¬ð¯}¡I B¨xªí±§Üì¬ðÅÜ ®e©öPÀù ª½¦Ü¦³¤@Ó¤H¡A¾ú¸g¤T¤Q¦~Áæ¦Ó¤£±Ë¦a°lÂÜ¡A²×©ó¯}¸Ñ³oÓ§xÂZÂå¬Éªø¤[ªºÁ¼¹Î¡A«÷´ê¥XB«¬¨xª¢¾ÉP¨xÀùªº§¹¾ã¹Ï¹³¡C³o¶µ¤j¬ð¯}ªº®Ö¤ß¤Hª«¡A´N¬O§ÜSARS¡]ÄY««æ©Ê©I§l¹D¯gÔ¸s¡^^¶¯¡B¯eºÞ§½¡]¤w§ï¨î¯eºÞ¸p¡^«e§½ªø¡A²{¬°°ê½Ã°|¯S¸u¬ã¨sû»P«n¥x¬ì§Þ¤j¾ÇÁ¿®y±Ð±ÂĬ¯q¤¯¡C ¥Lµo²{¡AB¨x¾ÉP¨xÀùªº¥@¬ö¤§Á¼¡Aµª®×´N¦bB«¬¨xª¢¯f¬rªí±§Ü쪺¤@¬q°ò¦]§Ç¦C¢w¢w ªí±§Üì¬ðÅÜ®è¡]pre-S mutant¡^¡CPre-S§@¬°¦MÀI«eÅX¦]¤l¡A¤@¥¹¥X²{¬ðÅܯʷl¡A·|²Ö¿n¦bt³d²ÓM¤ºª«½è¹B¿éªº¤º½èºô¡A¤Þ°_²ÓMÀ£¤O¡A¨Ã§e²{¤ò¬Á¼þ¨x²ÓM¡C ³ÌªñÁú°êªº¬ã¨sÅã¥Ü¡AB¨x±aìªÌ¿©±w¨xÀùªº¾÷²v¡A¤ñ¤@¯ë¨S±aìªÌ¼W¥[¤»¦¨¡A¨xµw¤Æªº·ÀI«h¼W¥[¤T¿¡C¤Ï¤§¡AY¥¼±a¦³¦¹°ò¦]¬ðÅܪ̡A¿©±w¨xÀùªº·ÀI«h¶È¦³¤¢H¦Ü¤@¡³¢H¡A¥x¤j°ª¹Å§»±Ð±Â¤Î°ª¶¯ªø©°³¯«Ø§»Âå®vªº¬ã¨s¡A¤]³£ÃÒ©ú³oÓµo²{¡C http://www.businesstoday.com.tw/article-content-80731-154903 |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/13 ¤U¤È 09:31:51²Ä 640 ½g¦^À³
|
´¼Àº¨ºÁû¤G½u¥ÎÃÄÃij̤j¥«³õ¦b¬ü°ê ¤]¤Áµ¹MM¤F¡A´¼Àº¥u³Ñ¼Ú¬w¥«³õ¦Ó¤w¡A¥«³õ¯à¦³¦h¤j? ¦AªÌ¡A³oÁûÃĪº OS ¥u¯à ¦h¬¡¤@Ó¦h¤ë( ±q¤ÆÀøÃÄ¥§¡ 5 Ó¤ë¹Ø©R©µªø¨ì 6 Ó¦h¤ë¦Ó¤w) ¡AµLªkªv¡¯ØŦÀù¡A§AÄ@·Nªá 4-5 ¸U¬üª÷¥h©µªø¤@Ó¤ë¹Ø©R¶Ü ? ¥«³õ¯à¦³¦h¤j ¦Ó¥B ¤j³¡¤À¯ØŦÀù¯f¤H ÁÙ¨S¥Î¨ì³oÁû¤G½uÃÄ´N¤w¸g¥h¨£¤W«Ò¤F¡A¥«³õ¯à¦³¦h¤j? |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2016/9/13 ¤U¤È 09:13:23²Ä 639 ½g¦^À³
|
¥un¤zÂZ¯À¦³¥Îªº¯e¯f,³£¦³¥i¯à¥Hoff-label use¥Î¨ìp1101¡C¤@¤è±¼W¥[À禬,¥tÁÙ¥i¥HÆ[¹î¨ì¹ï¨ä¥L¯e¯fªºÃĮġC»¡¤£©w¦³¤@¤Ñ¥¦¯uªºÅܦ¨ªv¦Ê¯fªº¯«ÃÄ¡C«¢«¢«¢«¢«¢.....¤zÂZ¯À§@¥Îªº½d³ò¤Ó¤j¤F,¥u¬O¤§«eªº¤zÂZ¯À¤£°÷¯Â¤~¨SÅã²{¥X¨Ó¦Ó¤w¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/13 ¤U¤È 09:06:13²Ä 638 ½g¦^À³
|
·sÃÄÀ禬 = ¥«³õ³W¼Ò X º¯³z²v X ¤À¼í¤ñ¨Ò ¤ÀªR®v³s³o°ò¥»·§©À³£¤£ª¾¹D¡A´N§O®ö¶O®É¶¡¬Ý¥Lªº¸`¥Ø¤F¡C ³o¤]¬O¬°¦ó´¼Àº¶i«×¨«ªº³Ì§Ö¡A¤½¥q¥«È«o¬O¤TÀɤ¤³Ì§Cªº¡C |
|
|
·|û¡Gsk2man10142897 µoªí®É¶¡:2016/9/13 ¤U¤È 08:08:08²Ä 637 ½g¦^À³
|
À¹²´Ãè¡B¥~ªí¬Ý°_¨Ó¦³¤@ÂIÂIºÖ®ð..........©m ¶À ¶Ü¡H |
|
|
·|û¡G°Î¦WªÌ10141057 µoªí®É¶¡:2016/9/13 ¤U¤È 06:47:43²Ä 636 ½g¦^À³
|
è¬Ý¹qµøµL·N¶¡¬Ý¨ì¤@Ó¦ÛºÙ·sÃÄÁ`¥q¥Oªº¤ÀªR®v ®³¤F±iªí®æ.¸Ì±¦³3ÀɪѲ¼ ´¼Àº ¥«³õ30»õ¬üª÷ ¤¤¸Î ¥«³õ20»õ¬üª÷ ÃÄµØ ¥«³õ10»õ¬üª÷ ¸Ó¤ÀªR®v¦b¸`¥Ø¤W¤@ª½±ÀÂË´¼Àº ´¼ÀºÁö»¡¦³30»õªº¥«³õ¦ý¦n¹³¦]¸ÓÄÝ©ó¤G½u¥ÎÃÄ ¥[¤W2´Á§¹´N±ÂÅv¥X¥h ´NºâÃĽæ¥X¥h100¶ô´¼Àº¥i¯à³Ì¦h©âÓ10% ¤¤¸Îºâ¬O·R´þ¥½½u¥ÎÃĹï¨ä¥LÃĦ³§ÜÃÄ©Ê«á¤~¥´ ¯uªº20»õ¥«³õ¥L¤S¯à¦Y¨ì¦h¤Ö% ¤zÂZ¯À¤G½u¥ÎÃij£¯à°µ¨ì10»õÀ禬¤F §ó¦óªpÃĵتºÃĬO¤@½u¥ÎÃÄ ¥«³õ¦³30»õ.¸Ó¤ÀªR®v©úÅã¤Þ¥Î¿ù»~ ÁÙ¬O¨è·N»~¾É»¡Ãĵإ«³õ³W¼Ò¶È¦³10»õ¬üª÷ ¼Ú¬wÁöµM±ÂÅvµ¹aop¦ý100¶ôÁÈÓ20-25%¦]¤£¦¨°ÝÃD ¥[¤W³Ì¤j¥«³õ¬ü°ê.¤½¥q·Q¦ÛÀç §Q¼í¤j³£¥i¥H«O¯d¦b¤½¥q¨¤W ¥[¤WÃÄÃÒ¹L¤F.·|ÂkÃþ¤@½u¥ÎÃÄ ¥i¦Y¤Uµ´¤j¦h¼Æ¥«³õ ¦³¨ÇÃÄ¥«³õ«Ü¤j ¦ý§Úı±o¯à¦Y¤U´X¢H¤~¬O¤ý¹D |
|
|
·|û¡GLordTA10143086 µoªí®É¶¡:2016/9/12 ¤U¤È 09:38:44²Ä 635 ½g¦^À³
|
³Ìªñ¤@ª½Ãöª`«D¤Z°Ó·~¥x¤Î¨ä¥L°Ó·~¥x¸`¥Ø¡Aµo²{¸`¥Ø¤W¦Ñ®v̳£¦b¤¶²Ð¥Í§Þ±Ú¸s¦æ±¡§Y±N¨Ó¨ì¡A·í¦b¤¶²Ð·sÃÄӪѮɡA³£¤£·|±NÃĵإX²{©ó¤¶²Ð¦W³æ¡]³£¦b¤¶²Ð¤¤¸Î¡A´¼Àº¡A¤j¦¿µ¥ÓªÑ¡^¡A³o¼Ë¤]¦n¡AÄw½X¶°¤¤«×¤ñ¸û¤£·|Åý´²¤áÌ¡I¡I¦æ±¡§Y±N¨ì¨Ó¡ã¤j®a¤@°_¥[ªo§a¡ã²¢¬üªG¹êÁ`¬On¸g¾ú¬K®L¬î¥V«á¤~¯à¥H³Ì²¢¬ü«ººA¶i¦æ±Ä¦¬¡ã |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/12 ¤W¤È 11:23:42²Ä 634 ½g¦^À³
|
§Ú¦b·Q..þ¦ì¤j¤j¶}Óª©±¡÷(ÃĵØÂåÃĪºÄ@´º¤Î§ë¸ê»ùÈ)°µ¬°ªø´Á°Q½×ª©¤]¤£¿à~¯Âºé·Q·Q |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/12 ¤W¤È 09:14:23²Ä 633 ½g¦^À³
|
¤W¶g§À½L¼É¶q¦¬¦b³Ì°ªÂI ¤w·t¥Ü¥»¶g¦æ±¡¤´·|«ùÄò °t¦X³ø¯È§Q¦h¤@ªi±µ¤@ªi,¦nÀ¸¤W³õ¤F |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/12 ¤W¤È 08:10:26²Ä 632 ½g¦^À³
|
¶}µoªø®Ä²£«~ Âå¬ÉªÖ©w 2016-09-12 05:45 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É B¡BC«¬¨xª¢Åý¤H»D¤§¦âÅÜ¡Aªñ´ÁC¨xÁö¦³±j¤Oªº¥D¬yÃĪ«°Ý¥@¡A³ôºÙ¯à°÷±N¯e¯f¡uªv¡¡v¡A¦ý¯ÊÂI¤´¤£¤Ö¡Aº¥ý³ÌÅý¤H¸á¯fªº¬OÃÄ»ù¤Ó¶Q¡A¦Ó°£¤FÃÄ»ù¶Q¡A¨xÁxÅv«Â¡B°ª¶¯Âå¾Ç¤j¾ÇÂå¾Ç¨t±Ð±Â§E©ú¶©«ü¥X´XÓÃöÁä¡A¥]¬A¦³§ÜÃÄ©Ê¡BªvÀøµL®Ä©Î¾ÉP¨xÀùªº±wªÌ¡A«h¥²¶·¥t³V³~®|ªvÀø¡C §E©ú¶©¤µ¦~¦b¨È¤Ó¨xŦ¬ã¨s¾Ç·|¡]APASL¡^¤W¡Aµoªí¡u§Ṳ́´»Ýn¤zÂZ¯À¶Ü¡H¡v¡]Do we still need IFN¡H¡^±MÃDºtÁ¿¡A¥Lªºµ²½×¬O¡AÁöµM¤p¤À¤lÃĪvÀøC«¬¨xª¢¨ã¦³¨}¦nÀø®Ä¡A¦ý¤´¦³¤£¤Ö¡u¯Ê¤f¡v¡AȱoÂå¬ÉÃöª`¡C¥LªÖ©w¦aªí¥Ü¡A¤zÂZ¯À¤´¬OªvÀø¨xª¢ªº§Q¾¹¡A¤£¯à±Ë±ó¡C §E©ú¶©«ü¥X¡AC«¬¨xª¢¥D¬yªº¤p¤À¤lÃĤ@°Ý¥@¡A³\¦hÂå¬É¤H¤h§¡ªí¡A¤zÂZ¯À¤w¸g¨«¨ìºÉÀY¡A¤£¹L¡A¦³Å³©ó¤p¤À¤lÃĪ«¦bªvÀø¨xª¢¤è±¡A¤´¦s¦b¨ä¯ÊÂI¡A¦b·s¤@¥Nªø®Ä¤zÂZ¯À°Ý¥@«á¡A³o¼Ëªº¡u¿W¥e¡v§½±±N¥i±æ§ï¼g¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/12 ¤W¤È 08:05:32²Ä 631 ½g¦^À³
|
Ãĵجãµo¤zÂZ¯À §ÜC¨x§Q¾¹ 2016-09-12 05:45 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É §Ü¨xª¢¤p¤À¤lÃIJ{¯Ê¤f¡A¥x¼t¦³§Q°ò¡C¼Ú¬w¨xŦ¡]¯e¯f¡^¬ã¨s¨ó·|¡]EASL¡^«ü¥X¡A·í«eC«¬¨xª¢Áö¦³Àø®Ä¬Æ¨Îªº¤p¤À¤lÃĪ«¡A¦p¦N¥ß¼w¡]Gilead¡^ªºSovaldi¡BHarvoni¡A¦ý§Y¨Ïªv¡¤´¦³¾ÉP¨xÀùªº·ÀI¡A·~¬É»{¬°¡A³o¬°¥x¼t¶}µoªø®Ä¤zÂZ¯ÀªºÃĵص¥¤½¥q¯d¤UªvÀø¥«³õ¯Ê¤f¡A¯¸ÃÄvª§§Q°ò¡C ¦bªvÀøC«¬¨xª¢ªº¥«³õ¡A¥xÆW¥Ø«e¦@¦³¦ã§Bºû¡]AbbVie¡^¡B¥²ªv§´¡]Bristol-Myers Squibb¡^¡B¦N¥ß¼wµ¥¤T®aÃļtC¨x¤fªA·sÃĨú±o¥xÆWÃÄÃÒ¡A¦ý§¡»Ý¦Û¶O¡A¨ä¤¤¥H¦N¥ß¼wÃÄ»ù³Ì°ª¡A¤@ÓÀøµ{¡]12©P¡^n»ù140¸U¤¸¡A¦ã§Bºû¡B¥²ªv§´¤À§O¬°85¸U¤Î40¸U¤¸¡C¾Ú±x¡A¤TÃļt¤¤¡A°£¦N¥ß¼w¥~§¡¦P·N¡u°»ù¡v¡A°ßÃĶO¤´°ª¡A±N¦³¤@³õ°·«O»ùª§¹Ü¾Ô¡C ¦bC«¬¨xª¢¯e¯fÀøµ{¤¤¡A¯f¤HªA¥Î¤Wz¤j¼tªº²£«~¨Ã§¹¦¨ªvÀø12©P«á¡A¦AÀË´ú±wªÌªº¦å¤¤¯f¬r¶q¡]SVR12¡^µo²{¡A³o¨Ç¤j¼tªº²£«~¡A¦h¯à¦³®ÄÀ£§í¯f¬r¡A¬Æ¦Ü¤£¤Ö±wªÌÅ餺¤wÀË´ú¤£¥X¯f¬r¡A±qÂå¾ÇªºÆ[ÂI¨Ó¬Ý³ôºÙ¡uªv¡¡v¡C ¦ý¨ÌEASL½×ÂI¡A§Y¨ÏC¨x±wªÌ¦å²G¤¤ªºC¨x¯f¬r§¹¥þ²M°£¡A¨xŦ²ÓM°ò¦]¬ðÅܤ´¦s¦b¡A¦]¦¹¡A§Y¨Ï¤wªv¡ªº±wªÌ¡A¦h¦~«á¤´¦³¿©±w¨xÀùªº·ÀI¡A¥B¤w¦³®×¨Òµo¥Í¡C Âå¾Ç¬É«ü¥X¡AYn°w¹ï¨x²ÓM¤¤¯f¬r¤©¥H²M°£¡A¶·¥õ¿à¤zÂZ¯À¡]Pegasys)¨ÓªvÀø¡A¤£¹L¡A¤zÂZ¯Àªº¯ÊÂI¬O¦³¹L¤jªº°Æ§@¥Î¡A¦p±w«·P«_ªº¯gª¬¡A¦³«Ü¤j¤ñ²vªº±wªÌ¦b°Ñ¥[Àøµ{¤£¨ì¤@¥b§Y°h¥X¡C§Y¨Ï²Ä¤G¥N¤zÂZ¯À±N¬I¥´®Éµ{©Ôªø¨ì¤@©P¡A¦Ó°Æ§@¥Î¤´¦b¡A±wªÌ¤]¦h»q¨¬¤£«e¡C ¤£¹L¡A¥x¼t¥Ø«e¤w¸g¦³¶}µo·s¤@¥N¤zÂZ¯Àªº¤½¥qÃĵءA¸Ó¤½¥q±ÂÅvªº¼Ú¬w¹Ù¦ñAOP¦b¨u¨£¦å²G¯e¯fPVªºÁ{§É¤T´Á¼Æ¾Ú¤w§¹¦¨¡A¥¿¦b¼Æ¾Ú¤ÀªR¶¥¬q¡A¹wp¦~©³«e¦V¼Ú·ùEMA°e¥ó¡CÃĵتí¥Ü¡A·s¤@¥Nªø®Ä¤zÂZ¯À¤]¬OªvÀøC«¬¨xª¢ªº§Q¾¹¡C ¨ä¤¤¡AÃĵػ{¬°¡AºX¤U¶}µoªºªø®Ä¤zÂZ¯À¡A¦³¨â©P¬I¥´¤@°wªºÀu¶Õ¡A¥B°Æ§@¥Î»·§C©ó«e¨â¥Nªº¤zÂZ¯À²£«~¡A¦b¨xª¢ªvÀø¤è±²[»\B¡BC«¬¨xª¢¡A¯à»P¤p¤À¤lÃĪ«¶i¦æ¦X¨ÖªvÀø¡A¯à¥[§Ö¯f¬r²M°£³t«×¡A¨Ã¥i±æÅý¨xª¢±wªÌ¤£¦Ü©óºtÅܦ¨¨xÀù¡C Ãĵتí¥Ü¡A¼Ú¬w¥«³õ±N¥æ¥Ñ¹Ù¦ñAOP¸gÀç¡A¦ÓAOP©Ò»Ýªº²£«~ì®Æ«h¥ÑÃĵإx¤¤¼t´£¨Ñ¡A¹wpAOP¦b¤µ¦~©³°e¥Ó½ÐÃÄÃÒ«á¡AEMA±N©ó©ú¦~º©u¦w±Æ¨Ó¥x¬d¼t¡F¦Ó¬ü°êÃÄÃҤ象A±N¥ÑÃĵئۦ滼¥ó¡A³Ì§Ö©ú¦~º©u§Y¥i»P¬ü°ê¹«~ÃĪ«ºÞ²z¸p¡]FDA¡^¨ó°Ó¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/10 ¤U¤È 11:28:13²Ä 630 ½g¦^À³
|
¦^À³RO¤j ¦Ñ®v³Û¶i¤D«Y§Ú®Ú¾Ú¶q»ùµ²ºc±ÀÂ_ªº ¥B¤µ¤é¤§¨«¶Õ§ó¥[¦Lµý§Úªº±ÀÂ_ ³q±`³oºØ·s¤W¥«ªÑ³q±`·|§@¤â¥ý°µ¤@ªi¦A¥Ñ§ë«H©Î¥~¸ê¨Ó±µ´Î Yè¦n¦p§Ú©Ò¨¥¡A¤]¬OÁr´ú¡A¯ÂÄÝ¥©¦X¡C |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/9/10 ¤U¤È 05:34:41²Ä 629 ½g¦^À³
|
Ãĵئb2016 12/3~12/6ªºASH meetingÀ³¸Ó¯à°÷¤j©ñ«³ªö§a! ´Á«Ý~ |
|
|
·|û¡GRookie10143115 µoªí®É¶¡:2016/9/10 ¤U¤È 03:45:41²Ä 628 ½g¦^À³
|
½Ð±Ð¤p°¨¤j¤j¡A¬Oþ¦ì¦Ñ®v¦b±ÀÂËÃĵءH |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2016/9/10 ¤U¤È 03:30:49²Ä 627 ½g¦^À³
|
³o¤äªÑ²¼¦³¤H¦bª£¡A§Ú¤]¤W¨®¤F |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/10 ¤U¤È 01:19:54²Ä 626 ½g¦^À³
|
©ú¦~2¤ëor5¤ë¯Ç¤JMSCI«ü¤é¥i«Ý¡A¥~¸ê«ùªÑ¨Ó¨ì10%ªº¸Ü¡An¦A¥[½X1¸U¦h±i¡A·|±À¤ÉªÑ»ù¡A¥[ªo!¥[ªo! |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/10 ¤W¤È 11:19:57²Ä 625 ½g¦^À³
|
¦hªÅ¤£Â_ű³y¦Ó¦¨ ªî¨ìªÅ¤âªº¤H¤F ¸É¤£¦^¨Ó¤F »{½ß¦^¸É±N¨Ó¤´¤j¦³¥i¬° n¤£µM´N ¯uÁ«¤j¤F |
|
|
·|û¡GLKK10000004 µoªí®É¶¡:2016/9/10 ¤W¤È 10:53:08²Ä 624 ½g¦^À³
|
«Cß¼C¬O¦p¦óű¦¨ªº¡H |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/10 ¤W¤È 10:12:36²Ä 623 ½g¦^À³
|
¦Ñ®v³Û¶iªºªÑ²¼,¦æ±¡¤£·|¥u¦³¤@¨â¤Ñ ¥BÃĵؾ֦³¼Æ¤£§¹ªº§Q¦h ¤£¥ú¦Ñ®v³Û¶i,¥~¸ê¤Îªk¤H¥ç¿n·¥¥d¦ì ¤j½L«ü¼Æ¤S±þ§C¤F ¦ýÃĵتº¶R½L¤´¬O±j±jºu |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/10 ¤W¤È 09:48:31²Ä 622 ½g¦^À³
|
ªÑ»ù¤@°Ê´N·|§l¤Þ§ó¦h¤H¨Ó¬ã¨sÃÄµØ ¦ÛµM·|·U¨Ó·U¦h¤H»{ÃÑ¥¦ °t¦X·sÃÄ«GÄRªº¼Æ¾Ú¤½§G¦b§Y ³o¤@ªi¦æ±¡¥i±æ¦¨¬°¥Í§ÞªÑªº¤¤¬y¯¡¬W |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2016/9/10 ¤W¤È 09:05:03²Ä 621 ½g¦^À³
|
¤S¤@°ï¤H¶Ã¤ñÂû»L,§â«Cß¼C®³¥h´«ÅK¯»¤F¡C«Ü´d«sªº¬O¤@°ï¤H¦P®É«ù¦³«Ü¦h«Cß¼C©MÅK¯»¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/10 ¤W¤È 07:42:30²Ä 620 ½g¦^À³
|
§ë¸ê»ùȳvº¥³Q¥~¬Éª¾±x °£¤F¦Ñ®v³Û¶i¥~,¥~¸ê¤Î§ë«H³£¶R¶i¦Ê±i¥H¤W |
|
|
·|û¡GAnderson10143089 µoªí®É¶¡:2016/9/9 ¤U¤È 02:16:26²Ä 619 ½g¦^À³
|
³o´X¤Ñ¬Ý¥XªÑ»ù¤îý´¡A¦n¸ñ¶H¡C |
|
|
·|û¡G¨¦¤Ö«L10143103 µoªí®É¶¡:2016/9/9 ¤U¤È 01:04:38²Ä 618 ½g¦^À³
|
ÁÂÁÂAlan Liu10136094¤j¤jªºÂ½Ä¶ |
|
|
·|û¡GAlan Liu10136094 µoªí®É¶¡:2016/9/9 ¤U¤È 12:50:55²Ä 617 ½g¦^À³
|
¦³Ãö©ó¬Q¤éÃĵØÃÄ©Ò´£¨Ñ¤§Â²³øÀÉ, ¤º®e½Ķ¾ã²z¦p¤U´£¨Ñ°Ñ¦Ò, ´Á³\§ó¦h¤H¤F¸ÑÃĵؤ½¥q»ùÈ¡C [¤½¥q·§ªp] Ãĵئ¨¥ß©ó2003¦~5¤ë, ¥Ø«e¥«È13»õ¬üª÷, û¤u¤H¼Æ150¤H, ¤½¥q±b¤W²{ª÷¶W¹L40»õ¡C¤½¥q¾Ö¦³°í±jªº¸gÀç¹Î¶¤, ³Ð¿ì¤H/¸³¨Æªø/Á`¸g²z§¡¾Ö¦³25-30¦~¥H¤Wªº¶}µo¸gÅç¡C # ¤½¥qªº®Ö¤ß§Þ³N 1. ©wÂIªºPEGylation §Þ³N¥¥x 2. ³Ì¯Âªºªø®Ä«¬¤zÂZ¯ÀP1101 - °Æ§@¥Î»´·L, ¥i¥Î©óªvÀø¦hºØ¾AÀ³¯g - ¾¯¶q½Õ¾ã´T«×¤j, ¥iµ¹¤©Âå®v¥ÎÃÄ°ª«×¼u©Ê 3. ´x´¤®Ö¤ß±M§Q, ±M§Q¨ì´Á¬°2034¦~ 4. ÃĵجãµoªºP1101 ¤zÂZ¯À»·Àu©ó»P¥Ø«e¥«³õ³Ì¤jªº¨âºØPEG-IFN£\¶Ç²Î¤zÂZ¯À(Àq§JªºPEG-Intron¡B¥H¤ÎRoche ªºPegasys)¡C # ÃÄµØ P1101 ¯S¦â¾ã²z¦p¤U¡G 1. ´Xªñ³æ¤@¤Æ¦Xª«°ª¯Â«×ªº³J¥Õ½è·sÃÄ¡Aªñ30»õ¬ü¤¸ªºªºÃþ¦ü²£«~, ¶V°ª¯Â«×®Ä¥Î¥i¦b¤HÅéºû«ù§óªø®É¶¡¡C - PEG-Intron(§t14Ó²V¦Xª«) - Pegasys (§t8Ó²V¦Xª«) 2. ¥Ø«e¤zÂZ¯À³ÌªøÃĮĮɶ¡ (Á{§É¼Æ¾ÚÅã¥Ü P1101¥i¨â©P¥´¤@°w, ¥ÎÃĤ@¦~«á¥i´î¬°¨C¥|©P¤@°w, ¥Ø«e¥«³õ¤W¨ä¥L¶Ç²Î¤zÂZ¯À¬°¤@©P¤@°w), ¸`¬Ù¯f±w¥ÎÃĦ¸¼Æ¡C 3. ÃĪ«°Æ§@¥Î¸û¤p¡A¤£¹³¥«±¤W¨ä¥L¤zÂZ¯À¨ã¦³¦hÓ¦P¤À²§ºcª«¦Ó³y¦¨¸û±jªº°Æ§@¥Î¤ÏÀ³¡F±N·|§ó¬°±wªÌ©Ò±µ¨ü¡C 4. Ãĵجãµo¤§P1101 ¥i¥H³QªvÀø¥Î©ó¦hºØ¾AÀ³¯g, Ãĵإثe¥Î©ó¨u¨£¦å²G¯e¯f¦p(PV¡BET)¡B·P¬V¯e¯f (B¨x¡BC¨x)¡BÀù¯g¡C5. ¥iÆF¬¡½Õ¾ã¾¯¶q 6. ¦]²£ª«¬°³æ¤@¤À¤l¡A¦b¯Â¤Æªº¨BÆJ±N²³æ³\¦h¡A¸`¬Ù¤F³\¦h«~ºÞªº®É¶¡©M¸ê·½¡C # ¥Ø«e¤½¥q¦bP1101¤zÂZ¯Àªº¥¬§½¤W¥Dn²£«~½u¬°¨â¤j°Ï¶ô¡G 1. ¦å²G¯e¯f (P1101) ¯u©Ê¬õ¦å²y¼W¦h¯g PV (¼Ú¡B¬ü)¡G Á{§É¤T´Á¤w¦¬®×, ¹wp¦~©³¬ü°ê¦å²G¦~·|(ASH) ¤½¥¬Á{§É¤T´Á¼Æ¾Ú¡C ºC©Ê°©Åè©Ê¥Õ¦å¯f CML(¼Ú)¡G¦]¼Ú¬wÁ{§É¼Æ¾ÚÅã¥Ü¨}¦n, ÃĵسW¹º¶i¦æÁ{§É¤T´Á¡C ¦å¤pªO¼W¥Í¯g ET (¼Ú¡B¬ü¡B¥x)¡GÃĵسW¹º¦~©³»¼¬ü°êFDA¤T´ÁÁ{§Épµe ìµo©Ê°©ÅèÅÖºû¤Æ¯g PMF (¬ü)¡G¥Ø«e¬°¤G´ÁÁ{§É 2. ·P¬V¯e¯f (P1101) Ãĵؤ½¥qÁ{§É¹êÅç¥Dn¥Î©óªvÀøB¨x¡BC¨x¡C B¨x (¥þ²y)¡G¹wp©ó106¦~Q1¶i¤J¤HÅé¤T´ÁÁ{§É¸ÕÅç¡C C¨x-°ò¦]«¬²Ä2«¬ (¥x¡BÁú)¡G ¥Ø«e¶i¦æÁ{§É¤T´Á¸ÕÅç¡C C¨x-°ò¦]«¬²Ä1«¬ (¥x)¡G ¥Ø«e¶i¦æÁ{§É¤T´Á¸ÕÅç¡C # ÃĵةҬãµoªºP1101 ¤zÂZ¯À, »P¥@¬É¤@¯Å¤jÃļt²@¤£»¹¦â - Á{§É¤@´Á¼Æ¾ÚÅã¥Ü¨}¦n¥B¯f¤H@¨ü«×°ª, ¥B¤½¥q¾¯¶q¤£¦]¼W¥[¦Ó¾ÉP°Æ§@¥Î¼W¥[ - ¥Ø«e¦b PVªºÁ{§É¹êÅç¤T´Á¤w¦¬®×, ¯f±w¥i2©P~4©Pª`®g¤@¦¸, - ¤½¥q¦b C¨x-°ò¦]«¬²Ä2«¬ Á{§É¤G´Á»P ¥«³õ¤W¥Ø«e¥«¥e³Ì°ªªº ù¤ó Pegasys ¬Û¸û¥i¨£¥H¤UÀu²§©Ê¡C 1. ¾¯¶q°ª (Pegasys ¬°180·L§J¡BÃĵØP1101 ¯f¤H³Ì¤j@¨ü«×¦Ü540·L§J) 2. ¸û§Cªº°Æ§@¥Î 3. ¯f¤H¶È»Ý¨â¶g¥´¤@°w - ¥Ø«eÀq§J¡Bù¤óªº¶Ç²Î¤zÂZ¯ÀÁö¤w¤W¥«, ¦ý¯f¤H¶È¯à©Ó¨ü¨C©P¤@°w, ¦Ó¿ÕµØ¡B¥²ªv§´ªº¤zÂZ¯À¬ãµo¤w¥¢±Ñ²×¤î¹êÅç # Ãĵز£«~½uµo®iª¬ªp¡G ¦å²G¼W¥Í¯e¯f (MPN)²¤¶¡G 1. PV 2. ET 3. CML 4. MF - °©Åè³y¦å²ÓM¤£¥¿±`¼W¥Í - ®e©ö¾ÉP¦¸µo©Ê°©ÅèÅÖºû¤Æ¡B¦å®ê¡B¥X¦å¥H¤Î¨ä¥L¦å²G¯fÅÜ¡AYµL§´µ½ªvÀø,³Ì«á·|ºtÅܦ¨¦åÀù¡C - FDA®ÖãJakafi¥Î©óªvÀø MF (2011¦~³q¹L) ¥H¤Î ®ÖãJakafi¬°ªvÀøPVªº²Ä¤G½u¥ÎÃÄ(2014¦~©³³q¹L)¡C - JakafiÃÄ»ù¥Ø«e¬° Àøµ{¤@¦~ ¬üª÷ $135,000¡C - ÃÄµØ ¤À§O©ó PV (2012¦~)/ ET (2014¦~) / MF (2014¦~) ¨ú±o¼Ú¬ü©t¨àÃĸê®æ¡C # ©t¨àÃÄÀu¶Õ¡G (1) ¥i¨É¦³¼Ú¬w10¦~/¬ü°ê7¦~¿W½æÅv, ±M§Q¥i«ùÄò¦Ü2032¦~ (2) ©t¨àÃÄ»ù¦³³v¦~½wº¦Àu¶Õ, ¤£¨ü¥«³õÁÖ½×À£¤O (3) ©t¨àÃļt°Ó¾Ö¦³ÁY¤p¸ÕÅç³W¼Ò¡B§Ö³t¼f¬d¹Lµ{ # ¯u©Ê¬õ¦å²y¼W¦h¯g (PV) ²¤¶¡G - ¯Ê¥Fªv¡ªºÀøªk - ¶È¤Ö¼Æªº¯f¤H¥i¥H°©Åè²¾´Óªv¡¡B©Î¥H¶Ç²Î¤zÂZ¯ÀªvÀø¹F¨ì°ò¦]¬ðÅܶqªº½w¸Ñ - ¥Ø«eªvÀø¤è¦¡¡G ¥Ø«e¨S¦³¬ü°êFDA®ÖãªvÀøPVªº²Ä¤@½u¥ÎÃÄ¡A¥Ø«eÀøªk¥]¬A©ñ¦åªvÀø¡B§C¾¯¶qªºªü´µ¤ÇÆF¡BHU¤Æ¾ÇªvÀø¡B¶Ç²Î¤zÂZ¯ÀªvÀø(Pegasys¥é³æ¥~)¤Î°©Åè²¾´Ó¡C¾¨ºÞ¦p¦¹¤´¦³¥|¤À¤§¤@¯f±wµLªk±Ä¥Î¥Ø«eªºªvÀø¤èªk - Jakafi(Incyte) :2014¦~12¤ë®Öã¡B¬O¥Ø«e¬ü°ê°ß¤@®Ö㪺PV¥ÎÃÄ¡A¦ý¶È©ó¥Î©ó¤WzÀøªkµL®Ä®Éªº²Ä¤G½u¥ÎÃÄ # 2011¦~¦å²G¦~·| (ASH Meeting)µoªí¡G 1. ÃĵئbP1101 ªvÀø©óPVªº¤W¥i¹F¨ì¨C¨â©P¤@¦¸, ¥B¯f¤H³Ì¤j@¨ü«×¬° 540·L§J 2. Æ[¹î«áµo²{ ¨C¤»Ó¤ëªºÃĮĤÏÀ³ °ª¹F70% # 2013¦~¦å²G¦~·| (ASH Meeting)µoªí¡G 1. ¤£ºÞ¦bP1101¾¯¶q°ª©Î§C, ³£ºû«ù§C¬r©Ê¥B¦w¥þ©Ê 2. ¯f±wªvÀøªº®Éµ{§ó¼u©Ê 3. Á{§É¹êÅç¼Æ¾ÚÅã¥Ü, ¯f±w¦³®ÄªvÀøµ{«×°ª©ó90%, §¹¥þªv¡²v¹F 45-50% 4. ¯f¤H¤£¶·©ñ¦å, ¦å²G°Ñ¼Æ¥¿±`, ¥H¤ÎµÊŦ¤j¤p©úÅãÁY¤p 5. ¦b28©PÀøµ{«áµo²{, JAK2 Åܲ§µ{«×´î¤Ö, ¥NªíP1101 ¦³ªv¡¥i¯à # 2014¦~¦å²G¦~·| (ASH Meeting)µoªí¡G 1. ¯f±w¦b«ùÄòªvÀø¤@¦~«á, ¥i½Õ¾ã¦Ü¨C¥|©P¤@°w, ¥Bºû«ù¨}¦nªºÃĪ«¤ÏÀ³²v ¯f±w¦bªì©l¨C¨â©P¤@°wªºÀøµ{, ¬ù¦³9%ªº¤£¨}¤ÏÀ³, ¦ý¦b¤@¦~ªºÀøµ{«á°¦Ü3% 2. «ùÄòµo²{JAK2 Åܲ§µ{«×´î¤Ö, ¥N |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/8 ¤U¤È 11:17:26²Ä 616 ½g¦^À³
|
^¶¯±¤^¶¯ ·¨¨|¥Á¬Ý¦nÃĵطsÃIJ£«~¬ãµo¯à¤O¡A»{¬°Ãĵعζ¤«Ü±j¡B«Ü§V¤O¡A¡¨°µªº¦h»¡ªº¤Ö¡¨¡A¦³«D±`¥ú©úªº¥¼¨Ó¡C http://www.chinatimes.com/newspapers/20151221000060-260202 ©Ò¥HÃĵتº¬ì¾Ç®a¯à¨«¥X¨Ó¤w¸gºâ¤£¿ù¤F¡CÀ³¸Ó¹ª¹ª´x¡C ¥i±¤¸ê®Æ³£¬O^¤å¡A¦]¬°¬O¡¨·ç¤h«H¶U¡¨ªº³õ¡AÀ³¸Ó¬Oµ¹¥~¸ê¬Ýªº¡A Y^¤å°ò¦¦nªº¤j¤j¥iºCºC®ø¤Æ¡A½Ķ»P¤j®a¤À¨É¡C http://mops.twse.com.tw/nas/STR/644620160908M001.pdf Æ[¬Ý¨ä¤º®e«D±`Â×´I¡A¤º¦æ¤H¥i¬Ý¨ìªù¹D¡C ¨Ò¦p: 1.±M§Q¨ì2034¦~(ÁaµM¨ì´Á¡A¤]¥i¥Î«Ü¦h¤èªkªý¤îCOPY) 2.ªL³Õ¤h¥X¨Biogen Inc. / Lead Scientist¡A³o¬Oªi¤h¹y³Ì¦Ñªº¥Í§Þ¤½¥q¡A ¤]¬O¥@¬É¥Í§Þ²Ä¤@»E¶°¦a;·¨¨|¥ÁªºÂª÷¤sÆW°Ï¬O¥@¬É²Ä¤Gªº»E¶°ÂI¡C¤]ºâ¬O^¶¯±¤^¶¯¡C http://www.genengnews.com/keywordsandtools/print/3/41375/ |
|
|
·|û¡GLordTA10143086 µoªí®É¶¡:2016/9/8 ¤U¤È 06:00:19²Ä 615 ½g¦^À³
|
TO ¤p¥¿¥¿¤j ÁÂÁ´£¨Ñ~ |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/8 ¤U¤È 05:24:14²Ä 614 ½g¦^À³
|
·ç¤h«H¶Uªk»¡·|¸ê®Æ³sµ²(§ë¼v¤ù¤º®e¦n¹³¸ò°ê²¼ªk»¡·|¤@¼Ë) http://mops.twse.com.tw/mops/web/t100sb07_1 |
|
|
·|û¡GLordTA10143086 µoªí®É¶¡:2016/9/8 ¤U¤È 04:29:29²Ä 613 ½g¦^À³
|
½Ð°Ý¦³µØ¤ÍÃöª`¤µ¤Ñ·ç¤h«H¶Uªk»¡·|¤º®e¶Ü?ÁÂÁÂ~ |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/9/7 ¤U¤È 06:36:08²Ä 612 ½g¦^À³
|
ÃĵØÃÄ6446 ¨Æ¹êµo¥Í¤é¡G105/09/08 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G105/09/08 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G14 ®É 30 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¥x¥_§g®®¶º©±(¥x¥_¥««H¸q°ÏªQ¹Ø¸ô2¸¹) 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q¨üÁÜ°Ñ¥[¥[·ç¤h«H¶UÁ|¿ì¤§¡u17th Annual Asian Technology Conference¡v¡A»¡©ú¥»¤½¥qÀç¹B·§ªp¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/7 ¤U¤È 12:09:33²Ä 611 ½g¦^À³
|
Hydroxyureaªº°ÝÃD¹ê¦b«Ü¤j¡AÃĵئۤ¤¬ã°|¤Þ¶i¦@¦P¶}µoªºÅI¤M«¬³h¦å¯g¤p¤À¤l·sÃÄ¡A¥¼¨Ó¤]¦³¾÷·|¶i¤JÁ{§É¡C www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=1f97bee5-5cfc-4c40-bbb3-115d30eb0aaf |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/9/7 ¤W¤È 11:29:20²Ä 610 ½g¦^À³
|
Áú°ê¤T¬P³Ì·Q·mªº¤H ¥X¥ôÃĵØÂåÃÄ¿W¥ß¸³¨Æ »·¨£Âø»x: ·¨¨|¥Á¹ï¥xÆW¤£¦Ç¤ß ¬°¥Í§Þ·~©é¤@±ø«~µP¸ô ´§§O¦t©÷®×³±Åµ¡A°ê»Ú¥Í§Þ·~¤j¦Ñ·¨¨|¥Á¥X¥ôÃĵØÂåÃÄ¿W¥ß¸³¨Æ¡A´¿¸g¤ß¦Ç·N§N¡A¹ï¥xÆW¥¢±æ¡A¦ý¹ï®a¶mªº±¡Ãh¡A¢¨Ï¥L«ªð¥xÆW¥Í§Þ·~¡AºÉ¤@¥÷¤ß¤O¡C ¤µ¦~3¤ë©³¡A¥Ñ°êµo°òª÷¡B¸gÀÙ³¡¡BÄ£µØµ¥§ë¸êªºÃĵØÂåÃÄ¡AªÑªF·|¤@P³q¹L¡A¸u½Ðù¤ó¤jÃļt¡]Roche¡^«e°õ¦æ°ÆÁ`µô·¨¨|¥Á¾á¥ô¿W¥ß¸³¨Æ¡A®ø®§¤@¥X¡A¤£ª¾¹DÅý¦h¤Ö¦P·~¤S¶ú§ª¤S¸r¼}¡C¤]¬O³Ð¿ì¤H¤§¤@ªºÃĵØÂåÃÄÁ`¸g²zªL°êÄÁ±»¤£¦íº¡¤ßÅw³ß¡AÀWÀW¥H¡u¤ÑªáªO¤Hª«¡v§Î®e³o¦ì¤£©ö½Ð¨ìªº°ê»Ú¥Í§Þ¬É¤j¦Ñ¤Hª«¡C ³o¶µ¨Mij¹ï¦Û¦æ¬ãµo¡B¤£¾a§ÞÂà¡B¦b¥x«Ø¼t¥Í²£ªº·sÃĤ½¥q¨Ó»¡¡A¤£³×¦pªê²KÁl¡Cì¨Ó3¤ë¤¤¦¯¡AÃĵØÂåÃĤ~¥H206¤¸ªº©ÓÁÊ»ùµn¤W¿³Âd¡A³Ð¤U¿³Âd¥Í§ÞÃþªÑ³Ì°ª©ÓÁÊ»ù¡A¶}½L·í¤Ñ³Ì°ª½Ä¨ìªñ255¤¸¡Aº¦´T¹F23.3¢H¡A¦¨¥æª÷ÃB¬°5»õ¤¸¡A¥«È¤@¤U¤l½Ä¯}300»õ¡A¦¨¬°¥Í§ÞªÑªº¼öªù¼Ðªº¡C ¾¨ºÞªÑ»ù¦b5¤ë¥÷¤U·Æ¨ì200¤¸¥H¤U¡AªL°êÄÁ«H¤ßº¡º¡¦a»¡¡AÃĵØÂåÃÄ¥þ¤O¬ãµoªºP1101·sÃÄ¡A¯àªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g¡B¨xÀù¡B¨xª¢¡A¥¿¦b¼Ú¬w¶i¦æ²Ä¤T´Á¤HÅéÁ{§É¹êÅç¡A¶i«×²¤¦³¶W«e¡A¤µ¦~²Ä¤T©u´N¯à°÷§¹¦¨¡A¹wp³Ì§Ö©ú¦~´N¥i¥H¥Ó½Ð¼Ú¬ü·sÃÄ»{ÃÒ¡C¦¹®É¡A¼ô±x°ê»ÚÃÄ·~¹B§@ªº·¨¨|¥Á¥[¤J¡A¥¿¦n¯à¨ó§U¦æ¾P®ü¥~¡C ©ñ²´¥H¦è¤è¤H¬°¥Dªº°ê»ÚÃÄ·~¡A·¨¨|¥Á¥i¬O¦ì¶¥³Ì°ªªºµØ¤H¡C¥L´¿¥ô¾¥þ²y²Ä¤E¤j¥ø·~ù¤óÃļt¡A±Æ¦W²Ä¥|¸¹¤Hª«¡A¦bÀq§JÃļt¡]Merck¡^°µ¹L°ÆÁ`µô¡A§ó¦b¥þ²y²Ä¤@®a§Q¥Î°ò¦]¤uµ{»sÃĪº°ò¦]¬ì§Þ¡]Genentech¡^¾á¥ô°õ¦æ°ÆÁ`µô¡A²`¿Ú·sÃÄ»s§@¹Lµ{¡C¥Ñ¥L¨ó§UÃĵءAÂåÃĹw®Æ±N±a»â¥xÆW¥Í§Þ·~¶i¤@¨B»P°ê»Ú±µy¡C ´§§O¦t©÷³±Åµ «ªð¥Í§Þ·~ ¡u¥L¬OÁú°ê¤T¬P³Ì·Q·mªº¤H¤~¡I¡vªL°êÄÁ¹D¥X·¨¨|¥Á¦b°ê»Ú¥Í§Þ¬Éªº¤À¶q¡Cì¨Ó¤T¬Pªñ´X¨Ó¤]¥¿¤j¤Oµo®i¥Í§Þ¡A¦³Áú°ê¬F©²°µ«á´©¡A¥|³B´M¤~¡A·¨¨|¥Á2013¦~¬K¤Ñ°h¥ð«e¤i¡A¤T¬P´N´¿¸g¥h«õ¨¤¡A°£¤FÁú°ê¡A¦Ü¤ÖÁÙ¦³¤j³°¡B·s¥[©Yªº¤Q´X®a¤j¤½¥q·mµÛ§ä¥L¡C http://store.gvm.com.tw/article_content_25571.html |
|
|
·|û¡Gaa18188810142040 µoªí®É¶¡:2016/9/7 ¤W¤È 11:20:11²Ä 609 ½g¦^À³
|
«¢«¢ ¦nªÑ²¼ ¦n¤½¥q ´N¬On¦³«H¤ß ©³³¡¦³¥[½X ·Ç³Æ¤Ï§ð ª½¹F¥ú©ú³» ·Ó³o¼Ë¬Ý §CÂI16¦h¦³¥i¯à¶R¤£¨ì¤F µ¥¤Q¤ë¤½§G¼Æ¾Ú ¦³¥i¯à´N¬Ý¨ì¤G¦rÀY¤F µØ¤ÍÌ¥[ªo |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/9/7 ¤W¤È 10:51:53²Ä 608 ½g¦^À³
|
¤µ¤Ñ©Ò¦³ªº´CÅé³£¦b³ø¥Í§Þ¤j©@·¨¨|¥Áªº½Í¸Ü¡A§ÚÌ¥ý¤F¸Ñ·¨¨|¥Á¬O½Ö¡C ¥Í§Þ¤j©@·¨¨|¥Á¡A¬°«e°ê»ÚÃÄ·~¥¨À¼Ã¹¤ó¡]Roche¡^¥þ²y§Þ³NÀç¹BÁ`µô¡A¥Ø«e¾á¥ôÃĵØÂåÃÄ¿W¥ß¸³¨Æ¡A±Mªø¬O³J¥Õ½èÃÄ¡B³æ®è§ÜÅ骺¥Í²£¡C 1948¦~¥X¥Íªº·¨¨|¥Á¡A¬O«e¥x¥_¥«ªø·¨ª÷ö檺ªø¤l¡A²¦·~©ó¥æ³q¤j¾Ç¡A«á¨Ó¥X°ê®³¨ì«X¥è«X¦{¥ß¤j¾Ç¹q¾÷³Õ¤h¾Ç¦ì¡F¥L´¿¥ô³q¥Î¡BÀq§J¡B°ò¦]¡]Genetech¡^¡Bù¤ó¤jÃļt¡A¬OµØ¤H¤Ö¦³ªº°ê»ÚÃļt¼h®p¤Hª«¤§¤@¡C http://money.udn.com/money/story/5629/1944780 |
|
|
·|û¡GAnderson10143089 µoªí®É¶¡:2016/9/7 ¤W¤È 10:03:44²Ä 607 ½g¦^À³
|
¦³¶}©l¥´©³ªº¸ñ¶H¡A¤£¤[À³¸Ó·|§j¤Ï§ð¸¹¨¤! |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/9/7 ¤W¤È 09:20:47²Ä 606 ½g¦^À³
|
ÃĵØ7/20¤WÂd¨´¤µ¦n¹³¨S¦³«G¬õ¿O¹L! ¥[ªo~ |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/9/6 ¤U¤È 10:36:02²Ä 605 ½g¦^À³
|
¤]¥Ñ©ó¹ï¤ñªºHydroxyurea ¯uªºÃĮĤӮt¤F ¸É¥R¤@¤U HÃĮĤ£®t ¦]¬°¥L¬O¦n Ãa ³q±þªºÃÄ ©Ò¥H¬O¦³¤£¿ùÀø®Ä ¥u¬O°Æ§@¥Î¤j ¥Î¤Ó¤[¨Åé·|¤£³ôt²ü |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/6 ¤U¤È 10:32:30²Ä 604 ½g¦^À³
|
¼@ÃÄ¡A¬rÃÄ? ¥@¬Éªº¨xŦ¾ÇÂø»xJournal of Hepatology ´£¨ì: ¨xª¢¤Þ°_ªº¨xµw¤Æ¡A¥un¤zÂZ¯À¥i¥HªvÀøªÌ¡A±wªÌªº¹Ø©R¥i¥H¸ò¤@¯ë±`¤H¤@¼Ë¡C ¦ý¬O§@ªÌ»{¬°:DAA(©Ò¿×ªñ´Á³ÌÉqªº¤p¤À¤lÃÄ)¡AÁaµM¥i¥H§â¯f¬rÀ£§C¤@¬q®É¶¡¡A ¹F¨ì©Ò¿×SVR¡A«o³Ì²×¦³·¥°ªªºP¦º²v¡C §@ªÌ¤H»{¬°:¥HSVR¨Ó°µµû¦ôÀø®Ä¬O¹ï¶Ü? https://www.sciencedaily.com/releases/2016/05/160504122020.htm §Ṳ́£¸Tn°Ý:³o¤@¨Ç§Ö³t¦³®ÄÀ£¨î¯f¬rªº DAA¡A¬O¼@ÃÄ?¬O¬rÃÄ? |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/6 ¤U¤È 10:15:26²Ä 603 ½g¦^À³
|
°ª¿vÀð ¼s¿n³ ½wºÙ¤ý ¤£¬Ýµu´ÁªÑ»ùªi°Ê¡A¤£n¨ü¥L¤H¨¥½×¥ª¥k¡A¦Û¤v»{¯u¤ã¹ê¬ã¨s¡A¬Û«H¦Û¤v! |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/6 ¤U¤È 09:05:37²Ä 602 ½g¦^À³
|
©Ò¦³¤HÅé¸ÕÅç¡A¥²¶·¸g¹L¼Ú¬wÃÄ«~ºÞ²z§½¡]EMA¡^ªº®Öã¡C¥]¬A¹êÅç¤H¼Æ¡B ±ý¹F¨ì¤§«ü¼Ð¡B¹êÅ礧¤è¦¡¡A§_«h¬F©²¤£»{±b¡A¦p¦ó¥Ó½ÐÃÄÃÒ? ¤@¯ë¹êÅ窺¤è¦¡§â¤H¤À¬°¹êÅç²Õ»P¹ï·Ó²Õ¡AªA¥Î¨âºØ¤£¦PÃĪ«°µ¹ï¤ñ¡C 1, open label ¶}©ñ ¨ü´úªÌ»P³Q´úªÌ³£ª¾¹D¨Ï¥Î¦óºØÃĪ« 2, single blind ³æª¼ ¨ü´úªÌª¾¹D¡A¦ý³Q´úªÌ¤£ª¾ 3, double blind Âùª¼ ³Q´úªÌ»P¨ü´úªÌ§¡¤£ª¾ ÃĵزĤT´Áªº¹êÅç¤è¦¡¬O¦¬256¤H¡A¹êÅç¤@¦~¡A±Äopen label¡A¦pªGÃĮĤ£¨Î¡A¦´Nª¾¹Dn¦¬Åu¤F¡C http://www.proud-pv.com/ P1101 PK Hydroxyurea ±q²Ä¤@´Á¡A¶}©l¤w¸g6¦~¤F¡A®ÄªG©_¨Î¡A³Ìªñ´X¦~¦X¹ÙªºAOP¤½¥q¥H¤Î¥@¬É¤Q´X°êªº¬ì¾Ç®a¡A ·|§â¨C¤@¦~§â¹êÅçµ²ªG¤½¥¬¦b¥@¬É³Ì¤jªº¦å²G·|ij¤W¤Î¬ÛÃöÂø»x¤W¡C®ÄªGÅåÆA¥þ¥@¬É¡C ¤]¥Ñ©ó¹ï¤ñªºHydroxyurea ¯uªºÃĮĤӮt¤F¡AP1101¦¤w»»»»»â¥ý¡CÁöµMÀò±o¼Ú·ùÃÄÃÒµ´¹ï¨S°ÝÃD¡C ¦ý¦è¤è¬ì¾Ç®a°µ¨Æ¡A¤@ªO¤@²´ªº¡A³W³W¯x¯xªº¨«§¹¬yµ{¡C ¬ü°êFDA¦P·N¥i¥H¥Î¼Ú·ùªº¼Æ¾Ú¥Ó½ÐÃÄÃÒ¡C |
|
|
·|û¡GET10143092 µoªí®É¶¡:2016/9/6 ¤U¤È 07:33:52²Ä 601 ½g¦^À³
|
½Ð°Ý¡G 1.Å¥»¡PV-3´Á¤£»Ý¦A¸Ñª¼¡A©Ò¥H¬O§_¥NªíPV-3´Á¤@©w¹L,¥u»Ý¤Q¤ë¤½¥¬3´Á¸ÕÅç¼Æ¾Ú§Y¥i 2.¥Ó½Ð¼Ú¬ü¤§ÃÄÃÒ¬O§_¤@©w·|¹L,¬O§_·|¦³¨ä¥L°ÝÃD¥d¦í ÁÂÁ |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/9/6 ¤U¤È 05:16:41²Ä 600 ½g¦^À³
|
¡i°ê»Ú¤jÃļt¦Ñ¤Æ ·¨¨|¥Á¡G¥xÆWªº¾÷·|¨Ó¤F¡j 2016-09-06 ¤u°Ó®É³ø°OªÌ§ù¿·»T ¡@«eù¤ó¤jÃļt¥þ²y§Þ³NÀç¹BÁ`µô·¨¨|¥Á¤W¤È¦bBTC¡]¥Í§Þ²£·~µ¦²¤¿Ôij©eû·|ij¡^¤¤ªí¥Ü¡A¥Í§Þ²£·~ªº¦X¨ÖÁö¬OÁͶաA¦ý¤jÃļt¦Ñ¤Æ¬ãµo¯à¶q´î§C¤]·|«ùÄòµo¥Í¡A¦Ó³o¨Ç³£¬O¥xÆWªº¾÷·|¡A¥xÆWÀ³¶X³oªi²£·~µ²ºc½Õ¾ã¤¤¡A§V¤O§ïµ½Àô¹Ò¡Aקïªk³W¡A·m¶i°ê»ÚÄv§Þ³õ¡C ·¨¨|¥Áªí¥Ü¡A10¦~«áªº¥@¬É¡A¬O¤@Ó¶W§Ö¶W¯à¹q¤l¹q«H¹q¸£¡B¶W°ª³tºô¸ô³sµ²¥þ²y¡B¦U¦¡¦U¼Ë¦Û°Ê¤Æ¡B¾÷¾¹¤H¨ú¥NªA°È¤Hûµ¥¡AÂåÀø¥Í§Þ³Ð·s«ùÄò¡B¥þ²y¤H¤f¦Ñ¤Æ«ùÄò¡Bºñ¯à³Ð·s¬ãµo¯à¶q¼Æ¿¡C ¥L«ü¥X¡A¥Í§Þ²£·~ªºÅܤƤ¤¡A²£·~¦X¨Ö¬OÁͶաA¥Í§Þ¦yºÝ·sÃIJ£¥X¡AÀù¯g¥i¥H§JªA¡A¦ý°ªÃÄ»ù¥i¯à¬O°ÝÃD¡A¦Ó¤jÃļt¦Ñ¤Æ¬ãµo¯à¶q´î§C¤]·|«ùÄòµo¥Í¡A¦Ó³o¨Ç³£¬O¥xÆWªº¾÷·|¡A¥xÆW¤£·|³Ð³y¤@Ó¦n´X¸U¤Hªº¤j«¬Ãļt¡A¦ý¾Ö¦³´X¦Ê¤Hªº³Ð·s¤½¥q¡A«h¬O¥xÆW¥Í²£·~¥i¥H«e¶iªº¤è¦V¡A¤]¬O¥xÆWªº°Ó¾÷¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/9/6 ¤U¤È 05:12:00²Ä 599 ½g¦^À³
|
²©öª©¦p¤U ¤¸¤j-(ÃĵØÃÄ) drive.google.com/file/d/0B4i_vGrdIb-ULVM2V3p0THNLSFk/view |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/6 ¤U¤È 04:50:23²Ä 598 ½g¦^À³
|
¥Ø«eKGIªº³ø§i¸û§¹¾ã www.sendspace.com/file/wmtxs5 |
|
|
·|û¡GAnderson10143089 µoªí®É¶¡:2016/9/6 ¤U¤È 01:54:02²Ä 597 ½g¦^À³
|
½Ð°ÝP1101¥Î©óªvÀøPVªº¨C¦~¼ç¦bEPS¬O¦h¤Ö? ¦³¬ã¨s³æ¦ìºâ¹L¶Ü? |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/6 ¤U¤È 12:55:40²Ä 596 ½g¦^À³
|
»{¦P+1 §Ú¤£´±»¡6446ªÑ»ù·|¯}¤d¤¸¡A¦ý¦Ü¤Ö©¹¥Í§ÞªÑ¤ý¾aªñ¤@©w·|¦³¾÷·|ªº~~~~µØ¤Í¥[ªo |
|
|
·|û¡G¤pÃÄ®v10142475 µoªí®É¶¡:2016/9/6 ¤U¤È 12:11:31²Ä 595 ½g¦^À³
|
«D±`·PÁµL¤j¦b¦Uª©¼ö¤ßªº¤ÀªR¡A¤p§Ì¤£À´§Þ³N±¡A¦]¬°¬Ý¦n°ò¥»±¡A©Ò¥H¤@ª½¨S¦³¥X³õ¡C¦ý³o°}¤l¥u¶^¤£º¦¡AµLªk§PÂ_·|¶^¨ìþ¸Ì¡A©Ò¥H¤]¤£´±¶TµM¦A¥[½X¡C½Ð°ÝµL¤j¨Ì·Ó§Þ³N±¦p¦ó§PÂ_¸¨©³¡A¥H¤Î¥[½Xªº®É¾÷©O¡H |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/9/6 ¤W¤È 11:50:02²Ä 594 ½g¦^À³
|
6446.. 1.¥ý½T¥ß°ò¥»±µL»~,¤´¬O´Â¥¿¦Vµo®i¦Ó«ùÄò¦V¤W.. 2.·íªÑ»ù²Ä¤@¦¸¨Ó¨ì¦~½u®É,¦~½u¤è¦V¥²©w¬O´Â¤W(§Y¨Ï¬O¦~½u¥Ñ¤WÂà¤U).... ¦¹®É,·í½T¥ß1µL»~,¨º1¦~ªº¥§¡¦¨¥»(¦h¤èÄw½X)´N¦b¦¹.. ªÑ»ù¤£ºÞ¬O¸I¦~½u©Î¬Æ¦Ü¶^¦Ü¦~½u¥H¤U,¥un1µL»~,¨º³£¬O²Å¦Xªø½u§ë¸ê»ùȪº½d³ò.. Y¬O¦p¦¹.. ¨º·íªÑ»ù¶^¯}¦~½u¥H¤U,³o¦bÄw½X±©|ºÙ§@..¥D¤O¬~½L+¶}©l¥´¸É§l³f..§Þ³N±¤W,´N·|¦³¸¨©³¼x¥ü»PºCºC¿v¥X©³³¡«¬ºA¨Ó(¥]§t¾÷²v§CªºVÂà).. ¦³¨Ç¾Ç§Þ³N±ªÌ,¦]¬°¨S¦³¾Ç²ß°ò¥»±©Î´x´¤°ò¥»±,±`±`·|¥H¬°¥un¤W´ªº¤¤ªø´Á§¡½u«ùÄò¤W´,ªÑ»ù¨Ó¦¹,´N¤@©w¤î¶^? µ²ªG,ªÑ»ù«ùÄò¶^¯}¤¤ªø´Á§¡½u,¤Ï¼u«á,¤]µLªk¦A«·s¯¸¦^,´N¤@ª½©ê,©ê¨ì¤¤ªø´Á§¡½u§Î¦¨¦º¤`¥æ¤e¦Ó§Î¦¨±j¤O»\ÀY¤ÏÀ£.. ªÑ»ù´N¦¹¤@Ãݤ£®¶,«ùÄò©¹¤U¯}©³..¶^¨ìÀY¥Öµo³Â..¤~¨Ó©Ç§Þ³N¤ÀªR®Ú¥»¤£·Ç.. ¬Oªº..´N§Þ³N±¨Ó»¡..¬O¤£·Ç.. ¦ý,¯Â§Þ³N±ªÌ,´Nnª¾¹D§Q¥Î§Þ³N±¨ÓÄY®æ°±·l,·í¦~½u©Î¤¤ªø´Á§¡½u¨Ó¦Ó¶R¶i,·íªÑ»ù½T¥ß¶^¯},´N¸Ó¥ß§Y°±·l,¥²¶·µ¥«ÝªÑ»ù½T¥ß«¦^§¡½u¥H¤W..³o¬O¯Â§Þ³N±¾Þ§@ªÌ¤@©wnÄY®æ°õ¦æ.. ¤d¿ù¸U¿ù,¨ä¹ê³£¬O¦Û¤vªº¿ù.. §O©Ç²z½×¿ù,n©Ç¦Û¤v¨S·Ó°µ.. ¦Ü©ó6446,·|¤£·|¨ì¤d¤¸..(¦³¤H»¡..©ú¦~´N¬Ý¨ì©Ô..³o¥i¬On¦³¥i¥H»¡ªA¤Hªº¨Ì¾Ú) §ÚÁÙ¬O³o¼Ëı±o.. ½Ð±N°ò¥»±¥J²Ó½¶}¨Ó,¥J²Ó¥hµû¦ô¥«³õ³W¼Ò»P¥i¥H¹w¨£ªºÀò§Q, ·íÃÄÃÒ¨ú±o,´N¬O¶}©l¹ê²{EPS.. ´Nºâºâ§a.. ¥H¤W°Ñ¦Ò |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/9/6 ¤W¤È 11:31:28²Ä 593 ½g¦^À³
|
¬Ý¨ìÃĵئb104¨D¤~:°w¾¯¼t¥DºÞ¤Î¤uµ{®v... ¬Ý±o¥X¤½¥q§G§½·Ç³Æ¶i¦æ¤¤! |
|
|
·|û¡Gªü³Ç10139080 µoªí®É¶¡:2016/9/6 ¤W¤È 11:12:59²Ä 592 ½g¦^À³
|
¤p°¨¤j+1 »{¦P¤p°¨¤j¡A¦nªº¤½¥q·í®É¶¡¨ì®É¦ÛµM´N·|ÁÙ6446¤½¹D¡A °O±o¥h¦~8¤ë6510ªºªÑ»ù¶^Ë156.5¤¸¡A¤@¦~«áªº¤µ¤ÑªÑ»ù1100¤¸¥H¤W¡C§Ú¤£´±»¡6446ªÑ»ù·|¯}¤d¤¸¡A¦ý¦Ü¤Ö©¹¥Í§ÞªÑ¤ý¾aªñ¤@©w·|¦³¾÷·|ªº~~~~µØ¤Í¥[ªo |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/6 ¤W¤È 08:32:48²Ä 591 ½g¦^À³
|
°ò¥»±¤~¬O³Ì«nªº MÀY§â¥¦Ë¹L¨Ó¬Ý,¤£¦¨W©³¶Ü? ¦³©³¤lªº¤½¥qºÞ¥¦n¦p¦óº¦¶^? ¸Õ·Q ¥h¦~ªº³oÓ®ÉÔÃĵتѻù40¦h¤¸,¦p¤µ160¦h¤¸ ¦U¦ì¦³·Q¹L¶Ü? ©ú¦~ªº¦P¤@®É¶¡,ªÑ»ù¦³¥i¯àÅÜ1600¦h ¦³¥i¯à¶Ü? ¤j®a§O§Ñ¤F ªÑ»ù³£·|¥ý¦æ¤ÏÀ³ ¨ì®Éº¦±o¤S«æ¤S²r,³s·Q¸õ¤W¨®ªº¾÷·|³£¨S¦³ |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/5 ¤U¤È 10:36:35²Ä 590 ½g¦^À³
|
·PÁµL¤j¤jªº¯¬ºÖ~ §ë¸êÃĵاڥ»¨Ó´N·Q°µªø´Á¡A¦ý¦bµL¤j´£¥Xªºªi®ö²z½×®É¡A§Ú¤]¥»·Q¤pÀò§Q¤Fµ²¡A¦ý£¸ª½¨S°µ¡A·Q»¡½æ¤F©È°l¤£¦^¡A¦ý¤£½æ¤S©È°l°ª¡A³o´N¬O§Ú³o¤p´²¤áªº´d«s¡A¬JµMµLªk°µµu´Á®M§Q¡Aˤ£¦p°µªø´Á§ë¸ê¤F¡A£¸¼Ë±j½Õ°ò¥»±¤£ÅÜ¡A©ú¦~pvÃÄÃÒ¨ì¤â,2019¦~ET¤Îc¨xÃÄÃÒ¤]¨ì¤â¡A¤½¥q¦³¹ê½èªºÀò§Q¡A´N¤£©ÈªÑ»ù¤£¬Û®¼¤F¡C |
|
|
·|û¡GLordTA10143086 µoªí®É¶¡:2016/9/5 ¤U¤È 08:24:16²Ä 589 ½g¦^À³
|
¦U¦ìµØ¤Í̦n¡A¤p§Ì¼ç¤ô¤w¤[¡A¤]¬O³Q®M¦b186¥ª¥k...§Æ±æ¤j®a¤@°_¦@Åé®ÉÁ}¡A¦³¹Ú³Ì¬ü§Æ±æ¬ÛÀH~ |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/9/5 ¤U¤È 07:59:58²Ä 588 ½g¦^À³
|
Y°ò¥»±¤£Åܪº¸Ü §Ú·|ªø´Á«ù¦³ §V¤O¤u§@Åý¦Û¤v²{ª÷¬y¤£Â_ ³]©w¦b2020¦~.5¦~¥ª¥k§a 5¦~«á..... ¥[ªo ¦U¦ìµØ¤ÍÌ ucss¤j... ´N¬O³o¼Ë¤l©Ô...Æg°Õ °ò¥»±¤~¬O³Ì«nªº,§Þ³N±¥u¬O¶i¥X¥Îªº.. Äw½X±·|§ïÅܧ޳N±,¤×¨ä¬O¤H¬°¨è·N³Ì©úÅã.. §Þ³N±¤W,¤×¨ä¬Oµu´Á¶¡¤ºªº¦æ±¡ªi°Ê,³Ì·|¨ü¤H¬°¨è·NÄw½X¨Ó§ïÅÜ, ¦ý§Þ³N±¦³Ó¦n³B,¥i¥HÁÈ´«§ó¤j¯Å¼Æªº´`Àô¨Ó¬ã§P,¦p©P.¤ë.. ¥un°ò¥»±¥¼ÅÜ,©ú¦~¼Ú¬wÃÄÃÒ±Nn¨ú±o.. ´N¸Ó¥H¤Î¼Æ¤jªº§Þ³N±¨Ó»²¦õ,¥Hªø½uªº§ë¸ê¨¤«×¨Ó¤Á¤J.. ¦~½u¦ÜÀò¥H¤U..³£¬O¥i¥HºCºCªº,¥H§ë¸ê¨¤«×¨Ó§G§½.. ¤ß¾iªø»P¤½¥q°ò¥»±¬°¤@Åé.. ³Ì²×ªº¤jĹ®a,¤@©wÄÝ©ó±zªº... ¯¬ºÖ±z.. |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/5 ¤U¤È 05:43:47²Ä 587 ½g¦^À³
|
ªÑ»ù¥»¨Ó´N¦³º¦¦³¶^ ¥~¸êor¥D¤O§ÚÌ´²¤á¬O°µ¤£Ä¹ªº ¤§«eµL¤j©ÒÁ¿ªº5®öº¦¦Ü233.4,·|¦^´ú¦~½uªþªñ (¯u·Ç)¦ý (¤¤ªø´Á»ùȧë¸ê¯B²{)Y¦~½u159¯u¦u¤£¦í ¥i¯à±j¶Õ¦^ÀÉ×¥¿¤§0.382,¬ù125¤¸¤]»¡¤£©w(§Ú·|¦s»È¼u¨Ã«ùÄò¥[½X) ¦p¦ó½Õ¾ã¦Û¤vªº¤ßºA´N¬Ý¦Û¤v¤F.§Ú¥i¯à¤ñ¸û²Â Y°ò¥»±¤£Åܪº¸Ü §Ú·|ªø´Á«ù¦³ §V¤O¤u§@Åý¦Û¤v²{ª÷¬y¤£Â_ ³]©w¦b2020¦~.5¦~¥ª¥k§a 5¦~«á..... ¥[ªo ¦U¦ìµØ¤ÍÌ |
|
|
·|û¡G½ä®{10141199 µoªí®É¶¡:2016/9/5 ¤U¤È 04:33:53²Ä 586 ½g¦^À³
|
¥~¸ê³s¤»½æ¡A¥~¸ê«ùªÑ¤ñ¤WÂd«eÁÙ¤Ö¡A¨ì©³«ç»ò¤F¡A³o»ò¤£¬Ý¦n |
|
|
·|û¡Gªü³Ç10139080 µoªí®É¶¡:2016/9/5 ¤U¤È 04:19:37²Ä 585 ½g¦^À³
|
Y¬O°ò¥»±¨SÅܪºª¬ªp¤U¡Aº¥ý159¤¸¤£¯à¯}¡AY¯à¦u¦í´N¯à¥H©ì®É¶¡«ÝÅÜ¡A¦ý¸U¤@¯}¤F~´Nn¦u¦í¥h¦~11/30¨ºÓ¤j¶q°Ï¶¡¡A¦u¶V¤[¤Ï§ðªº®É¶¡ÂI´N¶Vªñ¤F~~~ |
|
|
·|û¡Gadigo10135839 µoªí®É¶¡:2016/9/5 ¤U¤È 01:49:47²Ä 584 ½g¦^À³
|
¯uªº¬OÅÛ¤ý¡B¦n¤£®e©ö©Ô¦^1¤Ñ¡B¥i¥H¦³Ä~Äò¶^¦n´X¤Ñ¡I |
|
|
·|û¡Gsk2man10142897 µoªí®É¶¡:2016/9/5 ¤U¤È 01:24:37²Ä 583 ½g¦^À³
|
¥Ø«e¨Ì·Ó°¶¤j¤jµ¥µØ¤Í̪º¸ê®ÆÃD¨Ñ¡A³£¬O¦³¥¿±©Ê½èªº®ø®§¡A¥i¬OªÑ»ù½T¬O¨S¦³°_¬ð¥Xªí²{¡A¸Ó¤£·|µo¥Í¤°»ò¨Æ±¡¡H§Æ±æ¤Ñ¯§¦U¦ìµØ¤ÍÅK¯»Ì¡A´Á«ÝÃĵدuªº¦¨¬°¥Í§ÞªÑ¤ý¡I |
|
|
·|û¡GRabbit Kin10141833 µoªí®É¶¡:2016/9/5 ¤U¤È 12:34:07²Ä 582 ½g¦^À³
|
¯u·d¤£À´¡A¬°¦ó¦Ü±q¤WÂd«á¡AªÑ»ù´N¤@ª½®z¡A³s¤µ¤Ñ¤j½L©M¥Í§ÞªÑ(¥]¬A¯E¹©)³£ªí²{¤£¿ù¡A°ß¿WÃĵؼ¬±|... ¥Í§ÞªÑ¤ý¡H¥xªÑªÑ¤ý¡H²{¦b¬O¦bÁ¿þ¤@¤ä..... |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/9/5 ¤W¤È 07:49:07²Ä 581 ½g¦^À³
|
ªÑ»ù°_°_¸¨¸¨¤D«Y¥¿±` ¦ý°ò¥»±ªººt¤Æ Ãĵؤw¨ã³Æ¤F·í¥Í§ÞªÑªºªÑ¤ý¤D¦Ü¥xªÑªÑ¤ýªº°ò¦ ®É¶¡¤@¨ì¥²¤ô¨ì´ë¦¨ |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/4 ¤U¤È 10:05:28²Ä 580 ½g¦^À³
|
³o¤@¨ÇDAAªº¯ÊÂI¤wÅܦ¨¤@ºØ¦@ÃѤF¡A¤@©wn°t¦XP1101¤~¦³©ú¤Ñ¡C ½Ð¬Ý¥t¥~¤@½g³ø¾É¡A¼g±o§ó¸Ô²Ó: Direct-Acting Antiviral Treatment Linked with HCC Recurrence for Patients with Hepatitis C Infection - See more at: http://www.targetedonc.com/publications/hcc-monitor/2016/june-2016/direct-acting-antiviral-treatment-linked-with-hcc-recurrence-for-patients-with-hepatitis-c-infection?p=2 |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/4 ¤U¤È 09:46:49²Ä 579 ½g¦^À³
|
ÁÂÁ°¶¤j¤jªº¤À¨É~ ¤µ¦~³¯°öõÂå®v´N´¿¸g´£¥X®Ú¾Ú¤é¥»³Ìªñ´X¦~ªº¬ã¨s ¤p¤À¤lÃĪ«¦bªvÀøC¨x¤§«á¡Aªí±¤W¬Ý¨Ó¦ü¥G²¬Â¡¤F¡A¦ý¸g¹L´X¦~«á±o¨ì¨xÀù(º¦¸«D´_µo)ªº¤ñ¨Ò¤Ï¦Ó¬O¶Ç²Î¤zÂZ¯Àªº 3-4 ¿ ¦Ó³o½g¼Ú¬w¬ã¨s¬Ý¨Ó¡A¬O쥻±o¹L¨xÀùªº´_µo¾÷²v¤]¬O·|¤j´T´£°ª ¦ü¥G¨È¬w¨ì¼Ú¬w³£¶}©lµoı¶W¯Å¤Ñ»ùªº¤p¤À¤lÃĪ«ªvÀøC¨x¨Ã¤£¬O¨º»ò¯«¤F.... ¤p¤À¤lªvÀø³o´X¦~¦¨¬°ªvÀøC¨xÅã¾Ç¡A¦ý¬O¥Ñ©óÁÙ¬O«Ü·sªºÀøªk¡A¨S·Q¨ì³o¨â¦~¶}©l¬ã¨s½×¤å³°Äò¥X²{·íªì¨S·Q¨ìªº«áÄò¤ÏÀ³ ©Ò¥HÁÙ¬O¦^Âk¶Ç²Î¤zÂZ¯À¤ñ¸û¦w¥þ¡A¦Ó¥B»ù®æ¤]«K©y³\¦h¡A«ÂI¬O¥H«e¥«±¤W¨S¦³¨¬°÷¦nªº¤zÂZ¯À¡A ¦ý¥¼¨Ó³Ì±µªñ¤W«Òªº¤zÂZ¯À§Y±N°Ý¥@¤F~ |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/4 ¤U¤È 08:54:22²Ä 578 ½g¦^À³
|
ĵ³ø! ª½±µ§@¥Î§Ü¯f¬rÃĪ«(direct-acting antiviral agent, DAA) ªº¬ãµo¤£Â_¶i®i¡A ¥þ¤fªA§K¥Î¤zÂZ¯ÀªºªvÀø¡A¥i´£¨ÑÁ{§ÉÂå®v»P¯f±w¹ï§ÜC «¬¨xª¢¤@¶µ·sªº¿ï¾Ü¡C ¦ý¬O¹L©ó«æ©ó¤W¥«¡A²{¦b«á¿ò¯g¤w¤@¤@¯B²{¡C ¦]¬°ªvÀøC¨xªº³o¤@¨Ç©Ò¿×¡¨¯«©_ÃĪ«¡¨¡A¸g¹L³o´X¦~ªº¹êÃÒµ²ªG¬ÛÃö³ø¾É¤w¤@¥ó¥óºCºC¯B²{: ¦bªvÀø´Á¶¡¡A¥Ñ©ó±wªÌ·|§K¬Ì¤O¤U°¡A©ó¬Oì¥ý¤w±±¨î¦íªº¯f¬r¤j´_¬¡¡A¦p±o¹L¨xÀùªÌ¡A ì¥ý¤w±±¨î¦í¡A¥i¬O¬°¤FªvÀø¡¨C«¬¨xª¢¡¨¡A¨Ï¥Î³o¤@¨Ç©Ò¿×¡¨¯«©_ÃĪ«¡¨DAA¡A «æ©ó§â¡¨C«¬¨xª¢¡¨¯f¬r¹F¨ìSVR¡Aµ²ªG¨xÀù´_µo¡A²{¦b¤w³°³°ÄòÄòµo²{¡C ©Ò¥H¤@©wn¥Î¤zÂZ¯À¡AP1101±N¬OªvÀøC¨xªº¥@¬ö¤§ÃÄ¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/4 ¤U¤È 08:46:43²Ä 577 ½g¦^À³
|
Alarm over Cancer Recurrence after DAA Treatment Conference Coverage > EASL 2016 Apr 15, 2016 | Gale Scott Despite all the good news about direct-acting antivirals for treatment of hepatitis C virus (HCV) infection researchers from Italy have sounded a note of alarm. In a study fast-tracked for publication today in the Journal of Hepatology, a research team found that patients with a prior history of hepatocellular carcinoma (HCC) and treated with DAAs are having a higher than expected rate of cancer recurrence. Further, those cancers came back within a few months. The recurrence rate in some subgroups has been over 40%. In their conclusion in the journal article, the researchers said ¡§Our data show an unexpected high rate and pattern of tumor recurrence coinciding with HCV clearance and, though based in a very small cohort of patients, should be taken as a note of caution and prime a large scale assessment that exceeds the individual investigators capacity¡¨. The study authors believe the recurrences could be a result of having a weakened immune system following DAA therapy. ¡§Something is going here,¡¨ said Jordi Bruix a professor at the Barcelona Clinic Liver Cancer Group, Hospital Clinic Barcelona, discussing the alarming findings in a session today at the International Liver Congress in Barcelona, ¡§But nothing in life is without risk.¡¨ HCC is the most common form of liver cancer worldwide. According to the World Health Organization, liver cancer accounts for 662,000 deaths and is the third leading cause of cancer-related death, exceeded only by cancer of the lung and stomach. Approximately 75% to 80% of cases of HCC occur in Asia, however, there is considerable variation within continents. The overwhelming majority of HCC cases occur in patients with chronic liver disease, where approximately 80% to 90% have cirrhosis and most of the remainder have moderate to advanced fibrosis. ¡§Interferon-free regimens in particular are now being studied in many patient cohorts including those with other pre-existing disease such as HCC. Our data, even though from a relatively small number of patients, are so striking that it clearly signals we must exercise caution in the use of these agents in such patients, at least until data from further large-scale assessments are available,¡¨ Bruix said. The study included 103 patients across four hospitals who had HCV infection and a prior history of HCC. Of these, 58 patients had achieved complete response after treatment of their cancer and met inclusion criteria for the study. Baseline characteristics, laboratory and radiologic tumor response were registered in all patients before starting antiviral therapy and during the follow-up, according to the clinical practice policy. After a median follow-up of 57 months. Three patients died and 16 (27.6%) developed tumor recurrence. Median time between antiviral treatment and detection of recurrence was 3.5 months. "It is important that hepatologists continue to weigh up the risks and the benefits of DAA treatment for each individual patient, as these drugs are still relatively new.," said Massimo Colombo, Professor of Gastroenterology at the University of Milan, Italy and former Editor-in-Chief of the Journal of Hepatology. - See more at: http://www.hcplive.com/conference-coverage/easl-2016/alarm-over-cancer-recurrence-after-daa-treatment#sthash.7e4AMQbd.dpuf |
|
|
·|û¡Gsk2man10142897 µoªí®É¶¡:2016/9/4 ¤U¤È 01:36:21²Ä 576 ½g¦^À³
|
To ®Ç¤j¡G ¤@¦±¨x¸zÂ_¡AªÑ®ü¦ó³B³V§CÂI... »´ÃP¤@¤U¡A³Õ§g¤@¯º.... |
|
|
·|û¡G®ÇÆ[ªÌ10141545 µoªí®É¶¡:2016/9/4 ¤W¤È 09:37:13²Ä 575 ½g¦^À³
|
·PÁ¤j¤j̪º±M·~ª¾ÃÑ Ó¤H·Qªk ·Q¹³»ù®æ¨ì¨Ó....¦A¦ÊªÑ¿¼Æ¶R¶i »{¯uªº¤½¥qnµ¹¥L«öÆg.....¶}ªáµ²ªG«Ü§Öªº¤@®a¤½¥q ¤Ï¦V«ä¦Ò....¦pªG¥¼¨ÓªÑ»ù¦A¤U¬Ý110.....@¤ßµ¥¤U¤@¬q²M§ó¦hÄw½X....²{ª÷µ¥¦o¨ì¨Ó ·ÀI°³Ì§C@¤ßµ¥«Ý... ¦^Àɪº¦ÒÅ礤.....´Á«Ý¤j¤j̳£¥iÀò§Q |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/9/3 ¤U¤È 01:31:44²Ä 574 ½g¦^À³
|
105¦~4¤ë8¤é³Ì«á¤@Ó¯f¤HªvÀø§¹¦¨¡A ÃÒ¥æ©Ò«¤j°T®§¤½§i (6446)ÃĵØÃÄ-´CÅé³ø¾É»¡©ú 1.¨Æ¹êµo¥Í¤é:105/07/26 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.¶Ç¼½´CÅé¦WºÙ:¤u°Ó®É³øµ¥´CÅé 6.³ø¾É¤º®e: ÃĵØÃÄÄ~¦å²G¯e¯f±À¥X¥þ²y²Ä¤@Ó¥H·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¤w¸g§¹¦¨¤T´Á¤HÅéÁ{§É¸ÕÅç¡A¨Ã¿n·¥·Ç³Æ¤À§O¦V¼Ú·ùEMA¥Ó½Ð¦æ¾P³\¥i¡]MAA¡^¥H¤Î¬ü°êFDA¥Ó½Ð¥Íª«·sÃij\¥i¡]BLA¡^¥~¡A¦P®É¦b·P¬V¯e¯f»â°ìªvÀøC«¬¨xª¢GT2·sÃĤ]¤w±À¶i¥x¡BÁú¤T´ÁÁ{§É¸ÕÅç¡C 7.µo¥Í½t¥Ñ:´CÅé³ø¾É»¡©ú 8.¦]À³±¹¬I: ¥»¤½¥q·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¡A¸Ó·sÃÄP1101±ÂÅv¤©¶ø¦a§QAOP Orphan Pharmaceuticals AG(¥H¤U²ºÙAOP¤½¥q)©ó¼Ú¬w14Ó°ê®a¶i¦æ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A104¦~2¤ë¦¬®×§¹¦¨¡A105¦~4¤ë8¤é³Ì«á¤@Ó¯f¤HªvÀø§¹¦¨¡A¥Ø«e¾ã²z¤T´ÁÁ{§É¼Æ¾Ú¡A¨Ã¿n·¥·Ç³Æ¤À§O¦V¼Ú·ùEMA¥Ó½Ð¦æ¾P³\¥i¡]MAA¡^¥H¤Î¬ü°êFDA¥Ó½Ð¥Íª«·sÃij\¥i¡]BLA¡^¡CªvÀøC«¬¨xª¢GT2·sÃĤ]¤w±À¶i¥x¡BÁú¤T´ÁÁ{§É¸ÕÅç¡A¬ÛÃö°T®§¥i°Ñ¦Ò105.1.17¤Î105.3.10¥»¤½¥q«°T¤½§i¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/9/3 ¤U¤È 12:17:50²Ä 573 ½g¦^À³
|
How far it can go ¤pªL¥S©Ò´£PROUD-PV(ÃĵػPAOP¦X§@ªº¹êÅç) ¥h¦~¤G¤ë¦¬®×260¤H§¹¦¨¡A¨ì¤µ¦~4¤ëªì³Ì«á¤@¥¼¯f¤H§¹¦¨¤@¦~ªvÀø¡C ²Ä¤T´Áº¡¤@¦~¡A¹êÅçµ²§ô¤w¸g¥i¥H´£¥X¥Ó½ÐÃÄÃÒ¡CP1101 PK Hydroxyurea¦n¹³NBA²yûPK °ê¤¤¥Í¡A¦Ó¥B¹êÅç±ÄOpen label ³Ót¦¤wª¾¹D¡C ²{¤w±K¶°¾ã²z¡B¤ÀªR¸ê®Æ¤¤¡]¹M¤Î¥þ¼Ú¬w60¦hÂå¾Ç¤¤¤ß¡^¡A¦]¬°«Y¦h«ü¼Ð¼Æ¡A¥BÂå¾Ç¤¤¤ß¤À´²¼Ú¬w14°ê¡AÀ³·|¾¨³t´£¥X¡A³o´Nn¬ÝAOPÃĵتº¦æ¬F¯à¤O¡I©Ò©¯AOP¦h¶µ¦¨¥\¸gÅç(¦³¤ÓÃĦ¨¥\¸gÅç)¡A¾r»´´N¼ô¡C ¹wp¦~©³«e´N¥i¦V¼Ú·ùEMA,©ú¦~ªìÃĵئV¬ü°êFDA´£¥X¦æ¾PÃÄÃҥӽСC ©Ò¥H¥Ó½ÐÃÄÃÒ¤§®É¶¡¡AEverything is under control. ²Ä¤@¤Î²Ä¤G´Á¹êÅç¤wÀòµý¹ê¥B°ò©óÃĮĤӦn¤F¡]±q³Ì¦²Ä¤@¦ì¹êÅçªÌ¶}©l¤w¶W¹L¤¦~¡^¡A©Ò¥HEMA¦P·NÅýAOP°w¹ï¦b°Ñ¥[ÖפT´Áªº260¦ì¤¤¶W¹L¬I¥´P1101¤@¦~ªÌ¤¤¤§130±wªÌ«ùÄò°Ñ»P¤HÅé¹êÅç¡B³o¬O¬°¤F¶i¤@¨BÁA¸ÑP1101,How far it can go, ¬O§_¦³¦h¤Ö¤ñ²v§¹¥þªv¡PV¡]PV¥»¨´N¬O¤@ºØ«ÜÃøªvªº¦åÀù¡A¤@ºØJAK2°ò¦]¬ðÅÜ¡^¡A ³Ìªñ¤S±N°Ñ»P¯f±w±q130¼W¥[ªv170¤H¡A³oµ´¹ï¬O«¤j§Q¦h¡Cªí¥Ü260¯f±w°ª¤ñ²v»{¦P¡A¦³§ó¦h¤H¦ÛÄ@°Ñ¤©¡C³o¤]ªí¥ÜP1101°Æ§@¥Î¤p¡A®ÄªG¦n¡A¤~¦³³o¦h¤ñ¨Òªº¤HÄ@·N¦A¦¸°Ñ¤©¡C ¥H«á´N¥i¥H¦bÃIJ°¤W¼g»¡¡G¥i¥H«ùÄò¥´2¦~3¦~©Î§ó¦h¦~¡A ©Ò¥H³oConti¹êÅç¹ï¤½¥q¥¼¨Ó¦æ¾P¡B¦¬¤J¤W¬O¤@项¤F¤£°_ªº§Q¦h¡C, |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/3 ¤W¤È 10:48:09²Ä 572 ½g¦^À³
|
Walden¤j¡A ÁA¸Ñ¡AJakafi¥¼¨Óªº»ùÈÀ³¸Ó¬O¦bGVHDªº¶}µo¡C »¡¨ìCONTI-PV trial¡Aè¬Ý¨ì7/14§ó·sªºª¬ºA¡A©Û¶Ò¤H¼Æ±q쥻ªº130¤H(anticipated)¡A§ó·s¬°170¤H(actual)¡APROUD-PVªº256¤H¦³170¤HÄ~Äò°Ñ»PCONTI-PV¡A¤ÏÀ³¦ü¥GÁÙ¤£¿ù¡C |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/3 ¤W¤È 09:57:46²Ä 571 ½g¦^À³
|
¤pªL¤j RESPONSE-2 ¥u¬O RESPONSE trial ªº©µ¦ù¡A¨Ã¨S¦³Ô£¯S§Oªº ¥¦¤´Â¬O¤@Ó¤G½u¥ÎÃÄ AOP phase II ¤§«áªºCONTI trial³£¤ñ¥L¼F®` p1101 ¦¨¬°¤@½u¥ÎÃÄ«á¡AJakafiªº¤G½uÃÄ¥«³õ·|¨ü¼vÅT ¤p¤À¤lÃÄ»Ýn¨C¤ÑªA¥Î¡A²×¨ªA¥Î.... ³o¹ï¯f¤HªA±q©Ê¬O«Ü¤jªº¼vÅT¡A¦Ó¥B§O§Ñ¤F¤]¬O¦³³\¦h°Æ§@¥Îªº ³o¸ò¨C¨â©P¬Æ¦Ü¨CÓ¤ë¦Û¦æ¬I¥´¤@°w¤zÂZ¯À¬Û¤ñ¡A®t¤Ó¦h¤F BTW , Jakavi¤µ¦~À³¸Ó¥i¥H°µ¨ì 14»õ USD ªºÀ禬 ¡A°â»ù¦b 12-13 ¸U USD /¦~ |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/3 ¤W¤È 12:53:39²Ä 570 ½g¦^À³
|
°¶¤j¤j¡AWalden¤j¡A «Ü´Îªº¨£¸Ñ! ¥t¥~«e°}¤lIncyteµo¥¬¤F¥t¤@ÓPV¤T´Á´Á¤¤µ²ªG(Response-2 Trial)¡A§Ú¬O¬Ý¤£¥X¥¦¹ï¥Ø«eJakafiªºPVÃÄÃÒ¯à¦A³Ð³y¦h¤Ö»ùÈ(¨ÌµM¬O¤G½u)¡A¤£ª¾¹D±z̦³¦ó¬Ýªk? Incyte¡¦s Jakafi Positive in Phase III for Polycythemia Study by Zacks Equity Research Published on June 10, 2016 | Incyte Corporation (INCY) announced new 28-week data from a phase III study (RESPONSE-2) on Jakafi for the treatment polycythemia vera (PV). The multi-center, open-label, randomized study evaluated the safety and efficacy of Jakafi, in comparison to the best available therapy, in patients with PV who are resistant to or intolerant of hydroxyurea, dependent on phlebotomy for hematocrit control and do not have an enlarged spleen. Data from the study demonstrated that 62% of patients treated with Jakafi achieved hematocrit control without phlebotomy, compared to the 18% of patients treated with the best available therapy. Results were presented at the Congress of the European Hematology Association. Jakafi was generally well tolerated. Results from the RESPONSE-2 study were consistent with data from the RESPONSE study, which evaluated patients suffering from inadequately controlled PV with an enlarged spleen. We note that Jakafi is currently approved in the U.S. for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The company recorded Jakafi sales of $183.3 million in the first quarter of 2016, up 58.9% year over year. |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/9/2 ¤U¤È 11:49:15²Ä 569 ½g¦^À³
|
³oÁûÃĪº°ÝÃDÁ٫ܦh¡A¦Ó¥B´Nºâ¦³¼vÅT¤]¬O¼vÅT¨ì incyte Jakafi ¥Î¦bªvÀø MF ¯e¯f µ¥P1101 °Ý¥««á¡APV / ET ¬O¥i³Qªv¡ªº¡Aªø´ÁºtÅܦ¨ MFªº¯f±w·|¶V¨Ó¶V¤Ö...¦]¬° P1101 ¤w¸g¦b¤W´å´N§â¥¦ªýÂ_¤F ¦P¼Ëªº B/C ¨xªv¡ ¤]¥i¥H¤j¤j¦a°§CºtÅܦ¨¨xÀùªº·ÀI... ¦nÀ¸ÁÙ¦b«áÀY ~ |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/2 ¤U¤È 11:36:31²Ä 568 ½g¦^À³
|
http://www.curetoday.com/articles/pacritinib-for-myelofibrosis-placed-on-full-clinical-hold §ä¤F¬ÛÃöªººô¯¸¤~µo²{¡A¦¹ÃĦ]¬°¦³¯f¤H¦º¤`¡A©Ò¥H³QFDA©R¥O°±¤î¹êÅç¤F¡C ¸Ó¤½¥q¥u¬O§â¥ý«e(³Q¸T¤îÄ~Äò°µ¹êÅç«e)¤§¸ê®Æ¾ã²z¥X¨Ó¡A¦b¨â¤j«ü¼Ð¤¤: ¤@¦³¹F«ü¼Ð¡A¥t¤@¥¼¹F«ü¼Ð¡C¦ý³Ìªñµoªí¤§³o¨Ç¸ê®Æ¤]¥u¬O¤½¥q³æ¤è±¤§»¡ªk¡A¤]¥¼ÀòFDA¤§»{¥i¡C ¥¼¨Ó¥¦¥²¶·¥h§ä§ó¤p±Ú¸s¤¤(¨Ò¦p¯f¤H±w¦³¦å¤pªO¼W¦h¯g¤¤¡A¯á´Õ¤w¸gµw¤Æ¡A ¦Ó¥B¤w¸g²Ä¤T´Á¡K..¡A¦º°¨·í¬¡°¨Âå)¡A§Æ±æFDA¦Aµ¹¥¦±q·s¹êÅ礧¾÷·|¡C µ²½×:¤£§â¥¦·í¤@¦^¨Æ¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/2 ¤U¤È 09:14:59²Ä 567 ½g¦^À³
|
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up by Zacks Equity Research Published on August 30, 2016 | CTI BioPharma Corp.¡¦s (CTIC) shares gained 14.9% after the company announced top-line results from a phase III study (PERSIST-2) on pacritinib, wherein the study met one of the co-primary endpoints. The PERSIST-2 study evaluated pacritinib in comparison to the best available therapy (BAT), including Incyte Corporation¡¦s (INCY) Jakafi (ruxolitinib), for the treatment of myelofibrosis in patients whose platelet counts were less than 100,000 per microliter. Results from the study demonstrated a statistically significant improvement in spleen volume reduction (SVR) in patients treated with pacritinib, thereby meeting one of the co-primary endpoints. Although the study failed to meet the co-primary endpoint of greater than 50% reduction in Total Symptom Score (TSS), its preliminary analysis approached marginal significance in comparison with BAT. The most common adverse events associated with pacritinib were diarrhea, nausea and vomiting, which were found to be generally manageable. Note that in Aug 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high-risk myelofibrosis, including but not limited to patients with disease-related thrombocytopenia, patients experiencing treatment-emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. We remind investors that in Feb 2016, the FDA had placed the company¡¦s Investigational New Drug (IND) application for pacritinib on a full clinical hold. The company is currently working with the FDA to seek to address their recommendations for getting pacritinib off the hold. CTI BioPharma currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK) and ANI Pharmaceuticals, Inc. (ANIP) . Both the stocks sport a Zacks Rank #1 (Strong Buy). |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/9/2 ¤W¤È 11:18:22²Ä 566 ½g¦^À³
|
P1101 PK Jakafi ¡§2015¦~8¤ë28.29¸¹ªº¦å²G¯e¯f°ê»Úª¾¦WÂå®v·|ij¡u2015¬ü°ê°Ï¦å²G¼W¥Í¯e¯f·|ij¡v, ¨Ã½ÐSrdan VerstovsekÂå®v¯¸¥x (Srdan VerstovsekÂå®v¥ç¬°¥Ø«eJakafi ¥ÎÃĪº¦æ¾P¥DnÂå¥Í¡¨) http://www.imedex.com/us-myeloproliferative-neoplasms-myelodysplastic-syndromes/archive/2015/symposium/friday/index.asp https://www.youtube.com/watch?v=s92eZya9xlw µ²½×: 1 P1101¨C¨â©P¥ÎÃĤ@¦¸¡A§C¬r©Ê¡AÃĮĥi¦b¦å²G¤¤«ùÄòºû«ù°ª¿@«×¡C 2 ¤j¦h¼Æ¯f¤H¦³µÛ´î¤ÖJAK2µ¥¦ì°ò¦]ªºt¾á¡C (95¢HªºPV¯f±w¤Î50% ~ 60¢HªºET©ÎPMF¯f±w±a¦³JAK2¬ðÅÜ¡A¦]¦¹JAK2¬ðÅܬO°©Åè¼W¥Í©Ê¯e¯f¤§¥²nÀˬd¡A ¬OÁ{§É¶EÂ_¼Ð·Ç¤§¤@¡C) 3 AOP2014ªº¹êÅç(P1101¥ÑAOP¤½¥q¦b¼Ú¬w15°ê©Ò°µªº¹êÅç)¡A¨C¨â¶g¥´¤@°w¡A¨ÌÓ¤H¥i±µ¨üªºµ{«×¡A ¾¯¶q±q50-540µg¡A¥H¹F³Ì¨ÎÀø®Ä¡C ÅãµM³s¹ï¤âªº¥Dn¦æ¾PÂå®v³£ªÖ©w¡CP1101¦¨¬°¤@½u¥ÎÃÄ«ü¤é¥i«Ý¡C |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/1 ¤U¤È 08:32:49²Ä 565 ½g¦^À³
|
¤å³¹ºK¦Ü°ê²¼ÃÒ劵ӪѤÀªR: P1101¬Û¸û©ó¤w¤W¥«ªø®Ä«¬¤zÂZ¯À°Æ§@¥Î§ó§C¡A¥B¦³¾÷·|¦¨¬°PV¤@½u¥ÎÃÄ P1101¨ã¦³°ª¯Â«×ªº¥Dnì¦]¡A«YÃĵإi±NPEG±µ¨ì³J¥Õ½è³æ¤@¦ì¸m¦Ó´£¤Éªø®Ä«¬ÃĪ«ªº¤À¤l¯Â«×¨Ã°§CÃĪ«°Æ§@¥Î¡A¬G¹w´Á±N¸û¥Ø«e¥«±¤Wªºªø®Ä«¬¤zÂZ¯À¡GPegintron¡BPegasys¡A§ó¬°¯f±w¤ÎÂå®v©Ò±µ¨ü¡C¥t¤@¤è±¡A¥«±¤W¤wÀò®Öã¥Î©ó¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªº¤p¤À¤lÃĪ«Jakafi«h¶È¯à§@¬°²Ä¤G½u¥ÎÃÄ¡A¬GP1101¥Ñ©ó¨ã¦³¤À¤l³æ¤@¡B°Æ§@¥Î§C¡BÀø®Äªø¤§Àu¶Õ(¨äªA¥ÎÀøµ{©ó¤@¶}©l«Y2©P¤@¦¸¡A¤@¦~«á¥i½Õ¾ã¬°4©P¤@¦¸)¡A¨ÃÆ[¹î¨ì¥i±N¾ÉP¯u©Ê¬õ¦å²y¼W¥Í¯g¯e¯fªºJAK2 ¬ðÅÜ°ò¦]¶i¦æ×´_¡A¦Ó¨ã¦³¯e¯fªv¡¤§¥i¯à¡A¬G¥¼¨Ó¦³¾÷·|¦¨¬°ªvÀøPV¯e¯f¦Ó°ß¤@³q¹L®Ö㪺²Ä¤@½u¥ÎÃÄ¡C „« P1101©|¥i¥Î©óB¨x¤ÎC¨x¤§ªvÀø¡A¥«³õ±N§ó¥[ÂX¥R B¨x¤ÎC¨x¥þ²y¥«³õÃe¤j¡A¥B¨C¦~¥H¶W¹L10%³t«×¦¨ªø¡A¦¹¨â¯e¯f¥Ø«e¤´¥H¤zÂZ¯À¬°¥DnªvÀø¤è¦¡¡A¥Ñ©óP1101¨ã¦³§Ct§@¥Î¤ÎÃĮĪøªº¯S©Ê¡A¹w´Á±N§ó®e©ö¬°¯f±w©Ò±µ¨ü¡A¦Ó¦³±æ¨ú¥N¥Ø«e¤w¤W¥«¤§Pegintron©MPegasys¡CÃĵإثe±NB¨x¡BC¨x¤ÎCML³]©w¬°¦X¨ÖÀøªk¡A±q¥Ø«eÁ{§É¼Æ¾Ú¨Ó¬Ý¡A¥iÁYµuÀøµ{®É¶¡§Y¹F¨ì¦³®ÄÀø®Ä«ü¼Ð¡A¬G¥¼¨Ó¤W¥«¥i´Á¡C „« P1101¹wp©ó4Q17º¥ý©ó¼Ú¬w¤W¥«¡A1Q18©ó¬ü°ê¤W¥« Ãĵتñ´Á¥¿¦bµ¥«ÝÁ{§É¤T´Á¼Æ¾Ú¤ÀªRµ²ªG¤½¥¬¡A¨Ã¹wp©ó2016¦~©³©ó¼Ú¬w¡B2017¦~©ó¬ü°ê¤À§O´£¥XÃÄÃҥӽСA¨Ì®Éµ{±À¦ô¡A¼Ú¬w¹w´Á¥i©ó4Q17¤W¥«¡A¬ü°ê«h¹w´Á©ó1Q18¤W¥«¡A¥Î©óETªvÀø¤W³Ì§Ö¥i©ó2019¦~¥¿¦¡¥[¤J¾P°â¡C¬ã¨sû¹w´Á©ó¤W¥««e³o¬q´Á¶¡P1101¦³¾÷·|§l¤Þ§ó¦hÃļtÃöª`¦Ó¶i¤@¨B©Ý®iP1101°ê»Ú¥«³õ¡A¦p¥Ø«e¤w¦¨¥\§l¤Þ¤é¥»Âå¾Ç¹Î¶¤ª`·N¡A¥¼¨Ó¶È»Ý§@²³æbridge study§Y¦³¾÷·|Àò±oÃÄÃҨäW¥«¡C¹w´ÁP1101¥Î©óPVªvÀøªº¼Æ¾Ú±N©ó11¤ë¤½¥¬¡A¬ã¨sû¼ÖÆ[¬Ý«Ý¼Æ¾Ú¤½¥¬«á¨ú±oÃÄÃÒªº¾÷²v¡A¬G¤´ºû«ù¶R¶i«Øij¡A¥Ø¼Ð»ù283¤¸(NPV*1)¡C |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/9/1 ¤U¤È 12:37:26²Ä 564 ½g¦^À³
|
¨º¡D¡D¦pªG¯uªº°±²£~¨ºP1101¤W¥«¤£´N¦³«Ü¤jªº·Q¹³ªÅ¶¡¡A§Ú¤Sn§V¤O¦s¿ú¶R²¼¤F¡D¡D¡D |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/9/1 ¤U¤È 12:20:56²Ä 563 ½g¦^À³
|
·PÁÂAlan¤jªº¾ã²z! ¥Ø«eCML¦b¼Ú¬w¶ø¦a§Q¶i¦æªºInvestigator initiated trial¡A¦pªG¬O¥H¤U³o¤@µ§¡A±N¥i¯à¤]¬OÄâ¤âAOP¤@°_¶i¦æ¶}µo¡C ¥ý¶i§ðCMLªºµ¦²¤¹ê¦b¤£¿ù¡ACMLªº¾÷Âà¸òPV/ET¤ñ¸û±µªñ¡AMFªº·ÀI¸û°ª¥BJakafi¤w¸g·m¤U¤@½u¥ÎÃÄ¡APV/ET/CML¤Ï¦Ó¬OJakafi¸ûµLªk¬ð¯}ªº(³»¦h¤G½u)¡C clinicaltrials.gov/ct2/show/NCT01933906?term=P1101&rank=2 Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (µù¡GImatinibªº°Ó«~¦W´N¬OGlivec¡A¤¤¤å¦W¡G°ò§Q§J½¤¦ç¿õ) B¨xÀ³¸ÓÁÙ¬O¨Ö¥ÎRibavirin¡FC¨x¦X¨ÖSolvadi¬O¤@¤j«GÂI¡AÝÅU¸ûµuÀøµ{»P¯u¥¿ªv¡¡C §Ú¥»¨Ó¥H¬°Pagasys¬ü°ê»s³y¼tn°±²£¡A¥u¬O¦b¶}ª±¯º... |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/31 ¤U¤È 10:03:35²Ä 562 ½g¦^À³
|
P1101+Sovaldi ±j±jÁp¤â ´N¥þ¤è¦ìªº¾Ô°«¦ì¸m ¡§C¨x ±N±Ä¥ÎP1101 + ¤p¤À¤l¤fªA¥ÎÃÄ (Gilead Sovaldi)¦X¨ÖÀøªk¶i¦æÁ{§É¤T´Á¸ÕÅ硨¡A ³o±N·|¬OC¨x¤£±o¤Fªº¬ð¯}¡A¤]¬O¤Ñ¤jªº·s»D¡C ¦ÛSovaldi°Ý¥@«á¡A²{¦bªºÃĪ«¬ãµo¦³¤@ӳ̤jªº°g«ä¡A ¦¹Ãþ¡¨¤p¤À¤lÃÄ¡¨¬O³Ì²×ªZ¾¹¡A»{¬°¶V±j®Äªº¤p¤À¤lÃÄ¥i¥H¥Ã»·Äè·ÀC¨x¯f¬r¡C ©Ò¥H¤@ºÛ¸Á¬ãµoºë¨}ªº±þ¯fµßÃĪ«¡A»{¬°ªvC¨x´N¦p¦P¶i¦æªÅ¾Ô¡A §âSVR (Sustained Virologic Response)¡A«ùÄò¯f¬r¾Ç§í¨î¤ÏÀ³¤@¬q®É¶¡¡A§Y¥i¥H»¡¬OªvÀø¦¨¥\¡C ¥þ²y³Ì¶QC¨x¤jÃÄSovaldiµo©ú¤HJean-Pierre Sommadossiµo²{¤FªÅx¦¡ªºÅF¬µ¡A ÁÙ¬O»Ýn¦a±³¡¶¤¡B§ß«ù¦a±¶Õ¤O¡A¤~¯à¥Ã»·¦³®Ä¡C§_«hÀH®É´_µo¡A ©ÎµLªk°§C¨xÀùªº¤ñ²v¡C©Ò¥H±j½Õ§K¬ÌÀøªk¡A³J¥Õ½èÃĪºP1101 ¤~¬O²×·¥³Ì¨ÎªZ¾¹¡C ©Ò¥H¥L¦Ü¤Ö»PÃĵذª¼h¨£±¤»¦¸¡C http://money.udn.com/money/story/5612/1620846-C%E8%82%9D%E8%97%A5%E5%A4%A7%E5%92%96%E8%A8%AA%E5%8F%B0-%E7%9B%B8%E4%B8%AD%E8%97%A5%E8%8F%AF ¥¼¨Ó¡A©Ò¥H¤£ºÞ¬O¨º¤@ºØªvC¨x¤p¤À¤lÃĪ«¡A¥u¦³·f°tP1101 ¤~¬O³Ì¨ÎªºªvÀø¤è®×¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/31 ¤U¤È 08:40:49²Ä 561 ½g¦^À³
|
¤@±½§C®ðÀ£¡A¤h®ð¤j®¶¡A·PÁÂAlan¤j! ·sÃĬãµon¸Û¹ê¡A¦ý¹ï¥~ÁÙ¬On°ª½Õ¡A±`±`¹ï¥~»¡©ú¶i«×¡A ¤£µM¤[¤F«Ü¦h¤H«Ü¦h¨S«H¤ß¡CÁaµM¹³§Ú̳oºØ¦º©¾ªº¡A³Ìªñ¬Ý¨ì§O¤½¥qªº¨Ò¤l¡A ÁöµM¹ïÃĵؤ´¦³«H¤ß¡A¦ýÁÙ¬O·|¡¨¤ß±¡¤£¦n¡¨¡C ü¡AÃĵسo¤@¨Ç¬ì¾Ç®aÁ`¦³µÛÅý¤H·d¤£À´ªº¯S©Ê¡A ¤£µM´eµÛÀYW·F¡A¤£µM´N¬O¹L«×¤p¤ß¡A¦n¹³¨S¦³¹F¨ì¹w´Á¶i«×´N¬O¥@¬É¥½¤é¡A ©Ò¥H¹ï¥~³£¤£´±Á¿¸Ü¡C¨ä¹ê¥un¸Û¤ßªºÁ¿¡AÁaµM¦³¤@¨Ç¤£¦p¹w´Á¡A§ë¸ê¤H¤]·|Åé½Ì¡C À³¸Ó±`¥X¨Ó¸ò§ë¸êªÌ²á²á¤Ñ¡A¤À¨É§A̧V¤Oªº¦¨´N¥H¤Î¸I¨ìªº§xÃø¡C §Ú·Q¯u¤ß³ßÅw³o¤@¶¡¤½¥qªº·|§ó¯u¤ßªº¸ò¤½¥q¯¸¦b¤@°_¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/31 ¤U¤È 08:18:53²Ä 560 ½g¦^À³
|
¦hÁÂ |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/8/31 ¤U¤È 08:13:28²Ä 559 ½g¦^À³
|
·PÁÂAlan ¤j |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/31 ¤U¤È 08:04:00²Ä 558 ½g¦^À³
|
·PÁÂAlan¤j´£¨Ñªº¸ê°T¡A¯u¬O¥\¼wµL¶q¡A·P®¦¡C |
|
|
·|û¡GAlan Liu10136094 µoªí®É¶¡:2016/8/31 ¤U¤È 07:14:27²Ä 557 ½g¦^À³
|
§A¦n, ¥H¤U¬O¥»¦¸»¡©ú·|¤jºõ¨Ñ±z°Ñ¦Ò¡C ¥»¦¸Ãĵػ¡©ú·|§ë¼v¤ù¥i±q¦¹³sµ²¤U¸ü¡G mops.twse.com.tw/mops/web/t100sb07_1 ºK¿ý¥»¦¸»¡©ú·|¤jºõ¡G [¤½¥q¶i«×] PV¤T´Á¼Æ¾Ú¤w§¹¦¨, ²{¦b¦b¼Æ¾Ú¤ÀªR¶¥¬q, ¹wp10¤ë¦³Pre-submission meeting, ¦~©³EMA°e¥ó¡C 2016 ¦~10¤ë Pre-Submission meeting 2016 ¦~12¤ë3~6¤é ASH meeting ¤½¥¬¨Ãµoªí¤T´ÁÁ{§É¼Æ¾Ú 2017 ¦~Q1 ÃĵرN¦Û¦æ°e¥ó ¥Ó½Ð¬ü°ê¥Íª«·sÃij\¥iÃÒ(BLA¡GBiologic License Application) 2017 ¦~2¤ë ¼Ú¬w±N¶i¦æ¥x¤¤¤u¼t¬d¼t - ¤½¥qIPO«á, ¥Ø«e¦³40»õ¸êª÷, ¸êª÷±N¹B¥Î¦b±µ¤U¨ÓÁ{§É¤T´Áªº¶}®i 1. B¨x(HBV) ¶i¤JÁ{§É¤T´Á (¥x¡BÁú¡BªF«n¨È) 2. ¦å²G¯e¯f ET ¶i¤JÁ{§É¤T´Á (¼Ú¡B¬ü¡B¥x) 3. ¦å²G¯e¯f CML¶i¤JÁ{§É¤T´Á (¼Ú¬w¼Æ¾Ú¨}¦n) - B¨x¥Ø«eµLÃÄ¥iÂå, ¥Ø«e¥«³õ¤W¼Ð·ÇÀøªk¤´¬°¤zÂZ¯À(Pegasys), ¤p¤À¤l¤fªAÃĶȯà§í¨î, µLªkªv¡ ¼Æ¾ÚÅã¥Ü, ¨Ï¥Î¤p¤À¤l¤fªAÃÄ5¦~«á¤´©ö±o¨ì¨xÀù¥i¯à - (¦X¨ÖÀøªk) (1) C¨x ±N±Ä¥ÎP1101 + ¤p¤À¤l¤fªA¥ÎÃÄ (Gilead Sovaldi) ±Ä¦X¨ÖÀøªk¶i¦æÁ{§É¤T´Á¸ÕÅç (2) ¦å²G¯e¯f CML ±N¥Î P1101 + ²{¦³Àøµ{ Gleevec ±Ä¦X¨ÖÀøªk¶i¦æ¤T´ÁÁ{§É¹êÅç - ¤é¥»¦a°Ï±N±Ä¤p¼Ë¥»¾ô±µ¸ÕÅç(Bridge trial)¥´¤J¤é¥»¥«³õ [¤½¥q¦æ¾P] - Á{§É¤T´Á¼Æ¾Ú ¤½¥q¤£»Ýn¸Ñª¼,¤£¹³¯E¹©¡B°ò¨È, Á{§É¹êÅ笰Open Label, ¼Æ¾Ú¤½¶}, Á{§É¤G´Á§Y¥i¨£¤½¥q¼Æ¾Ú¡C - Ãĵؤ½¥q¦æ¾Pµ¦²¤¥Ø«e±Ä¥Î (1)ª½±µ¥Ñ¬ü°ê¦å²G¯e¯fÅv«Â¤Î«n·N¨£»â³S¬°Ãĵد¸¥x (2)«n¬ã°Q·|·N¨£»â³Sªº¬ã°Q·|¤¬°Ê, ª½±µ´£¨Ñ§ó¦h¬ÛÃöªºÁ{§É¬ã¨s©Î²£«~°T®§¡AÂǥѻP³o¨Çªº¤À¨É°Q½×¡A´£¤É·sÃĪºÃn¥ú«×¤ÎÂå®vªº¥ÎÃÄ·NÄ@ - Ãĵؤ½¥qÃÙ§U¥Ø«e¤Ó¦å²G¬ã°Q·|, ¦p2015¦~8¤ë28.29¸¹ªº¦å²G¯e¯f°ê»Úª¾¦WÂå®v·|ij¡u2015¬ü°ê°Ï¦å²G¼W¥Í¯e¯f·|ij¡v, ¨Ã½ÐSrdan VerstovsekÂå®v¯¸¥x, Srdan VerstovsekÂå®v¥ç¬°¥Ø«eJakafi ¥ÎÃĪº¦æ¾P¥DnÂå¥Í¡C [¥«³õ®ø®§ & ºÃ¼{] - ¥Ø«e°ªÃÄ»ùºÃ¼{, ¼Ú¬ü©t¨à¯e¯f¤£¨ü°ªÃÄ»ù¼vÅT, ¤½¥qªº¦å²G¯e¯fPV(¼Ú¬ü)¡BET(¬ü°ê)¡BMF(¬ü°ê)§¡¦³¨ú±o©t¨àÃÄ»{ÃÒ, ¾Ö¦³¬ü°ê¿W½æÅv7¦~¡B¼Ú¬w¿W½æÅv10¦~ªºÀu¶Õ, ¨Ã¯à©w»ù¤£¨üÁÖ½×¼vÅTÀu¶Õ - ¤½¥qPV¼Æ¾Ú¤ÎÀø®Ä¥i±q Blood¡BAjH´Á¥Z¤¤¥Z¸ü¤º®e¬Ý¥X¡C - ù¤ó Pegasys ¦b¬ü°ê»s³y¼t¹wp°±²£, ¥Ñ©ó¬ü°ê¥Ø«e¤´¦³5000¦W¨Ï¥ÎPegasys ªvÀøPVªº¯f±w (±Äoff-label use) ¤½¥q¦b¬ü°ê¥Ó½Ð¡uÂX¥RÀøµ{¤è®×¡v¡]EAP) ªº±¡ªp¤U, ¦³¾÷·|Åý¦¹5000¦W±wªÌ§ï±Ä¥ÎP1101¶i¦æªvÀø¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/31 ¤U¤È 04:25:32²Ä 556 ½g¦^À³
|
¤£ª¾¦³µLºô¤Í¡A°Ñ¥[ÃĵØÂåÃÄ¡u2016°ê²¼ÃÒ¨é§ë¸ê½×¾Â¡v¡A¥i§_§iª¾³Ì·s°T®§? |
|
|
·|û¡GµØ½ü10141250 µoªí®É¶¡:2016/8/31 ¤U¤È 02:03:13²Ä 555 ½g¦^À³
|
±q°ªÂI¶^¦Ü¤µ¶^´T¬ù35%, ¤µ¤Ñ¦¬ªø¤U¼v½u ,¦b«eªi§CÂI¤§¤W¡CÓ¤Hı±oµL¶·¤Ó´dÆ[ |
|
|
·|û¡Gªü³Ç10139080 µoªí®É¶¡:2016/8/31 ¤W¤È 11:58:18²Ä 554 ½g¦^À³
|
¤µ¤é¦~½u¤w¯}¡A¼È®É¨S¬Ý¨ì¤î¶^°T¸¹¡]ª`·NÄw½X¡^¡A´N¥ý¥H¦~½u¬°°ò¦¡A¬Ý¬Ý¬O§_¯à¦u¦í¡C«Øij¤£n¶TµMÅu¥¡A³Ìªñ¦hÆ[¹î¡A¦ý¤]¤£n´dÆ[¡A°T¸¹¤@¥X²{´N¦³¾÷·|¶}©l©¹¤Wª¦¤F¡C |
|
|
·|û¡Gaa18188810142040 µoªí®É¶¡:2016/8/31 ¤W¤È 11:12:56²Ä 553 ½g¦^À³
|
§Úı±o ¨ü¯E¹©¼vÅT ¥[¤W©âÅҪѽæÀ£ §CÂI´±½Äªº¤H¥i¸É ©Ô§C§¡»ù ªø´Á§Ü¯¸ ¤@©w·|º¦¦^¥hªº ¦nªÑ¬On¦³@¤ßªº |
|
|
·|û¡G®ÇÆ[ªÌ10141545 µoªí®É¶¡:2016/8/31 ¤W¤È 07:55:00²Ä 552 ½g¦^À³
|
Ó¤H·Qªk ¨SÀò§Q¬O³Ì¤j·ÀI ¨£ªñ160´²¤á¶R¦ÊªÑ ªÅÀY¤U¤´ÂÔ·Vµ¥§ó§C»ù¥i¶R ·Q¹³6575¥i¬O¸y±Ù»ù³á¡H?? ÄòÆ[¨äÄw½X¥X¶q§_! ·V¤§¤~¤Ö·l¥¢¬Û¹ïÁÈ¿ú¤£Ãø¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/31 ¤W¤È 12:55:54²Ä 551 ½g¦^À³
|
sk2man¤j¡A 6446°ò¥»±¤£¬O¤T¨¥¨â»y´N»¡±o§¹¡A¦pªG¬O¥´ºâªø´Á§ë¸ê¡A«Øij¥h¬Ý¤U¦C³o¨Ç¤½¶}ªº¸ê°T¡A·j´M¤@¤U³£§ä±o¨ì¡C ¬ã¨s6446¤£»Ýn°ª²`ªº¾Ç°Ý¡AÄ@·Nªá®É¶¡´N¯àÁA¸Ñ¡AºI¦Ü¥Ø«eªº¶i«×³£²M²M·¡·¡ªº¡AªO¤W¨S¬Æ»ò¶i¤@¨Bªº°ò¥»±°Q½×¤]«Ü¥¿±`¡C ¤½¥q¸ê°T ¡÷ ¤WÂd¤½¶}»¡©ú®Ñ¡B¤WÂdªk»¡·|²³ø¡B105¦~¦~³ø¡B¤½¶}¸ê°TÆ[´ú¯¸¾ú¥v¤½§i ¾Ç³N¬ã°Q ¡÷ 2013/2014 ASH Meeting¡BBlood´Á¥Z ¬ã¨s³ø§i ¡÷ ³Í°ò¡B¤¸¤j¡B¤¸´I Á{§É¸ê°T ¡÷ clinicaltrials.gov ·j´MPolycythemia Vera |
|
|
·|û¡Gsk2man10142897 µoªí®É¶¡:2016/8/30 ¤U¤È 11:00:13²Ä 550 ½g¦^À³
|
To £~¤j¡G «D±`¦P·N§A»¡¨S¦³¤H¯à«OÃÒÃÁÈ©Îýߪº,´±ÁÈ´N±o´±½ß¡CÁöµM»¡¤Q¦~¿i¤@¼C¡A³Ì©È¬O¿i¤£¥X«Cß¼C¡A¦Ó¬O¤@°ïÅK¯»¡C To¤pªL¤j¡G ¯à¤£¯à»¡¸Ô²Ó»¡©ú»P¨ÒÁ| 6446ªº°ò¥»±¦³¨º¨Ç¡H Toªü}ô¤j¡G ©ú©ú´N¦³¤@°ï¤H¦bpo¤å©Î³Û¸Ü¡A¨Ò¦p¤Ñ¤j¡B°¶¤j¡B¤p¥¿¤j¡BD¤j¡B¤pªL¤jµ¥¤H¡A«ç»ò·|¨S¦³¤H¥X¨Ó«H¤ß³Û¸Ü©O¡H¯S§O¬O¤Ñ¤j¦b¤C¤ë©³®Épo¤F¤WÂd«eªk»¡³sµ²¡A´£¿ô¤j®a»°§Ö¶R²¼¡A¯u¬O@¤H´M¨ý¡I ³Ì«á¡A¯u¬O´Á«Ý¤Q¤ëÁ{§É¦nµ²ªG¡A¡A¥´¤J¤@°w±j¤ß¾¯¡IÃĵػP¦U¦ìÃĤÍÌ¡A¥[ªo°Õ¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/30 ¤U¤È 06:09:28²Ä 549 ½g¦^À³
|
2016/08/30 17:05 ¡m¥ÍÂåªÑ¡nÃĵØÂåÃÄ©ú°Ñ¥[°ê²¼ÃÒ¨é§ë¸ê½×¾Â ¡i®É³ø-¥x¥_¹q¡jÃĵØÂåÃÄ(6446)8¤ë31¤é15:30¨üÁÜ°Ñ¥[°ê²¼ºî¦XÃÒ¨éªÑ¥÷¦³¤½¥qÁ|¿ì¤§¡u2016°ê²¼ÃÒ¨é§ë ¸ê½×¾Â¡v¡A¦aÂI¡G¥x¥_´¹µØ°s©± (Regent Taipei) ¥x¥_¥«¤¤¤s¥_¸ô¤G¬q39«Ñ3¸¹¡C(½s¿è¾ã²z¡G²ø¶®¬Ã) |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2016/8/30 ¤U¤È 01:11:55²Ä 548 ½g¦^À³
|
¨S¦³«H¤ßªºªB¤Í,¨Ó!¨Ä!µ¹§AºNºNÀY,¨Ä®@!¥V¤Ñ¨ì¤F,¨Ó!§Ú¦³¤õÄl,µ¹§A¨ú·x³á.....³Q¶^À~¨ì¤F?«Ü¦nªü,½Ö³W©wªÑ²¼¤£¯à¶^?©È¶R¿ù¶Ü?«¢«¢!§A©È§Ú¤]©Èªü,¤S¤£¬O¥u¦³§A©È!§Ñ°OÄ@½äªA¿é³o¥y¸Ü¶Ü?©È©È?«Ü²³æ³Â,§â¥¦½æ¥ú´N¤£¥²©È¤Fªü¡C©Èº¦¶Ü?«Ü²³æ¹À!§â¥¦¶R¦^¨Ó´N¦n¤F§r?µ´¹ï¨S¦³¤H¯à«OÃÒÃÁÈ©Îýߪº,´±ÁÈ´N±o´±½ß¡C¤£¾A¦Xªº´N¤£n¨Ó,¤×¨ä¬O¤Q¦~¿i¤@¼Cªº·sÃĪѡC |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/30 ¤U¤È 12:55:21²Ä 547 ½g¦^À³
|
ªÑ»ù¨Ó¨ì¦~½u¦ì¸mªþªñ¡A§Ú¤S¥[½X¤@±i¡A´N©ñªø´Á§a(§Ú®M¦b185¡AÁöµL«Ü¤j¸êª÷À£¤O¡A¦ý³£¬O¦s¨Óªº¦Ñ¥»)¡AÃĤÍÌ¡A¥[ªo§a |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/30 ¤U¤È 12:32:04²Ä 546 ½g¦^À³
|
¦h¼Æ§ë¸ê¤H¤´¥H¹q¤lªÑªº§ë¸êÅÞ¿è¨Ó¾Þ§@·sÃĪѡA´Á«Ý¨C©P/¨C¤ë³£¦³·s®ø®§¡C·sÃĤ½¥qªº¸gÀç¹Î¶¤ÃÛ¤F¤Q´X¦~²×¨£ÀÆ¥ú¡A§ë¸ê¤H¤~«ù¦³´XÓ¤ë´N·Q¨£¨ìÆv¶§°ª·Ó¡C ªÑ»ù¥Ñ©Ò¦³§ë¸ê¤H¥æ©ö¨M©w¡A¦³¶R´N¦³½æ¡A¦³½æ´N¦³¶R¡C°ò¥»±¤w¸g²M²M·¡·¡¤F¡A¤£»Ýn¬Æ»ò«H¤ß³Û¸Ü¡A»ùȬO°ª¬O§C´N¦b¨CÓ¤H¤ß¤¤¡C |
|
|
·|û¡Gadigo10135839 µoªí®É¶¡:2016/8/30 ¤W¤È 11:21:41²Ä 545 ½g¦^À³
|
10¤ë¤½§G¦¬®×µ²ªG¡B«ç»òÁÙ¤@ª½¶^¡I¤w¸g¨ì§Úªº¶RÂI¤F¡B¦A¤U¥h´Nn¦Y¤g¤F¡I11¤ë·sÃĪÑÁÙ¦³§Æ©Ô¿¶ªº¥´À£¡I ³Ìªñ¤]¨S¬Ý¨£¦³¤H¥X¨Ó«H¤ß³Û¸Ü¡B¬O¤j®a³£¶^«ÜºG¶Ü¡H |
|
|
·|û¡GRabbit Kin10141833 µoªí®É¶¡:2016/8/30 ¤W¤È 11:07:50²Ä 544 ½g¦^À³
|
²{¦b¦^·Q°_¨Ó¡A¤C¤ë©³®É¡A¤p¸ê±Ú´£¿ô¤j®a§Q¦h¤£º¦¡An»°ºò¤U¨®¡AÁÙÆZ¤¤ªÖªº..... ¥ý¶i¤j¸ò¤p°¨¤jªº180ªþªñªº¥[½X³æ¡A¤£ª¾¤U¨®¤F¨S¡A§Æ±æ¦¹ªi¶^¶Õ¡AµØ¤Í̧O¨ü¶Ë.. |
|
|
·|û¡Gadigo10135839 µoªí®É¶¡:2016/8/30 ¤W¤È 09:10:13²Ä 543 ½g¦^À³
|
ªÑ»ù¨C¤Ñ¶^¡IµL¨¥¡K |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/28 ¤U¤È 08:33:56²Ä 542 ½g¦^À³
|
Dr. Silver¡G ¦n§a¡A§A°Ý¤F«Ü¦h°ÝÃD¡C§Ú»{¬°¡A§ÚÌÀ³¸Ó§i¶DÆ[²³¡A³o¬O¥¼¸g±Æ½mªº¡C ¦ý¬O¡A§A°Ý¯u¥¿¦nªº°ÝÃD¡C¦]¬°§ÚÌ»{¬°¡A³oºØÃĪ«¡A©Òz¤zÂZ¯À¡A ¤]¥i¥H¬O¦³®Äªº¡AªvÀø¦´Á°©ÅèÅÖºû¤Æ¡C ³o¬O¦]¬°¦b°©ÅèÅÖºû¤Æ¤§¦´Á¶¥¬q¡A°©Åè²ÓMºc¦¨©|¦³«O¯d¡A ¦pªG¯à°÷¦b°©ÅèÅܵw¤Æ«e§ÚÌ¥i¥H´î¤ÖÅÖºû¤Æ¡A¨º³o±N¬O¦³§QªºªvÀø¡C ¨Æ¹ê¤W¡A§Ú̵oªí¤F¡A¤p¶q¼Ë¥»ªº¹êÅç¡A¤zÂZ¯ÀªºªvÀø¥i°fÂàÅÖºû¤Æ¡A ©ó2011¦~µoªí¦b¡§¦å²G¡¨´Á¥Z¡C¦Ó²{¦b§Ṳ́w¸gÂX¤j¤F¹êÅç¡C§Ú̦³32Ó±wªÌªvÀø10¦~©Î15¦~¡A¦³¤@Ó«ùÄòªº¤ÏÀ³¡A80¢Hªº¤H¦b¯f±¡Ã©w©Î§ïµ½¡A§¹¥þ©Î³¡¤À½w¸Ñ¡C ·íµM¡A§Ú̵oªí¦bASH(¬ü°ê¦å²G·|ij)¡A§Úªº¦P¨Æ¡A¦³«ùÃhºÃºA«×¡A ¥LÌ·|»¡¡G¡§¶â¡A³o¬O¤@Ó³æÁu¬ã¨s¡¨¡A¦ý¦b³o¬O¨u¨£ªº¯e¯f¡A «ùÄò®É¶¡ªøªº¯e¯f¡A¦³®É³æÁu¬ã¨s¥i¥H¡A¨Æ¹ê¤W¡A¬O¦³®Äªº¡C Andrew Schorr: Dr. Silver¡A¥u¬OÁ`µ²¤@¤U¡A§A¤w¸g¬O¤zÂZ¯Àªº¦h¦~¨Ó¤ä«ùªÌ¡A§A¤w¸g¸ÑÄÀ¤Fì¦]¡C §Aı±o²{¦bªº¤zÂZ¯À©M¤zÂZ¯Àªº¾¯¶q¡A§ÚÌ¥¿¨«¦Vªº°ò¦]¤uµ{¡A ¥¦¥i¥H¦bªvÀøMPNÃþ§OùØ¡A¦¨¬°¤é¯q¦³¥Îªº¤â¬q¡H Dr. Silver¡G µ´¹ï¡C§Ú·Q±j½Õªº¬O¡A·í§Ú³o¼Ë»¡¡A§Ú»P³o®a¤½¥q¨S¦³¥ô¦óÃö«Y¡A §Ú³Q¤¶²Ð¦¹¤@²£«~¡C§Ú¹ï¦¹«Ü¼ö°J¡A¦]¬°±qÂå¥Íªº¨¤«×¨Ó¬Ý¡A §Ú»{¬°¦³ªþ¥[È1¡A¡¨ªø®É¶¡¡¨ ¦³®Ä(ºû«ù¤@©w¿@«×)ªº¤zÂZ¯À¯àº¡¨¬¯f»Ý¨D¡A ¤@¤è±¬O¦]¬°¹ê»Ú¤W¥i¥H¨C¤ë¤@¦¸¥ÎÃÄ¡C §Ú»{¬°¡A¨C¤ë¤@¦¸¡A§A¥²¶·½T«O¯f¤H±µ¨ü¥¦¡A ¦]¬°¦³®É¤H̦³§Ñ°O¥¦Ìªº¶É¦V¡C¦³¤@Ó°ò¥»ªº¥Í²zì¦]¡A ¦]¦¹³o¥i¯à¬OÀu¶Õ¡A¦]¬°¤zÂZ¯Àªº¤ô¥¿@«×«ùÄò¬°¦bªø®É¶¡¤º¡A ¤]´N¬O¤@Ó¤ë¡A¦Ó¤£¬O§ÚÌè¤~½Í¨ìªº¦y®p©M§C¨¦®ÄÀ³(©¿°ª©¿§Cªº¿@«×)¡C Andrew Schorr: ²z¬d¼w³Õ¤h»È¡A§Ún·PÁ§A̪º©^Äm¤F´X¤Q¦~... Dr. Silver¡G ¦n¤F¡AÁÂÁ§A¡C Andrew Schorr: ......µ¹§Ú̪ºMPNªvÀø¡A¯uªº¡C³o¬O«Ü°ª¿³ªº¤@¥ó¬O¡A ¯à¨£¨ì¶Éª`¤F¦Û¤vªº¥Í©Rµ¹¤j²³ªº¤H¡A¦Ó¥B¡A¦p¦P§AÅ¥¨ìªº¡A Ãö«Y¨ìªvÀø°}¦Cªº¤@Ó²Õ¦¨³¡¤À¡A¤zÂZ¯À¡C°ò¦]¤uµ{±N¨Ï²£«~§ó¹ê¥Î¡A§ó¦nªº@¨ü©Ê©M¬°§ó¦hªº¤H¡C ½Ðª`«¥H¤W¹ï¸Ü¡A¬Ý¬Ý¥¦¬O¦p¦ó¾A¥Î©ó§A¡C»P§AªºÂå¥Í°µ¹ï¸Ü¡A ¦pªG§A¦³PV¡A©ÎªÌ¦p¥L©Ò»¡¡A°©ÅèÅÖºû¤Æ¡A³o¬O¨ººØ§Úªº±¡ªp¡A¬Ý¬Ý¯àÀ°§UªvÀøªº§ó¦n¡H ²{¦b¦ì³BASHªº·|³õ¡A»P¨Ó¦Û¯Ã¬ù¥«ªºDr. Silver¡A§Ú¬OAndrew Schorr¡C½Ð°O¦í¡Aª¾ÃѬO³Ì¦nªº¨}ÃÄ¡C ½Ð°O¦í¡¨Patient Power¡¨©Òªí¹Fªº·N¨£¨Ã¤£¤@©w¬O§Ú̪ºÃÙ§U°Ó¡A®½§UªÌ¡A ¦X§@¹Ù¦ñ©ÎPatient Powerªº·N¨£¡C§Ú̪º°Q½×¤£¬O±q¦Û¤vªºÂå¥Í´M¨D ÂåÀø¿Ô¸ß©ÎÅ@²zªº´À¥N«~¡C³o¬O§A±N¦p¦ó±o¨ì³Ì¾A¦X§Aªº·ÓÅU¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/26 ¤W¤È 01:12:03²Ä 541 ½g¦^À³
|
ťťDr. Richard Silver «ç»ò»¡ https://www.patientpower.info/video/new-horizons-for-interferon-therapy-in-mpns Andrew Schorr¡G Andrew Schorrªº¦ì¸m¡A¦b¦òù¨½¹F¦{¶øÄõ¦h¡A2015¦~ASH¬ü°ê¦å²G¦~·|¡C §Ú»P Dr. Richard Silver¯¸¦b¯Ã¬ù¥««Âº¸Âå¾Ç°|±d¤Dº¸¤j¾Ç¡C Dr. Richard Silver¡G±d¤Dº¸¤j¾Ç«Âº¸Âå¾Ç°| Andrew Schorr¡G ±d¤Dº¸¤j¾Ç«Âº¸Âå¾Ç°|¡C§ÚÁ`¬O§Æ±æ¥s¹ï¥¦ªº¦W¦r¡C ³o¦ì¥ý¥Í(Dr. Richard Silver)¦Ü¤Ö45¦~¤@ª½P¤O©ó ¬°ªvÀøªºMPN±wªÌ¦Ó§V¤O¡C§ÚÌ·Q©M¥L½Í¡¨ªvÀø¡¨ªº³o¤@°Ï¶ô¡A ³o¤w¸g§V¤O¤F¤@¬q®É¶¡¡A¨Ã«ùÄò§ï¶i¡A§ó¥[¦³©Ò§@¬°¡A¤]µ¹ §Ú̪º«e´º¦³©Ò§ïµ½¡C§Ú»¡ªº¬O¨Ï¥Î¤zÂZ¯À¡ADr. Richard Silver¡C º¥ý¡AÅý§Ṳ́F¸Ñ¤zÂZ¯À¬O¤°»ò¡C Dr. Richard Silver¡G ¤zÂZ¯À¬O¤@ºØ²ÓM¦]¤l¡A³o·N¨ýµÛ¥¦¬O³J¥Õ½è¡C¥¦³q±`¦s¦b©ó¤HÅ餤«D±`·L¶qªº¡A ¥¦¥Dn¬O§@¬°¦^À³¯f¬r·P¬V(¤zÂZ¯fµßªº·P¬V)¡A¦]¦¹©R¦W¬°¤zÂZ¯À¡C ¥¦¤j¬ù40¦~«e¡A¥i¥H¦X¦¨¤F«Ü¤p«Ü¤pªº¼Æ¶q¡C³q¹L°ò¦]¤uµ{ªº©_ÂÝ¡A ²{¦b¥i¥H¦bÅé¥~¦X¦¨³oºØ²£«~¡A¤]¬Û¹ï¤j¶qµ¹ÃÄ¡C ¤zÂZ¯À¨ã¦³¦UºØ¦U¼Ëªº¬¡°Ê¡A¦]¬°¥¦¤£¶È¨ã¦³¦b¯f¬r©Ê¯e¯fªº®ÄªG¡A ¥¦¥i¯à½á¤©¬YºØÃþ«¬ªº§K¬Ì¡A©M²Óµß©Ê¯e¯f¡A¥H¤Î¦b¦hºØÀù¯g¤¤³Q¨Ï¥Î¡C Andrew Schorr:¡G ¦nªº¡C¦n§a¡AÅý§Ú̽ͽץ¦¡A¦³ÃöMPN³¡¥÷¡C¤zÂZ¯À¦p¦óÀ°§UMPN?²z½×»P¹B¥Î¡H Dr. Richard Silver¡G ³o¬O¤@Ó«D±`¦nªº°ÝÃD¡C§Ú¤j¬ù25¦~«e¤Þ¤J¨Ï¥Î¦b¯u©Ê¬õ²ÓM¼W¦h¯gªºªvÀø¤¤¤zÂZ¯À¡A ¥¦¬O°ò©ó¤@Өƹê¡A§Y¤zÂZ¯À¬O¦³®ÄªºªvÀøºC©Ê°©Åè²ÓM©Ê¥Õ¦å¯f (Chronic Myeloid Leukemia¡ACML)¡C ¨Æ¹ê¤W¡A³o¬O³Ì¦¥ÎÃĪvÀø¤èªk¤§¤@¡A³o¬O¤@ÓÃÄ¡A¾ÉP¤£¶È¯à´£°ª¥Í¦s²v¡A ¦³¼ç¤OÅý¤Hªø´Á¦s¬¡©M±µªñªv¡¡A¦ý«Ü¤£©¯ªº¡A¥u¦³¤Ö¼Æ¯f¤H¯à¦bªø®É¶¡¤º¡A @¨ü¤j¾¯¶q¤zÂZ¯À¶i¤JÅ餺¡C ²{¦b¡A¦]¬°¬õ¦å²y¼W¦h¯g¬O°©Åè¼W¥Í©Ê¯e¯f¤§¤@¡A·í§ÚÁÙ¬O¦~»´ªº®ÉÔ¡A³Q¦³¡¨°©Åè¼W¥Í©Ê¯e¯f¤§¤÷¡¨¤§ºÙªºDr. William Dameshek¤Þ¶iªù¡A§Úı±o³o¨Ç¯e¯f¦³«Ü¤jªº¬Û¦ü©Ê¡A¤×¨ä¬OPV©MCML¡C ·í®É§Ú¬O¤£º¡ªº¡A²{¦b¤]¬O¤@¼Ë¡A¡A¦]¬°§Úı±o¨Ï¥Îßm°ò脲¡]Hydrea¡^¦³¼ç¦b¬r©Ê¡C§Ú»{¬°ªø´Á¡B¬Û·í¼Æ¶qªº¨Ï¥Î¥i¯à·|¾ÉP¦åÀù¡A¥¦¥i¯à·|¾ÉP¥Ö½§Àù¡A¹ï¨x¡BµÇµ¥¬r©Ê¡A©Ò¥H¥²¶·§ä¨ì´À¥NÀøªk¡C ²{¦b¡A¤zÂZ¯À¨Ï¥Î¤W¬O¨ã¦³¥Íª«¾Ç°ò¦ªº¡C¥¦·|¼vÅT·F²ÓMªº¤Àµõ¡A¥¦·|¼vÅT¥¨®Ö²ÓM¡C¥¨®Ö²ÓM¬O¦b°©Åè¡A¾ÉP¦å¤pªO¥Í¦¨¡A¦å¤pªO¡A§A¤]ª¾¹D¡A³q±`¤É°ªªº±wªÌ°©Åè¼W¥Í©Ê¯e¯f¡C ¥¦¤]¥i¥H¼vÅT¬õ²ÓMªº´`Àô¡A©Ò¥H¹ï©ó©Ò¦³³o¨Çì¦]¡A§Ú»¡¡A¡§§Úªº¶ý§r¡A§Ṳ́@©wn¸Õ¸Õ¤zÂZ¯À¡C¡¨¦b§ÚÌ¡§¬h¸¤M¡¨ ªº³ø¾É¡A¥¦¦b²Ä¤@§å¤Ö¼Æ±wªÌ¨¤W®i²{Åå¤H®ÄªG¡C §ÚÌÂX¤j¤F³o¨Ç¸ÕÅç¡A¨Ã¦b±d©`º¸¤j¾ÇÂå°|¦¨¬°Àu¥ý¨Ï¥Î¡C²{¦b¡A¥²¶·±j½Õ¥Î¤zÂZ¯À¬O³Ì«nªº¡A¥¦¥²¶·¦b¶}©l¥ý¨Ï¥Î§C¾¯¶q¡AÀH«á¾¯¶q¤É¯Å¡C¥¦¤£¯à¶W¹L¦b¸Ó±wªÌªºCMLªvÀø¾¯¶q¬Û¦P¡Bªø®É¶¡¨Ï¥Î¡A¦]¬°±wªÌ¤£¯à§Ô¨ü¡C ¨Ò¦p¡A¦b¶Â¯À½FªºªvÀø¤¤¡A¤zÂZ¯À¾¯¶q¬°20¸U³æ¦ì¡A¨C¶g¤T¦¸µ¹¥X¡C³o¬O¥¨¤jªº¡C±wªÌ¤£¯à@¨ü³o¤@ÂI¡A©Ò¥H¥L̦b§É¤W§b¤F´X¦~¡C³o¬O¥Í¬¡©Î¦º¤`ªº°ÝÃD¡C ¦pªG§A¦³¨º¼Ëªº¿ï¶µ¡A¨º»ò§A¯d¦b§É¤W¡A§Ô¨üÃĪ«¡A¦ý³o¬O¥i¯àªº¡A±w¦³°©Åè¼W¥Í©Ê¯e¯f¡C¬Û¤ñ¤§¤U¡A§Ú̥Ϋܤpªº¾¯¶q¡A¨C¶g45·L§J¡A©Ò¥H³o¬O¤@Ó·L¤£¨¬¹Dªº¾¯¶q¡A§ÚÌ¥i¥Hªø®É¶¡ªvÀø¯f¤H¡C Andrew Schorr¡G §Úªº°ÝÃD¬O¡A§Ú̲{¦b¦bþ¸Ì¦³¼ç¤Oªº·s²£«~¡A¥i¥H¨Ï¤zÂZ¯À§ó¦n¨Ï¥Î¡H Dr. Richard Silver¡G ¦A¦¸¡A³o¬O¤@Ó«D±`¦nªº°ÝÃD¡C«nªº¬On±j½Õ¡A§Ú̪ºÆ[²³¡A©Ò¦³ªº¤zÂZ¯À©w©Ê¬O«D±`«nªº¡A³o·N¨ýµÛ¥¦Y¦P¤@¾÷ºc¥XªºÃĪ«ªº¬O¬Û¦Pªº¡C ¦³´XºØ²£«~¥«°â¡A¨ä¤¤¤§¤@¥Ñ¥ýÆF¸¶¶®´£¥X¡A³o¬O¤zÂZ¯À£\-2b¡A²{¦b¥s°µ¡A¥ýÆF¸¶¶®Àq§J¡CÁÙ¦³¤@Ó¥Ñù¤ó´£¥Xªº¡A³o¬OPegasys¡A¨Ã¦³¤@Ó·sªº¡A²{¦b¥¿¥ÑAOP©MPharmaEssentia»s³y¡A«ùÄò®É¶¡§óªø¡C ¦pªG§ÚÌ¥i¥Hµ¹«ùÄò®É¶¡¸ûªø»Pª`®gÃĪ«¡A¦Ó¤£¬O¨C¶g¤T¦¸¡A¨Ã¨Ï¨ä¨C¤ë¤@¦¸¡A³oµ¹±wªÌ«D±`¦³§l¤Þ¤O¡C Andrew Schorr¡G @¨ü©Ê¨}¦n¡C Dr. Richard Silver¡G @¨ü©Ê¨}¦n¡C²{¦b¡A²Ä¤G¥ó¨Æ±¡¬O¡A¥¦¤£¶È¬O§ó¦nªº@¨ü©Ê¡A¤zÂZ¯Àºû«ù¤@©w¿@«×¥i¤¹³\¦³¸û¦nªºªvÀø®ÄªG(ª`:P1101¥iºû«ù¨â¬P´Á¡A¬Æ©Î¤@¤ëªºÃ©w¿@«×)¡A¦Ó¤£¬O§A¬Ý¨ìªº¡A¨C¶g¥´¤T¦¸ªºÃÄ¡A¿@«×©¿°ª©¿§C¡C Andrew Schorr¡G ¦nªº¡C²{¦b¡A§A´£¨ìªº´£¨Ñµ¹PV¡C¥i¯à³o¤]¦³¨ä¥LªºMPNªvÀø¡AÅý§ÚÌ»¡¡A°©ÅèÅÖºû¤Æ©O¡H¡K¡K¡K. |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/24 ¤U¤È 05:43:44²Ä 540 ½g¦^À³
|
辉·ç140¬ü¤¸¦¬购Medivation 来·½¡G¬ü¤¤药·½ 2016-8-23 ¤µ¤Ñ辉·ç¥H¨CªÑ81.5¬ü¤¸¡A总È140亿¬ü¤¸¦¬购¤FMedivation¡C这个¤L个¤ë¥H来¨î药¬É³Ì热门©ç卖¥H¤g»¨ªº¤j¤â笔¤¶¤J¦Ó结§ô¡C¤µ¤Ñªº¦¬购¤£仅¥O©Ò¦³¦³PARP项¥Øªº¤½¥qªÑ²¼³£¤£¦Pµ{«×¤W扬¡A¦Ó¥B¦]为§ë资ªÌ¬Ý¨ì¤j药ÉD¦³钱无产«~ªº现实¥i¯à会诱发¤U¤@轮©ç卖¦Ó¥O¾ã个¥Íª«¨î药´¶¹M¤W涨¡C Medivation¨Æ¥ó¦b¥Íª«¨î药¥v¤W³£¤£¦h见¡A赛诺µá¡B¦w进¡B辉·ç¡B¦N§Q±o¡B赛尔°ò¦]¡Bªü´µ¦C±d¡B诺华¡BÀq¨F东¡Bªü´µ¯S©Ôµ¥药¥ø¤L¥G¦P时ªí¥Ü±ý¦¬购这个¥u¦³¤@个产«~ªº¤½¥q¡C³Ì¦Z辉·ç¥H辉·ç¬£头¦¨为³Ì¦Z赢®a¡A¥HMedivation销°â额11¿ªºÉ²®æ¦¬购¦¨¥\¡A¦Ó辉·ç¥«È¥u¦³¦Û¤v销°â额ªº4.5¿¡C虽µM¥Íª«§Þ术¤½¥q©M药ÉDªÑɲ¦³区别¡A¦ý还¬O¦³¤H质ºÃ辉·ç¥Xɲ¤Ó°ª¡CMedivation°£¤FXtandi¥h¦~¦¬¤J22亿¡]ÉOªü´µ¯S©Ô¦@¨É¡^¡A还¦³PARP§í¨î剂talazoparib©MIO产«~pidilizumab¡C现¦b¥t¥~两个PARPÉD®aTesaro¡BClovis¥«È¬Û®tªñ10¿¡A¤À别为50亿©M6亿¡A©Ò¥H«Ü难ãÚ̦ôɲtalazoparib¡C 辉·ç现¦b«æ»Ý«n产«~扩¥R产«~线¡A过¥h两¦~´¿¥ý¦Z试图¦¬购ªü´µ¦C±d©M¦ã尔«Ø¡A¦ý§¡¥¼±o¤â¡C获±oMedivation¦Z辉·ç将拥¦³¥¼来¤L¦~10¤j§ÜÀù药ªº两个¡]Ibrance©MXtandi¡^¡A©Ò¥H会¦b肿½F这个³Ì«n竞争领°ì¥e¦³¤@®u¤§¦a¡C¥t¥~这个¦¬购对辉·ç¤]¦³¤@©w战²¤¨¾±s·N义¡C¦pªGÀq¨F东©Î赛诺µá赢±o竞©ç¡A¦Ó³Ì¦ZXtandiÓì应¯g扩¤j¨ì«e¦C¸¢Àù¥H¥~¡A©Îtalazoparib¯u¦¨为best in class¡A辉·ç¦b肿½F领°ì¤S±o¸¨¦Z10¦~¡C辉·ç¤w经错过¤F§K¬Ì疗ªk¤j¼é¡A¦A错过PARPªºÉó会¦¨¥»«Ü°ª¡C¥t¥~«e¦C¸¢Àù¬O¤Ö数ï¥d§í¨î剂无®Äªº¤j¯fÏú¡A©Ò¥HXtandi¨üO¡BK挤压¤L²v较§C¡C Medivation¤L¦~«e´¿从«X罗´µ¦¬购¤F¤@个诡Éݪºªü尔¯ý®üÀq药ª«dimebon¡A¦}¦¨¥\获±o辉·ç2亿¦h¬ü¤¸¦@¦P开发¡C³Ì¦Zdimebon¯»¨¸H°©¡A¦ýMedivation¥Î这笔钱¦¬购¤FXtandi¡A¦}¤j获¦¨¥\¡C¦Z来从BioMarin¥H5亿¬ü¤¸¦¬购¤Ftalazoparib¡A¦p¤µ³Q¦ôɲ40-50亿¡C¦Ó辉·ç则§â¦Û¤vªºPARP卖给Clovis¡A现¦b¥«È¥u¦³6亿¬ü¤¸¡C©Ò¥H净结ªG¬O辉·ç8¦~«eÉ给Medivation 2亿¬ü¤¸¥h赌³Õ¡AµM¦Z¤µ¤Ñªá140亿§âMedivation赢ªº资产买¤U¡C 现¦b«Ü¦h药ÉD³£ªZ¥\¤£济¡A«æ»Ý¯«©_§L¾¹¥ß¨¬¦¿´ò¡C¤µ¤Ñ辉·ç°ªÉ²夺¨ì¡§Ê¤Ñ剑¡¨¡A³Ñ¤U¨º¨Ç´¿参ÉOMedivation竞©çªº¥ø业»Ýn¥h§ä¡§±O龙¤M¡¨¡CBioMarin¡B¦A¥Í¤¸¡B¦Ê«Ø³£³Q¦C为¦¬购对¶H¡CMedivation¨Æ¥ó¤j®aªº¦@识¬O当ªì赛诺µá¥Xɲ¤£够ªG断¡A©Ò¥H¥i¥H预测¤U¤@轮¦¬购¥Xɲ会°¾°ª¡A这¤]¬OIBB¤µ¤Ñ¤W扬ªºì¦]¡C¦Ü¤_CEO David Hung则¦¨¤F§ë资ªÌ¤ß¤¤ªº^¶¯¡C药ÉD¦³钱¯Ê产«~ªº§½±µu´Á内¤£会§ï变¡A©Ò¥H专®a预测Hung«Ü§Ö会«¥X¦¿´ò¡A¤â«ù¤@§â±O龙¤M¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/24 ¤U¤È 04:58:36²Ä 539 ½g¦^À³
|
½÷·ç°ª»ùÁʨ֡AMedivation¶g¤@ªÑ»ùötº¦ªñ¨â¦¨ 2016/08/23 08:50 °]°T§Ö³ø ½±©{¦p ¬ü°ê»sÃÄ¥¨À¼½÷·ç(Pfizer Inc.)22¤é«Å¥¬¥¸¸ê140»õ¬ü¤¸¨ÖÁʪ¾¦W«e¦C¸¢ÀùÀøªk¿W¥ßÃļtMedivation Inc.¡A³o¶µ®ø®§¿EÀyMedivationªÑ»ù¶g¤@¦¬½L¤@¤f®ðötº¦19.74%¡A¦¬80.42¬ü¤¸¡A½l³y¦¬¥«·s°ª¬ö¿ý¡A¤µ¦~¨Óº¦´TÂX¤j¨ì66.36%¡C Who¡¦s Next After Medivation? Pfizer¡¦s (PFE) $14bn takeout of Medivation (MDVN) sent the Nasdaq biotech index up 2% yesterday, supposedly presaging a buying spree among big pharma groups desperate to restock pipelines. At least that¡¦s what deal bankers and biotech bulls will be hoping for. Looking for the next Medivation: mid caps* reliant on a single, marketed drug Company Market cap Top drug¡¦s share of 2015 sales Top drug Top drug¡¦s 2015 sales Top drug¡¦s 2015-22 CAGR Incyte $15.4bn 100% Jakafi $601m 17% 2016 Financial Guidance Current Previous Jakafi net product revenues $825-$835 million $815-$830 million |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/8/24 ¤W¤È 12:54:29²Ä 538 ½g¦^À³
|
¥[ªo! ¯u¥¿ªº¥xÆW¤§¥ú~ |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/8/23 ¤U¤È 10:18:40²Ä 537 ½g¦^À³
|
ÃĵجO·sÃĬãµo¤½¥q¡A·íªì¬°¤F§Þ³N¤£¥~¬yµ¥¦]¯À¡A °í«ù¦Û¤v¦¨¥ß³J¥Õ½èÃļt¡AÃļt¥u¬OªþÄÝ¡A ·Q¤£¨ì³sÃļt¤]¬O¥xÆW¡B»´äNO1¡A¥´±Ñ¨º¤@¨Ç±M§ð³J¥Õ½èÃĪº¤j¼t¡C ¡¨ª±²¼ªÌ¡¨³Ó¹L¡¨±M¾ªÌ¡¨¡A¯u¬O¤£¥i«äij¡C ¦³¤H´£¨ì:¥¦¨S¦³´Iª¨ª¨¡A¨S¦³°]¹Î¤ä«ù¡A´N¦n¹³¤p®ÉÔ¡A ¨S¦³I´ºªº¤p«Ä¤l¡A¥u¯à¾aµÛ¦Û¤v¤Ñ½á¡B»{¯uŪ®Ñ¡A¤~¯à¥X¤HÀY¦a¡C ³o¨Ç¬ì¾Ç®a¤]ª§®ð¡B¦U¤è±¥XÃþ©ÞµÑ¡A³o´N¬OÃĵذg¤Hªº¦a¤è¡A ³o¤]¬O¬°¤°»ò¡A¦h¦~¨Ó§Ú¥H¤Î«Ü¦h¦º©¾ªº¡¨¤¤¤p©@¡¨¡A¾ÖÅ@¨ì©³ªºì¦]¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/8/23 ¤U¤È 10:10:42²Ä 536 ½g¦^À³
|
ÃĵØÃÄÀò¥xÆW³Ì¨Î¥Íª«»sµ{¨ô¶V¼ú ÃĵØÃÄ¡]6446¡^Àò¡u¨È¤Ó¦a°Ï¥Íª«»sµ{¨ô¶V¼ú¡v´£¦W¡A ¥x¤¤³J¥Õ½èÃļt¨ü°ê»Ú»P¬F©²ªÖ©w¡A¦~©³«e§¹¦¨¬d¼t·Ç³Æ¡A ÃĵØÃĤµ¤éªí¥Ü¡A¤w±µÀò¨Ó¦Û2017·s¥[©Y¥Íª«»s¾¯»s³y¾Ç·|¨È¬w¤j·| ¡]Biologics Manufacturing Asia 2017¡^³qª¾¡A³Q´£¦W¬° ¡u¨È¤Ó¦a°Ï¥Íª«»sµ{¨ô¶V¼ú¡v¡]APAC Bioprocessing Excellence Awards¡^ ¹{µo¤§¡u¥xÆW³Ì¨Î¥Íª«»sµ{¨ô¶V¼ú¡v¡]Best Bioprocessing Excellence in Taiwan¡^ ¡A¹wp¦b©ú¦~2¤ë¶¡Á|¿ìªº¤j·|¤W¥¿¦¡¨ü¼ú¡C ¡@ ÃĵØÃĪí¥Ü¡A¸Ó¼ú¶µ¬Oªí¹ü¨È¤Ó°Ï¤º¦b¥Íª«»s¾¯»â°ì¨ã¦³³»¦y§Þ³N¡B ³Ð·s»sµ{»PÀu¨q«~½èªº·~ªÌ¡A¥H¦¨¬°¼é¬y»s©wªÌ¡A ¦b¨È¤Ó°Ï¤ºªº¨CÓ°ê®a³£·|¿ï¥X«ü¼Ð¥ø·~¡A¦Ó¥xÆW«h¥ÑÃĵØÂåÃÄÀò¦¹®íºa¡C ¡@ ¦¹¥~¡AÃĵØÃĵ¦²¤ªøªL°êÄÁ§óÀòÁܬ°©ú¦~¤j·|¤Wªº±MÃDºtÁ¿¥DÁ¿¤H ¡]Key Note Speaker¡^¡A±N©ó°ê»Ú¥Í§Þ»R¥xµoªí±MÃDºt»¡¡A ®i²{ÃĵØÂåÃĦb·sÃĬãµoªº¨ãÅ馨ªG¡C ¡@ ¤½¥q«ü¥X¡A¦¹Á|¦A«×¬MÃÒÃĵØÂåÃĤw¸g±q·sÃĪº³Ð·s¬ãµo¡BÁ{§É¸ÕÅç¡A ¥¿¦¡¸ó¤J¥Í²£»s³y»P¾P°âºÝ¡A¥x¤¤³J¥Õ½èÃļt¦³«H¤ß¦b¤µ¦~©³«e§¹¦¨²Å¦X ¼Ú·ùEMA»P¬ü°êFDAªº¬d®Ö»{ÃÒ¡]Pre-Approval Inspection, PAI¡^·Ç³Æ¡C https://video.udn.com/news/547224 |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/23 ¤W¤È 11:57:57²Ä 535 ½g¦^À³
|
APAC Bioprocessing Excellence Awards 15th February, 2017 Singapore held in conjunction with the pre-eminent 4th Biologics Manufacturing Asia 2017 APAC Bioprocessing Excellence Awards aims to recognize outstanding bioprocessing people, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and bets practices in manufacturing, Asia¡¦s Bioprocessing Excellence Awards aims to recognize outstanding leaders & trend-setters of today, and inspire innovators of tomorrow. APAC Bioprocessing Excellence Awards¡B2017 Best Bioprocessing Excellcnce Award; Shortlisted Nominees; Taiwan; Pharmaessentia |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/23 ¤W¤È 11:09:38²Ä 534 ½g¦^À³
|
ӪѡGÃĵØÃÄ(6446)¥x¤¤³J¥Õ½èÃļt¨üªÖ©w¡AÀò¡u¨È¤Ó°Ï¥Íª«»sµ{¨ô¶V¼ú¡v´£¦W 2016/08/23 10:36 °]°T§Ö³ø ¦ó¬ü¦p ¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡jÃĵØÃÄ(6446)¥x¤¤³J¥Õ½èÃļt¹wp¤µ¦~©³«e§¹¦¨²Å¦X¼Ú·ùEMA»P¬ü°êFDAªº¬d®Ö»{ÃÒ(Pre-Approval Inspection, PAI)·Ç³Æ¡A¤µ(23)¤é±µÀò2017·s¥[©Y¥Íª«»s¾¯»s³y¾Ç·|¨È¬w¤j·|(Biologics Manufacturing Asia 2017)³qª¾¡A³Q´£¦W¬°¡u¨È¤Ó¦a°Ï¥Íª«»sµ{¨ô¶V¼ú¡v¹{µo¤§¡u¥xÆW³Ì¨Î¥Íª«»sµ{¨ô¶V¼ú¡v¡A¹wp©ú¦~2¤ë¶¡Á|¿ìªº¤j·|¤W¥¿¦¡¨ü¼ú¡Aµ¦²¤ªøªL°êÄÁ§óÀòÁܵoªí±MÃDºt»¡¡C ¡@¡@ÃĵØÃĪí¥Ü¡A¸Ó¼ú¶µ¬Oªí¹ü¨È¤Ó°Ï¤º¦b¥Íª«»s¾¯»â°ì¨ã¦³³»¦y§Þ³N¡B³Ð·s»sµ{»PÀu¨q«~½èªº·~ªÌ¡A¥H¦¨¬°¼é¬y»s©wªÌ¡A¦b¨È¤Ó°Ï¤ºªº¨CÓ°ê®a³£·|¿ï¥X«ü¼Ð¥ø·~¡A¦Ó¥xÆW«h¥ÑÃĵØÂåÃÄÀò¦¹®íºa¡C ¡@¡@ÃĵØÃĪí¥Ü¡A¬°¤F°t¦XªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)·sÃÄP1101(INN: Ropeginterferon alfa-2b¡A°Ó«~¦WBESREMi)¤é«á¤W¥«ªº°Ó·~¤Æ¶q²£®Éµ{¡A¥x¤¤³J¥Õ½èÃļt¤w¥þ¤è¦ì§ë¤J¦V¼Ú·ùEMA¥Ó½Ð·sÃĤW¥«¾P°â³\¥i(Marketing Authorisation Application, MAA)¤Î¬ü°êFDA¥Íª«·sÃĤW¥«¥Ó½Ð(Biologics License Application, BLA)ªº·Ç³Æ¤u§@¡A¤£¦ý¦¨¥\©e°U¥þ²yª¾¦Wªº±M·~¥R¶ñ¼t¼w°êVetter Pharma¬°ÃĵØÂåÃĶi¦æ°w¾¯¥R¶ñ¥N¤u¡A¨Ã§¸u^°êª¾¦W«~½èÅU°Ý¤½¥q¶i¦æ¾n¼t»²¾É¡C ¡@¡@¨ä¤¤¡AÆF»î¤Hª«Steve PorterÅU°Ý¾Ö¦³¶W¹L35¦~ªºÃļt¸gÅç¡A´¿¥ôAstraZenecaªº¥þ²y«~«OÁ`ºÊ¡B¨ã¼Ú·ùQualified Person¸ê®æ¡A¦P®É§óݳƳ\¦h©x¤è¬d®Ö¸g¾ú¦p¬ü°êFDA¡B^°êÃÄ«~°·±dºÞ²z§½(MHRA)¡B·ç¨åÂåÃIJ£«~§½(MPA)µ¥¡A¬°ÃĵØÂåÃĶq¨¨îq§¹¾ãpµe¡A©w´Á¨Ó¥x¾n¼t¶i¦æû¤u°V½m»P»²¾É¡A¤]·|»P¦X§@¹Ù¦ñAOP¤½¥q¾á¥ôÃÄ«~¨ÑÀ³ªºÁ`t³d¤HMr. Gunnar Neumeier¦@¦P·|°Ó°t¦X¦æ¾P¥Îªº¥Í²£»sµ{¡A¥H¹F¨ì»P¼Ú¬ü«~½è¨t²Îªº±µy¡C ¡@¡@Steve Porterªñ´Áªí¥Ü¡A¡uÃĵØÂåÃĤw¸g°µ¦n¤F·Ç³Æ¡v¡A±µ¤U¨ÓVetter±N·|¬£û°µ°t¦X«ü¾É¡A¥Ñ©ó¥Íª«·sÃij̨ã¬D¾Ôªº³¡¤À´NÄÝ°w¾¯ªº»s³y¡A¬°¤F±j¤Æ¦¹³¡¤Àªº¥Í²£¹B§@¡AÃĵØÂåÃĦA©µÅó¨ã¦³¹O30¦~¥]¬A³J¥Õ½èÃļt¡B¬Ì]»P°w¾¯¼t¸gÅ窺¼B¬³°¶¥ý¥Í¾á¥ô¾n¼tÅU°Ý¡C ¡@¡@¼BÅU°Ý¾ú¥ô¼w°ê¨©®ÔÂåÀø¶°¹Î(Ĭ¦{)¤½¥q¡B¤¤°ê®ü¥¿ÃÄ·~¡B½÷·ç¡BAMO¨È°ö²´¤O°·¡B´¶±j(Upjohn)Ãļt¡B¥ýÆF¸¶¶®µ¥°ê»Ú¦U¤jÃļt¡A¨ä¤¤¦b¥ýÆF¸¶¶®¥ô¾´Á¶¡(2005-2007¦~)¡A´¿¨ó§U¶°¹Îªº·s¥[©Y°w¾¯¼t¦¨¥\³q¹LEMA»PFDA¬d¼t¡A¨ã¦³¬Û·íÂ×´Iªº¹ê»Ú¸gÅç¡A¥¼¨Ó±N¦b¥x¤¤¼tªº¥Í²£¹B§@¡B»sµ{³]³Æµ¥¶q²£Àô¸`´£¨Ñ±M·~ªº¿Ô¸ß»P«Øij¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/23 ¤W¤È 09:50:59²Ä 533 ½g¦^À³
|
¡m¥ÍÂåªÑ¡nÃĵØÂåÃÄÀò¥xÆW³Ì¨Î¥Íª«»sµ{¨ô¶V¼ú 2016¦~08¤ë23¤é 09:43 ¡i®É³ø°OªÌ³¢ÂE¼z¥x¥_³ø¾É¡j ÃĵØÂåÃÄ(6446)±µÀò2017·s¥[©Y¥Íª«»s¾¯»s³y¾Ç·|¨È¬w¤j·|(Biologics Manufacturing Asia 2017)³qª¾¡A³Q´£¦W¬°¡u¨È¤Ó¦a°Ï¥Íª«»sµ{¨ô¶V¼ú¡v(APAC Bioprocessing Excellence Awards)¹{µoªº¡u¥xÆW³Ì¨Î¥Íª«»sµ{¨ô¶V¼ú¡v(Best Bioprocessing Excellence in Taiwan)¡A¹wp¦b©ú¦~2¤ë¶¡¥¿¦¡¨ü¼ú¡C ¦¹¤@¼ú¶µ¬Oªí¹ü¨È¤Ó°Ï¤º¦b¥Íª«»s¾¯»â°ì¨ã¦³³»¦y§Þ³N¡B³Ð·s»sµ{»PÀu¨q«~½èªº·~ªÌ¡A¥H¦¨¬°¼é¬y»s©wªÌ¡A¦b¨È¤Ó°Ï¤ºªº¨CÓ°ê®a³£·|¿ï¥X«ü¼Ð¥ø·~¡A¥xÆW¥ÑÃĵØÂåÃÄÀò¦¹®íºa¡C Ãĵص¦²¤ªøªL°êÄÁ§óÀòÁܬ°©ú¦~¤j·|¤Wªº±MÃDºtÁ¿¥DÁ¿¤H(Key Note Speaker)¡A±N©ó°ê»Ú¥Í§Þ»R¥xµoªí±MÃDºt»¡¡A®i²{ÃĵØÂåÃĦb·sÃĬãµoªº¨ãÅ馨ªG¡C¤½¥q«ü¥X¡A¦¹Á|¦A«×¦LÃÒÃĵØÂåÃĤw¸g±q·sÃĪº³Ð·s¬ãµo¡BÁ{§É¸ÕÅç¡A¥¿¦¡¸ó¤J¥Í²£»s³y»P¾P°âºÝ¡A¥x¤¤³J¥Õ½èÃļt¦³«H¤ß¦b¤µ¦~©³«e§¹¦¨²Å¦X¼Ú·ùEMA»P¬ü°êFDAªº¬d®Ö»{ÃÒ(Pre-Approval Inspection, PAI)·Ç³Æ¡C (®É³ø¸ê°T) www.chinatimes.com/realtimenews/20160823002397-260410 |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/22 ¤U¤È 11:27:10²Ä 532 ½g¦^À³
|
¦AťťRichard Silver³Õ¤h«ç»ò»¡ ¡K¤½¥q¶i¤@¨B«ü¥X ¦b11¤ë¨üÁÜ°Ñ¥[¨ÃÃÙ§U¥ÑDr.Richard SilverÂå®v¥D«ùªº¯Ã¬ù¦å²G¯e¯fÂå®v·|ij¦À\·|¤W¡A ¦b¿ÕµØ¡BIncyte¡BShireµ¥¦h®a©t¨àÃÄ¥ÎÃÄ»â°ì¤j¼t¶³¶°¤U¡A BESREMi(P1101)¤]Àò±o¥]¬ARichard SilverÂå®v¦b¤ºªºÂå¬É±M®a¤@PªÖ©w¡A ¨Ã²`«H·s¤@¥N¤zÂZ¯À¦³¾÷·|¯àªv¡PV¯e¯f¡CÃĵØÃĪí¥Ü¡A IncyteªºJakafi¬°¤p¤À¤l¤Æ¦Xª«(¤G½u¥ÎÃÄ)¡A BESREMi¬°³J¥Õ½è¡B¤j¤À¤lÃĪ«¡A¬OªvÀøPVªº¤@½u¥ÎÃÄ¡A ¨â®a±Ä¥Îªº¾÷Âà§@¥Î¤£¦P¡A¦ý¥i¬Û»²¬Û¦¨¡B¨}©ÊÄvª§¡AIncyte¬OÓȱo´L·qªº¹ï¤â¡AÃĵØÃıNºò°l¨ä«á¡C (MoneyDJ·s»D 2015-12-24 14:58:15 °OªÌ ·s»D¤¤¤ß ³ø¾É) |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/22 ¤U¤È 10:45:18²Ä 531 ½g¦^À³
|
¤zÂZ¯ÀalfaªvÀø°©Åè¼W´Þ©Ê¡]MPN¡^¯e¯f CR¡®T(Cancer Research & Treatment Fund)©M§Ú̪º³Ð©l¤H Richard T. Silver³Õ¤h,¤@ª½§V¤OÅý¤zÂZ¯Àµo®i¦¨ªvÀø PV(¯u©Ê¬õ²ÓM¼W¦h¯g)©M¨ä¥L°©Åè¼W´Þ©Ê¯e¯f¡]MPN¡^¦Ó§V¤O¡C ¦b¹L¥hªº¥|¤Q¦~¸Ì¡ASilver³Õ¤h¤w³Q¼sªx»{¥i¬°¤zÂZ¯ÀªvÀøMPNªº ¥ýÅX©M±a°ÊªÌ¡A¸g¥Ñ¡¨Á{§É½Õ¬d¡A¬ã¨s©M¥X¤å³¹¡¨ÅãµÛ±À¶i¦¹Àøªk¡C Silver³Õ¤h¤u§@¤§«e¡A¦³¹ï°©Åè¼W´Þ©Ê¯e¯f (¸~½F¯SÂI¬O°©Å誺¹L«×¬¡°Ê) ¡A ¨S¦³ªvÀø¤èªk¥i¥H±µ¨ü¡C ¤zÂZ¯À¡A§ÜÅÖºû¤Æ»P©Mhemalogic®ÄªGªºÃĪ«¡A°±¤î°©Å褤ªº·F²ÓM¶g´Á¡C ³q¹LSilver³Õ¤h©M¨ä¥L¤Hªº¤u§@¤¤¡A¤w¸gªí©ú¡A¦b§C¾¯¶q¾A·í¦a¨Ï¥Î®É¡A ¤zÂZ¯À¨ã¦³«D±`¨ãÅ骺®ÄªG¡A¨Ã¥B¬O°ß¤@¥iªvÀøMPN-°±¤î©Î°fÂà°©Åè¯e¯f¡C CR¡®T¸ê§U¨Ï¥Î¤zÂZ¯ÀªvÀøMPN¡A¤]¾ÉP¤F¤@Ó«nªº°ò¦]¡A Janus¿E酶2¡]«UºÙJAK2¡^ªºµo²{¡C³q¹L§í¨îJAK2°ò¦]¡A ¤zÂZ¯À´£¨Ñ¤F§ï¶iªºªvÀø¤è®×¡A¨Ãµ¹¯u©Ê¬õ²ÓM¼W¦h¯g©M¨ä¥L°©Åè¼W´Þ©Ê¯e¯f±wªÌ·sªº§Æ±æ¡C ª`:P1101´N¬O¥@¤W³Ì¦nªº¤zÂZ¯Àalfa http://www.crt.org/Development-of-Interferon-in-MPN-Therapy |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/22 ¤U¤È 06:28:26²Ä 530 ½g¦^À³
|
Radius·s«¬°©质²¨ªQ¯g药ª«abaloparatide III´Á临§É获±o¦¨¥\¡A将¦¨礼来«½S药ª«Forteo¡]¯S¥ß©¬肽¡^劲敌 来·½¡G¥»¯¸ì创 2016-08-18 ¬ü国¥Íª«¨î药¤½¥qRadius Healthªñ¤é¤½¥¬¤F·s«¬°©质²¨ªQ¯g药ª«abaloparatide¤@项¨½µ{¸O·N义ªºIII´Á临§É¬ã¨s¡]ACTIVE¡^ªº积Ìå数Õu¡C该¬ã¨s¦b2463¨Ò绝经¦Z°©质²¨ªQ¯g¤k©Ê±wªÌ¤¤开®i¡A评¦ô¤F¨C¤é¤@¦¸¥Ö¤Uª`®gabaloparatide°§C´ÕÊ^©M«D´ÕÊ^°©§é风险ªº疗®Ä©M¦w¥þ©Ê¡C数Õu显¥Ü¡A连续ªv疗18个¤ë时¡AÉO¦w¼¢剂¬Û¤ñ¡A¨C¤é¤@¦¸¥Ö¤Uª`®g80·L§Jabaloparatide¨Ï·s发´ÕÊ^°©§é¡]p¡Õ0.001¡^©M«D´ÕÊ^°©§é¡]p=0.049¡^发¥Í²v§¡实现统计学·N义ªº显µÛ°§C¡C详细数Õu¤w发ªí¤_¥»©Pªº¬ü国医学协会杂§Ó¡]JAMA¡^¡C abaloparatide¬O¤@Ïú·s«¬¦X¦¨肽¡A¬O¥Ò状®Ç¸¢¿E¯À¨üÊ^¡]PTH1¨üÊ^¡^ªº¤@Ïú选择©Ê¿E¬¡剂¡A¥Ñ¤_¨ä¨ã¦³¨}¦nªº¦¨°©¬¡©Ê¡A¦]¦¹³Q±À进临§É开发¡A¥Î¤_¦ñ¦³°©§é°ª风险ªº绝经¦Z¤k©Ê°©质²¨ªQ¯gªºªv疗¡C¥Ø«e¡Aabaloparatide¤w§¹¦¨III´Á临§É开发¡A§@为¤@Ïú¤é±`¦Û§Úª`®g药ª«¡]abaloparatide-SC¡A¥Ö¤Uª`®g剂«¬¡^¡A¥Î¤_绝经¦Z°©质²¨ªQ¯g¤k©Ê±wªÌ¸sÊ^¡C 监ºÞ¤è±¡ARadius¤½¥q¤w¤_2015¦~²Ä¥|©u«×¦V欧·ù©e员会¡]EC¡^´£¥æ¤Fabaloparatide-SCªº¤W¥«¥Ó请¤å¥ó¡A预计将¦b¦~©³获§å¡C¬ü国¤è±¡A该¤½¥q¤w¤_2016¦~²Ä¤@©u«×¦VFDA´£¥æ¤Fabaloparatide-SCªº·s药¥Ó请¡]NDA¡^¡A预计将¦b2017¦~3¤ë获§å¡C¦¹¥~¡A该¤½¥q¤]¥¿¦b开发³z¥Ö给药剂«¬ªºabaloparatide¡]abaloparatide-TD¡^¡A这Ïú³z¥Ö剂«¬ªö¥Î¤F¨ä3M专§Qªº·L³z¥Ö给药¨t统§Þ术¡C ¥Ø«e¡A°©质²¨ªQ¯g·s药¬ã发领°ì¡A¬ü国¥Íª«§Þ术¥¨头¦w进¡]Amgen¡^ÉO¦X§@¥ë¦ñUCB¦X§@开发ªº¥t¤@´Ú·s«¬°©质²¨ªQ¯g药ª«romosozumab¤]«D±`ȱo´Á«Ý¡A该药¬O¤@Ïú单§Ü¡A³q过§í¨î°©µw¤Æ³J¥Õ¡]sclerostin¡^¬¡©Ê¦Ó«P进°©§Î¦¨¦}减¤Ö°©§l¦¬¡C临§É±À进¤è±¡Aromosozumab¤_¤µ¦~¦~ªì¦¨¥\§¹¦¨ªv疗¤k©Ê°©质²¨ªQ¯gªº¤j«¬III´Á临§É项¥Ø¡C¦¹¥~¡Aromosozumabªv疗¨k©Ê°©质²¨ªQ¯gIII´Á¬ã¨s¤]获±o¤F¦¨¥\¡AÉO¦w¼¢剂¬Û¤ñ¡Aromosozumabªv疗12个¤ë¨Ï°©质²¨ªQ¯g¨k©Ê±wªÌªº¸y´Õ¡BªÑ°©颈¡B¥þ髋关节°©±K«×¡]BMD¡^§¡实现统计学·N义ªº显µÛ¼W¥[¡C 业¬É对abaloparatide©Mromosozumabªº°Ó业«e´º¤Q¤À¬Ý¦n¡A¦pªG¤W¥«¡A这2Ïú药ª«³£将对礼来ªº药ª«Forteo¡]teriparatide¡A¯S¥ß©¬肽¡^§Î¦¨严««Â胁¡A¦ZªÌ¬O¤@´Ú¦~销°â额¶W过10亿¬ü¤¸ªº°©质²¨ªQ¯g«½S药ª«¡C Radius Health¬O¤@®a¬ì¬ã驱动ªº¥Íª«¨î药¤½¥q¡A专ª`¤_°©质²¨ªQ¯g¡B肿½F学¤Î内¤Àªc¯e¯f¡C该¤½¥q¤_2014¦~IPO¡A当¦~Éo诞节«e¤i¡Aabaloparatide¦b¤@项III´Á临§É¤¤®i现Õa¤H疗®Ä¡A§U±À该¤½¥qªÑ²¼飙¤Éªñ4¿¡C¥Ø«e该¤½¥q¥«È¤w达¨ì23亿¬ü¤¸¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/22 ¤U¤È 06:15:26²Ä 529 ½g¦^À³
|
¦¹¦¸GEMINI临§É项¥Ø¡A¤]¬OViiV¤½¥qûD动ªº¤G¦X¤@¤è®×ªº²Ä3个III´Á临§É项¥Ø¡C°£¤FTivicay/Epivir¤§¥~¡AViiV¤]¥¿¦bÉOüL¥Í¦X§@开发¥þ²yº个长®Ä¡]1¤ë©Î2¤ë¦Ù¦×ª`®g¤@¦¸¡^¤G¦X¤@鸡§À°s¡i¾ã¦X酶§í¨î剂cabotegravir©M«D®Ö苷类°f转录酶§í¨î剂¡]NNRTI¡^rilpivirine¡j¡A该¤è®×¨C¤ë©Î¨C2¤ëª`®g¤@¦¸¡A将¨ú¥N¨C¤é¤fªA¤è®×¡F¤µ¦~2¤ë¡A这¤@长®Ä¤G¦X¤@鸡§À°s¦bII´Á临§É¤¤获±o¦¨¥\¡]详±¡点击¡GHIVºÖµ¡IüL¥Í¥þ²yº个长®Ä¡]1¤ë©Î2¤ëª`®g¤@¦¸¡^¦ã´þ¯f鸡§À°sIIb´Á临§É获±o¦¨¥\¡^¡C°£¦¹¤§¥~¡AViiV¤]¥¿¦b调¬ddolutegravir/rilpivirine¤G¦X¤@¤ù剂ªº疗®Ä©M¦w¥þ©Ê¡C ¨CÓ¤ëª`®g¤@¦¸·R´þ¯fÃÄn¨ú¥N¤fªAÃÄ C¨x¥bӤ르¤@¦¸·|¦p¦ó |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/8/22 ¤U¤È 03:50:14²Ä 528 ½g¦^À³
|
¤µ¤Ñ¥~¸ê+7±i¡B§ë«H-39±i¡B¦ÛÀç°Ó-147±i |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/8/22 ¤U¤È 03:46:21²Ä 527 ½g¦^À³
|
¤µ¤Ñ¤£¬O¦³¬ü°ê¬£»¡nײzÃÄ»ùªº·s»D~ ªÑ»ù¤]³Q·s»Dײz¤F! |
|
|
·|û¡G¥d¤ñÃ~10143017 µoªí®É¶¡:2016/8/22 ¤U¤È 02:52:51²Ä 526 ½g¦^À³
|
½Ð°Ý¤@¤U¤µ¤Ñ³£¬O½Ö¦b¥X³fªü¡A¶^¦¨³oӼˤl |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/21 ¤U¤È 10:31:17²Ä 525 ½g¦^À³
|
ªï±µ¤zÂZ¯À¤åÃÀ´_¿³®Éªº¨ÓÁ{ «U»y»¡¨k©È¤J¿ù¦æ¡A¤k©È¶ù¿ù¦¡C ·sÃĬãµo´N¬O³Ì¦nªº¨Ò¤l¡C ¹Ú·QÁöµM¦n¡A¦ý¤]nIJ¤â¥i¤Î¡A¦pªG¹Ú¤Ó»»»·¡AÅܦ¨ªÅ¡C ¦pªG¿ï¿ùÃD§÷¡A¿ï¿ù¤è¦V¡A¦A«ç»ò§V¤O¤]¬OªÅ¡C ¤zÂZ¯À±N¬O¥¼¨Ó·sÃĪº¥D¬y¡C¦]¬°¥¦¬O¤w¦b²´«e¡AÅý§AºK¨ú¡C ¦]¬°¤HÅé¹B§@¾÷¨î¤Ó½ÆÂø¡A¨C¤@ÓÓÅé¤]¤£¤@¼Ë¡C¥u¦³¤HÅé¦Û¦³ªºªF¦è¡A¶¶¨ä¦Û¦³¹B§@¾÷¨î¡A¤~¬O¤ý¹D¡C ¤G¤Q¦~«eªL³Õ¤h¹Î¶¤´N°ªÂ¤»·Æf¡A¬Ý¨ì·sÃĪº¥¼¨Ó¡CÂê©w¡¨¤zÂZ¯À¡¨-1957¦~´Nµo²{ªº¤HÅé¦Û¦³ªº§K¬Ìª«½è¡C¥¦¦]¬O¤HÅé©Ò¦³¡A©Ò¥H¨S¦³·N¥~¡A³Ì¦w¥þªºÃÄ¡A¹B¥Î¤]³Ì¼s¡C ¦pP1101¬Ointerferon alpha 2b§Q¥Î°ò¦]¤uµ{§â¥¦×¦¨¦p¤W«Ò¿Ë¤â»s³y¡A ³Ì±µªñ¤HÅ骺§K¬Ìª«½è¡A¥´¤@°w¥i¥H¦b¤HÅéºû«ù2¶g¡A¬Æ¦Ü¤@¤ëºû«ù¤@Ó¿@«×¡A ©Ò¥H¥¦¬O³Ì·Å©M¤]³Ì±`®Ä¡C ¤zÂZ¯À¥\¯à»P§@¥Î¥¿¤è¿³¥¼¦ã¡A´X¥GµL©Ò¤£¥]¡C¥]¬AÀù¯gµ¥¡C ¹B¥Î¦b¥ô¦ó»â°ì¡A¤£ºÞ¥«±¤w¬ãµo¥X¦h»ò±j¡B¦³®Ä¥i¥H±þ¦º¯fµßªº¤p¤À¤lÃÄ¡A ³Ì²×ÁÙ¬On¦ÛÅé§K¬Ì¡A¤~¬Oªv¥»¡C Åý§Ú̪ﱵ¤zÂZ¯À¤åÃÀ´_¿³®Éªº¨ÓÁ{¡C¥ý±qP1101¶}©l! |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/21 ¤U¤È 09:13:15²Ä 524 ½g¦^À³
|
¤zÂZ¯À [ºû°ò¦Ê¬ì] ¤zÂZ¯À(Interferon¡AIFN)¬O°Êª«²ÓM¦b¨ü¨ì¬Y¨Ç¯f¬r·P¬V«á¤Àªcªº¨ã¦³§Ü¯f¬r¥\¯àªº±J¥D¯S²§©Ê¿}³J¥Õ¡C ²ÓM·P¬V¯f¬r«á¤Àªcªº¤zÂZ¯À¯à°÷»P©P³ò¥¼·P¬Vªº²ÓM¤Wªº¬ÛÃö¨üÅé§@¥Î¡A«P¨Ï³o¨Ç²ÓM¦X¦¨§Ü¯f¬r³J¥Õ ¨¾¤î¶i¤@¨Bªº·P¬V¡A±q¦Ó°_¨ì§Ü¯f¬rªº§@¥Î¡A¦ý¤zÂZ¯À¹ï¤w³Q·P¬Vªº²ÓM¨S¦³À°§U¡C ©Ê½è 1954¦~¡A¤é¥»¶Ç¬V¯f¬ã¨s©Òªºªø³¥®õ¤@¡B¤p®q«O«Ûµoªí¤F¡u¯f¬r¤zÂZ¯Àµo²{¡vªº³ø§i¡C 1957¦~¡A^°ê¬ì¾Ç®aIsaacs©MLindenmann¥çµo²{¤F¤zÂZ¯À¡A¨Ã±N¤§©R¦W¬°¡uInterferon¡v¡C ©Ò¿×¯f¬r¤zÂZ²{¶H´N¬O¤@ºØ¯f¬r·P¬V¬YÓ²ÓM«á¯à°÷¤zÂZÀH«áªº¨ä¥¦¯f¬r¹ï¸Ó²ÓMªº·P¬V¡C ³Ìªì¡A¬ì¾Ç®a̧â·À¬¡ªº¬y·P¯f¬r±µºØ©óÂûF²ÓM¤º¡Aµ²ªGµo²{³o¨Ç²ÓM¥i¥H¤Àªc ¤@ºØ¥i·»©Êª«½è¨Ó§í¨î©M¤zÂZ¬y·P¯f¬rªº½Æ»s¡A©Ò¥H±N³oºØª«½è©R¦W¬°¤zÂZ¯À¡C ³q±`²ÓM¥u¦b¨ü¨ì§C¯f¬r¤Oªº¯f¬r·P¬V¤§«á¤~¯à¤j¶q¦X¦¨¤zÂZ¯À¡A¦Ó°ª¯f¬r¤Oªº ·P¬V·|¨Ï±o²ÓM¦b¦X¦¨¤zÂZ¯À¤§«e´N¤wP¦º¡C¥t¥~¤@Ó¥i¥H»¤¾É²ÓM¦X¦¨¤zÂZ¯À ªº¦]¯À¬OÂùÃìRNAªº¦s¦b¡C¦]¬°ÂùÃìRNA¦b¥¿±`ªº²ÓM¤¤¤£¦s¦b¡A¦Ó¥u¦s¦b©óRNA¯f¬r ©Î¬O¨üRNA¯f¬r·P¬Vªº²ÓM¤¤¡C¦]¦¹µL½×¬O¤ÑµMÁÙ¬O¦X¦¨ªºÂùÃìRNA¥i¥H§@¬°¤@Ó ¯f¬r·P¬V«H¸¹¨Ó»¤¾É²ÓM¦X¦¨¤zÂZ¯À¡C ¤zÂZ¯À©M¾Fªñ¥B¥¼·P¬Vªº²ÓMµ²¦X«á·|§Î¦¨¤@ºØ¥Ñ®Ö苷»Äºc¦¨ªº¯S®í¤À¤l¡A ¦¹¤À¤l¥i¥H¬¡¤Æ®ÖÁޮֻĤô¸Ñ酶L(RNAseL)¡A®ÖÁޮֻĤô¸Ñ酶L¯à§â²ÓM¤ºªº ¯f¬rRNA¥þ³¡ºR·´¡C¦P®É¡A¤zÂZ¯À¤]¥i¥H¬¡¤Æ³J¥Õ¿E酶¡A§â²ÓM¤º¥¼§¹¦¨ªº ¯f¬r³J¥Õ½èµ¹¯}Ãa±¼¡C ¤zÂZ¯À(IFN)ÄÝ©ó¿}³J¥Õ¡C¥Ø«e¦b¤HÃþ¨¤W¦@µo²{£\¡B£]¡B£^¤TºØÃþ«¬¡G £\«¬¤zÂZ¯À(IFN-£\)¬O¥Ñ¥Õ²ÓM²£¥Íªº¡F £]«¬¤zÂZ¯À(IFN-£])¬O¥Ñ¦¨ÅÖºû²ÓM(ÅÖºû¥À²ÓM)²£¥Íªº¡F £^«¬¤zÂZ¯À¬O(IFN-£^)¥Ñ§K¬Ì¨t²Î¤¤ªºT²ÓM©M¦ÛµM±þ¶Ë²ÓM²£¥Íªº¡C ©Ò¦³ªº³o¤TºØ³£¬O¦³®Äªº¯f¬r§í¨î¾¯¡A¨Ã¨ã¦³¤@©wªº§ÜÀù§@¥Î[¨Ó·½½Ð¨D]¡C »P¤@¯ë§Ü¯f¬rÃĪ«¤£¦Pªº¬O¤zÂZ¯À¬O±J¥D¯S²§ªº¡C ¦P¤@ÓÄÝ[¨Ó·½½Ð¨D]ªº²ÓM¦X¦¨ªº¤zÂZ¯À¥u¯à°÷ÃѧO ¦P¤@Äݪº²ÓM¤Wªº¨üÅé¡C©Ò¥H¡A¤@ºØ°Êª«²ÓM¦X¦¨ªº¤zÂZ¯À¥u¯à§í¨î¸ÓºØ°Êª« §K¨ü¨ä¥¦¯f¬rªº·P¬V¡A¦Ó¨Ã¤£¯àÀ³¥Î©ó¨ä¥¦°Êª«©è§Ü¯f¬r·P¬V¡C 1980¦~¥N¥H«á¡A¤HÃþ¤w¸g¥i¥H³q¹L¥Íª«¤uµ{¤â¬q§å¶q¥Í²£¤zÂZ¯À¥Î©óÁ{§ÉªvÀø¡C ¥Ñ©ó¤zÂZ¯À¥²¶·¦b§½³¡²ÓM¤¤¹F¨ì¸û°ªªº¿@«×¤~¯à»¤¾É±J¥D²ÓM¦X¦¨§Ü¯f¬r³J¥Õ¡A ¦]¦¹¤zÂZ¯ÀªvÀø®ÄªG¨ú¨M©ó¯à§_±N¤@©w¾¯¶qªº¤zÂZ¯À¿é°e©Îª`®g¨ì¯f¨_¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/8/19 ¤W¤È 09:49:17²Ä 523 ½g¦^À³
|
¡uC¨x·sÃÄ¡v¯Ç°·«O 10¤ë©çªO °OªÌªL´fµ^¡þ¥x¥_³ø¾É C¨x·sÃĬO§_¯Ç¤J°·«O¡H¹wp10¤ë´¦¾å¡I °ê¤ºC¨x²±¦æ²v¬ù4%¡A¤fªA·sÃĬ۸û©ó¡u¶Ç²Îªø®Ä«¬¤zÂZ¯À·f°t§Ü¯f¬rÃĪ«¡y¹p¤Ú«ÂªL¡z¡v¡A¤£¶ÈªA¥Î¦¸¼Æ´î¤Ö¡A¥B¤j´T°§C°Æ§@¥Î¡Aªv¡²v«h±q쥻7¡B8¦¨´£°ª¨ì9¦¨¥H¤W¡A¦ý»ù®æ°Ê»³¦Ê¸U¡C¤é«e½ÃºÖ³¡ªø«Å¥¬C¨x·sÃįǤJ°·«O«á¡A¤£¤Ö¥Á²³º¡¤ß´Á«Ý¡C ±wªÌ³¡¤Àt¾á¤ñ¨Ò«Ý¨ó°Ó ¬Q¤é¥þ¥Á°·±d«OÀIÃĪ«µ¹¥I¶µ¥Ø¤Î¤ä¥I¼Ð·Ç¦@¦PÀÀq·|ij¡]¥H¤U²ºÙ¡u¦@ÀÀ·|ij¡v¡^°w¹ïC¨x·sÃįǤJ°·«O¤@®×¶i¦æ°Q½×¡A·|ij¥D®u³¯¬L«ºªí¥Ü¡A²{¤w³W¹º4ºØ°]·½¤è®×¡A¨Ì§Ç¬°¡u¤½°È¹wºâ¡v¡B¡u¤½°È¹wºâ¥[°·«OÁ`ÃB¨ä¥L³¡ªù¡v¡B¡u¤½°È¹wºâ¥[°·«OÁ`ÃB¨ä¥L³¡ªù¡A¦A¥[³¡¤Àt¾á¡v¡B¡u°·«OÁ`ÃB¨ä¥L³¡ªù¥[³¡¤Àt¾á¡v¡C ³¯¬L«º«ü¥X¡AÁöµM¥H¤½°È¹wºâ¬°Àu¥ý¡A¦ýY¨Ì·Ó¤½°È¹wºâ¥²¶·´£«e½s¦C¨Ó¬Ý¡A¥i¯à³Ì§Ö¤]n2018¦~¾A¥Î¡A¦]¦¹n»°¦b©ú¦~¤W¸ôªº¸Ü¡A©Z¨¥¤½°È¹wºâ¥[¡u°·«OÁ`ÃB¨ä¥L³¡ªù¡v¥[±wªÌ³¡¤Àt¾áªº¥i¯à©Ê³Ì¤j¡C ¦Ü©ó³¡¤Àt¾á¤ñ¨Ò¡A·|¤¤¦³¤H´£¥X20%¦Ü30%¡A¥H¥Ø«eC¨x·sÃÄij»ù25¸U¤¸pºâ¡Aµ¥©ó±wªÌn¦Û¦æ¤ä¥I5¸U¤¸©Î7.5¸U¤¸¡A²Ó¸`¤´«Ý9¤ë°·«O·|Á`ÃB¨ó°Óµ²ªG¡A¦A¸g10¤ë¦@ÀÀ·|ij°Q½×¡A¤~¯à©çªO¡C ³¯¬L«º±j½Õ¡A°ê¤ºC¨x²±¦æ²v¬ù4%¡A°ª©ó°ê¥~ªº1%¡A·|¤¤¦U¬É¥Nªí§¡¹ï©óC¨x·sÃĪº¦w¥þ©Ê¡BÀø®Ä»P¦¨¥»®Ä¯q¹F¦¨¦@ÃÑ¡A¥u¬O°]·½¤´¦³«Ý°Q½×¡A³W¹ºC¨x±wªÌ±N¤À§å¯Ç¤J¡A¾A¥Î±ø¥ó¨Ì§Ç¬°¡u¨Ï¥Îªø®Ä¤zÂZ¯À¥[¹p¤Ú«ÂªLªvÀø¥¢±Ñ¡v¡B¡uÄY«¨xÅÖºû¤Æ®£¤Þµo¨xµw¤Æ©Î¨xÀù¡v¡B¡u¤w§¹¦¨¨xŦ²¾´Ó¡v¡B¡uµ¥«Ý´«¨x¡v¡B¦³¡u¨ä¥L¨t²Î©Ê¯e¯f¡v¡B¡u·R´þ·P¬VªÌ¡vµ¥¡A¦ôp¦¹¬Fµ¦3¦~¤º¥iªvÀø¬ù3.2¸U¤H¡C Y¥H3¦~¤º¥iªvÀø¬ù3.2¸U¤H¡B¥§¡¤@¦~¬ù¤@¸U¤Hpºâ¡Aµ¥©ó¨C¦~»Ýn¬ù25»õ¤¸¡C°·«O¸pÂå¼f¤ÎÃħ÷²Õªø¬I¦p«G»¡¡A°·«OÁ`ÃB¨ä¥L³¡ªù¥h¦~¬ù104»õ¤¸¡A©|¶·³B²z©~®aÂåÀø©Î¨ä¥L¶µ¥Ø¡A¦]¦¹¥i¥Îªº¿ú¤]©Ò³Ñ¤£¦h¡A¦ý¥Ñ©ó½ÃºÖ³¡ªø¤w¹ï¥~«Å¥ÜC¨x·sÃįǤJ°·«O¡A¦]¦¹¡u¾÷·|¤´«Ü¤j¡v¡C news.ltn.com.tw/news/life/paper/1023335 |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/19 ¤W¤È 06:23:44²Ä 522 ½g¦^À³
|
·PÁÂucss¤j¡BDesert¤jªºÄÀºÃ¡C ¤jªÑªFÄÀªÑì¨Ó¬O¹LÃB°t°â¡A ¤S¾Ç¤F¤@½Ò¡A·P®¦¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/8/18 ¤U¤È 11:47:20²Ä 521 ½g¦^À³
|
¹LÃB°t°e ªì¦¸IPO ¤p¥¿¥¿¤j: ¦bªì¦¸¤W¥«Âd®É¡A¥D¿ì¨é°Ó·|n¨D¤jªÑªF¥H§C»ù½æµ¹ú³°Ó¡A§@¬°©e©w¥«³õ»ù®æ¤§¥Î¡C©Ò¥H¤~·|¦³¤jªÑªFÄÀªÑ¤§±¡§Î¡C ¡u¹LÃB°t°â¾÷¨î¡v¡A¨ä«Y«ü¥D¿ì©Ó¾P°Ó©ó¥Ó½Ð¤W¥««eÀ³»Pµo¦æ¤½¥qñq¹LÃB°t°â¨óij¡A©úq¥D¿ì©Ó¾P°ÓÀ³n¨Dµo¦æ¤½¥q¨ó½ÕìªÑªF´£¥X¥eµo¦æ¤½¥q·í¦¸²{ª÷¼W¸êµo¦æ·sªÑ¿ì²z¹ï¥~¤½¶}¾P°âªÑ¼Æ¤§¦Ê¤À¤§¤Q¤¤§¼Æ¶q¤§¤wµo¦æªÑ²¼¡A¨Ñ¥D¿ì©Ó¾P°Ó¿ì²z¹LÃB°t°â¡A±©¥D¿ì©Ó¾P°Ó±oµø¸ß»ù°éÁÊ©ÎÄv»ù©ç½æ¤§µ²ªG¡A¨M©w¬O§_¹LÃB°t°â¤Î¹ê»Ú¹LÃB°t°â¼Æ¶q¡Cªì¦¸¤W¥«´¶³qªÑ²¼±¾µPº¤Ó¥æ©ö¤é¡AY¥X²{¶^¯}©Ó¾P»ù®æªÌ¡A¥D¿ì©Ó¾P°Ó±o¹B¥Î¹LÃB°t°â©Ò±o¤§»ù´Ú¡A¦Û¥«³õ¶R¤JªÑ²¼¦^¸É¹LÃB°t°â¤§³¡¦ì(µo´§»ù®æ¤ä¼µ¥\¯à)¡A¨Ã©ó°õ¦æéw»ù®æ¾Þ§@´Á¶¡©¡º¡«á¡A±NªÑ²¼ªðÁÙµo¦æ¤½¥q¡CY¥X²{¤Wº¦¶W¹L©Ó¾P»ù®æªÌ¡A¥D¿ì©Ó¾P°ÓÀ³±N¹LÃB°t°â©Ò±o¤§»ù´Ú¥æ¥Iµo¦æ¤½¥q¡C http://www.csa.org.tw/downdoc/law/%E6%89%BF%E9%8A%B7%E5%95%86%E8%BE%A6%E7%90%86%E5%88%9D%E6%AC%A1%E4%B8%8A%E5%B8%82%E6%AB%83%E6%A1%88%E4%BB%B6%E6%89%BF%E9%8A%B7%E4%BD%9C%E6%A5%AD%E6%87%89%E8%A1%8C%E6%B3%A8%E6%84%8F%E4%BA%8B%E9%A0%85%E8%A6%81%E9%BB%9E.doc |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/18 ¤U¤È 12:29:29²Ä 520 ½g¦^À³
|
https://www.104.com.tw/jobbank/custjob/index.php?r=cust&j=4c4a432656463f2130683b1d1d1d1d5f2443a363189j99#info03 "MS ¦hµo©Êµwµo¯g"¡A¦Ñ¦´N¤U¤â¬ã¨s¡A¥u¬O¤£ª¾¹D¶i«×¦p¦ó? ¥i¯à²{¶¥¬q¦£µÛ¦å²G¯e¯f¡A¨xª¢¡A |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/8/18 ¤W¤È 11:51:50²Ä 519 ½g¦^À³
|
¬Ý¨ÓÃĵجãµo§ï¨}IFN-£\§¹«á,¥iÄ~Äò¬ãµo§ï¨}¤§ IFN-£]¤ÎIFN-£^µ¥ ¡mÂå¾Ç¬ã¨s¡n¦ÛÅé§ÜÅé§ðÀ»¦Û¤v ªø©°§ä¥XªvÀø¾÷Âà ¡u§Ü¦÷º¿¤zÂZ¯À¡v¦ÛÅé§ÜÅé¯e¯f¬O2005¦~·sµo²{ªº¨u¨£¯e¯f¡A³o¬O¤@ºØ¦]·P¬VÄjº©©Ê¤ÀªK±ìµß¦Ó¤Þµo±wªÌ¦ÛÅé§K¬Ì¤ÏÀ³¡A¾ÉP¥X²{«ùÄò°ª¿N¡B²O¤Ú¸~¤j¡B°©Àf¯kµh¤£³ôµ¥¯gª¬¡A¥Ø«e¥xÆW¦³ªñ¦Ê¤H½T¶E¿©¯f¡AµLªk®Úªv¡A¥u¯à¦Y§Ü¥Í¯Àªv¼Ð¡C • ¡¶ªø©°¤j¾Ç§U²z±Ð±ÂÅU¥¿±[¡]¤¤¡^¥D«ùªº¬ã¨spµe§ä¨ì¡u§Ü¦÷º¿¤zÂZ¯À¡v¦ÛÅé§ÜÅé¯e¯f©Ç¯f¾÷Âàì²z¡C ¡]°OªÌ§d«G»öÄá¡^ ªø©°¤j¾ÇÂå¾Ç°|©Mªø©°Âå°|ÂåÀø¹Î¶¤¸g¹L5¦~¬ã¨s¡A§ä¨ì¡u§Ü¦÷º¿¤zÂZ¯À¡v§Î¦¨ªº¾÷¨î¡A§Æ±æ¯à¦³§U©ó¶}µo·sÃÄ©MªvÀø¤è¦¡¡C ªø©°¤j¾ÇÂå¾Ç°|Á{§ÉÂå¾Ç¬ã¨s©Ò§U²z±Ð±ÂÅU¥¿±[»¡¡A¡u¦÷º¿¤zÂZ¯À¡v¬O¤HÅé쥻´N¦³ªº§K¬Ì¾÷¨î¡A·í¤@Ó¤H·P¬V¤F¡uÄTµß¡vÃþªºÅðµß®É¡A§K¬Ì¨t²Î·|¦ÛµM²£¥Í§ÜÅén±þ¦ºÅðµß¡A¦ý¦pªG¦ÛÅé§K¬Ì¨t²Î¥X°ÝÃDªº¤H«o·|¥X²{²V²c¡C ·íÅ餺ªº§ÜÅé¦b§ðÀ»Åðµß«á¡A¤]·|§ðÀ»¦Û¤vªº¡u¦÷º¿¤zÂZ¯À¡v¡A¥HPÄè·À¤FÅðµß«á¡A³Ñ¤Uªº§ÜÅé«o«ùÄò§ðÀ»¦÷º¿¤zÂZ¯À¡A¦]¦¹·|Åý±wªÌªº§K¬Ì¤O³QÃö¾÷¡A®e©ö¤£Â_¾D¨ü¹³¬OÅðµß©M²Óµßªº·P¬V¡A§Y¥X²{¡u§Ü¦÷º¿¤zÂZ¯À¡v¦ÛÅé§ÜÅé¯e¯f¡C ¬ã¨s¹Î¶¤§Q¥Î¯f¤Hªº¦å²G¶i¦æÅé¥~¸ÕºÞ¹êÅç¡AµM«á¥h°£±¼§ÜÅéµ²¦Xªº°Ï°ì¡Bקï¤zÂZ¯Àºc³y¡Aµo²{¥i¦¨¥\¸úÁקÜÅ骺§ðÀ»¡A«ì´_§K¬Ì¤O¡C ÅU¥¿±[»¡¡A2012¦~¶}©l¥X²{¤j¶qªº¡u§Ü¦÷º¿¤zÂZ¯À¡v¦ÛÅé§ÜÅé¯e¯f¯f¤H¡A¥þ²y¥Ø«e¤wª¾¦³200¦h¨Ò¡A³£¶°¤¤¦bªF«n¨È¡A·í¤¤¥H®õ°ê©M¥xÆW³Ì¦h¡C ÅU¥¿±[»¡¡A¤w¸g§ä¨ì¾÷Âà¤è¦¡¡A¥LÌ·|³]pªø±o¤£¤@¼Ëªº¦÷º¿¤zÂZ¯À¡A¥Ø«e¸g¹LÅé¥~¸ÕºÞ¹êÅç¤wÃÒ¹ê¯à°÷Á׶}§ðÀ»¡A¶i¦Ó¬¡¤Æ§Ü²Óµß©MÅðµßªº§K¬Ì¤O¡B§ïµ½·P¬V°ÝÃD¡C ³o¶µ¦¨ªG¤wµoªí¦b°ê»Ú´Á¥Z¡mNature Medicine¡n¡]¦ÛµMÂå¾Ç¡^¡C ÅU¥¿±[»¡¡A³o¶µ¬ã¨s¤w¥Ó½Ð±M§Q¡A§Æ±æ¦b¥¼¨Ó¯à¶}µo·sÃÄ¡A§ïµ½±wªÌ¥Í¬¡«~½è¡C news.ltn.com.tw/news/life/paper/1022930 |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/18 ¤W¤È 09:44:34²Ä 518 ½g¦^À³
|
¥Ñ¦¹¥i¨£¡A¤zÂZ¯ÀªºÀ³¥Î½d³ò«D±`¼s¡AP1101±N¨Ó¤W¥««á¡A¦³¥i¯à¨ú¥N²{¦³ªºPegasys,¦¨¬°¥D¬y¥«³õ~ |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/18 ¤W¤È 09:28:04²Ä 517 ½g¦^À³
|
¤zÂZ¯À (Interferons) ¦bÀù¯gªvÀø¤WªºÀ³¥Î ³¯¼CºX ÃÄ®v. ¿½«W¼z ÃÄ®v ¤zÂZ¯À¡]Interferons, ²ºÙIFN¡^¬O1957¦~¥Ñ^°êAlick Isaacs©MJean Lindenmann¨â¦ì¬ã¨s¤Hû©Òµo²{¡A·í²ÓM¨ü¨ì¯f¬r·P¬V®É¡A·|¥ß§Y»s³y¥X¤zÂZ¯À¥H©è§Ü¯f¬r¡A¨Ã¦P®Éĵ§i¾Fªñ¥¿±`ªº²ÓM¡A´£°ªÄµÄ±¡A¥H¨¾¯f¬r¤J«I¡Cºî¦X¹L¥hªñ40¦~ªº¬ãµo,§Ú̪¾¹D¡A¤zÂZ¯À°£¤F§Ü¯f¬r¥~¡AÁÙ¦³§í¨îÀù²ÓM¥Íªø¡B«P¶i²ÓM¤À¤Æ©M¼W±j§K¬Ì¤Oªº¥\¯à¡A¦ý¬O¤zÂZ¯À¦b¤HÅ骺§t¶q·¥§C¡A¤SµL¾A·íªº»s³y¤è¦¡¡A¦]¦Ó¨î¤FÁ{§ÉÀ³¥Îªº»ùÈ¡Cª½¨ì³Ìªñ¡A¥Íª«§Þ³Nªº¬ð¸²r¶i¡A¤zÂZ¯À¤~±o¥H¶q²£¦Ó¼sªx¦aÀ³¥Î©óÂåÀø¤W¡C¤zÂZ¯À¥Ø«e¥Dn¥i¤À¤T¤jÃþ¡RIFN-£\, IFN-£]¡AIFN-£^¡A¨ä¤¤IFN-£\¦bÅ餺¥b°I´Áªø¹F4-16¤p®É¡A¤]¬O©Ò¦³¤zÂZ¯À¤¤¡A³Ì±`¨Ï¥Îªº¡C¨ä§ëÃĤ覡¬°¦Ù¦×©Î¥Ö¤Uª`®g¡C ¾AÀ³¯g IFN-£\¥Ø«e¸g¬ü¡B^¡B¤é¡B¼wµ¥¥ý¶i°ê®a®Ö㪺¾AÀ³¯g¥]¬A¡G(1)¯f¬r©Ò¤Þ°_ªº¯e¯f¡R¨Ò¦p¡AºC©ÊB«¬¨xª¢¡BºC©ÊC«¬¨xª¢¡Bµæªá(¦yÀYÀã¬Ð)¡B·R´þ¯f±w±`¨£ªº¥dªi¦è¤ó¦×½F(Kaposi¡¦s sarcoma)µ¥¡C(2)¦å²G¯e¯f¡R¨Ò¦p¡A¤òª¬²ÓM¥Õ¦å¯fºC©Ê°©Åè©Ê¥Õ¦å¯f¡B¦hµo©Ê°©Åè½F¡B§C«×«D¦óªNª÷¥Â²O¤Ú½Fµ¥¡C(3)¨ä¥¦¸~½F¡R¨Ò¦p¡A¶Â¦â¯À½F(Melanoma)¡BµÇ²ÓMÀù¡B°ò©³²ÓMÀùµ¥¡C ¦b¥xÆW¥Ø«e¤wÀò¥þ¥Á°·«Oµ¹¥Iªº¯e¯f¦³¡R¤òª¬²ÓM¥Õ¦å¯f¡BºC©Ê°©Åè©Ê¥Õ¦å¯f¡B¦hµo©Ê°©Åè½F¡B¥H¤Î¨Ï¥Î¶Ç²ÎÀøªkµL®Ä¤§T²ÓM²O¤Ú½Fµ¥¡C §@¥Î¾÷Âà ¹ïIFN-£\ªº¥Íª«¬¡©Ê¤Î§@¥Î¾÷Â઺¬ã¨s¡A¥Ø«e¥¿«ùÄò¶i¦æ¤¤¡C¥Ø«e¤wª¾ªº§@¥Î¥]¬A¡R1)§í¨î¯f¬rªº½Æ»s¼W¥Í¡C2)¼W±j§K¬Ì²ÓM¹ïÀù²ÓM¤Î¨ü¯f¬r·P¬V²ÓMªº±þ¶Ë¤O¡C3)¨ë¿EÀù²ÓM¤Î¯f¬r·P¬V²ÓMªí²{²Ä¤@Ãþ¤£¬Û®e§Üì©ó²ÓMªí±¡A¨Ï³o¨Ç²ÓM©ö©óÅý§K¬Ì²ÓM¿ë»{¦Ó³Q®ø·À¡C4)§í¨îÀù²ÓM®Ö»Ä©M³J¥Õ½èªº¦X¦¨¡A¨Ï²ÓM¥Íªø°±º¢¡C5)IFN-*¥i¼vÅT¬ù40ºØ©MÀù¯g¥Í¦¨¦³Ãö°ò¦]ªºªí¹F¡C Á{§ÉÀ³¥Î ¤zÂZ¯À¹ïÀù¯gªºªvÀø§@¥Î»P¤@¯ë¤ÆÀø¤£¦P¡A¥¦¤£¬Oª½±µ±þ®`Àù²ÓM¡A¦Ó¬O¥H½Õ¸`¤HÅ餺¦hºØ¨t²Î¨Ó¹ï§ÜÀù²ÓM¡A¦]¦Ó¥¦ªº§@¥Î¸û½wºC¡C¦bÁ{§ÉÀ³¥Î¤è±³q±`»Ýn¤@¦Ü¤TÓ¤ë¤~¯à¦³©úÅ㪺Àø®Ä¡A¤]»Ýn¸ûªø´Áªº¨Ï¥Î¡A©l¯à¹F¨ì²z·Qªº®ÄªG¡C ¥HºC©Ê°©Åè©Ê¥Õ¦å¯f(CML)ªºªvÀø¬°¨Ò¡AÁöµM¤ÆÀø¾¯Hydroxyurea©ÎBusulphan¥i¥H¦³®Ä¦a±±¨î¯gª¬»P¥Õ¦å²y¼Æ¡A¦ý¹ï¯f±wªº¦s¬¡´Á¼vÅT¤£¤j¡A²§Åé°©Åè²¾´Ó¥i¥Hªv¡¬Y¨Ç¯f¤H¡A¦ý¥u¦³³¡¥÷¯f¤H¯à±µ¨ü²§Åé°©Åè²¾´Ó¡C¦ÓIFN-£\¥i¸g¥Ñ½Õ¸`¨Ã§ïÅÜCML´c©Ê²ÓMªº¯S©Ê¡A¨Ï±o10-25%ªº¯f±w¹F¨ìªø´Áªº½w¸Ñ¡C¨Ì¬ü°êMD AndersonÂå¾Ç¤¤¤ßªº«Øij¡A¾¯¶q¬°5MU/m2/Day©Î¯f±w¥i®e§Ôªº³Ì¤j¾¯¶q¡C·í¥Õ¦å²y³Q±±¨î¦b2000¨ì6000/ul®É¡A¥i¹F¨ì³Ì¨ÎªºÀø®Ä¡C³Ìªñªº³ø§i§ó«ü¥X¡A¥HAra-c¥[¤WIFN-£\ªvÀøÀø®Ä¥i¥H§ó¦n¡C ¹ï±ß´Áªº§C«×«D¦óªNª÷¤ó²O¤Ú½F¡A¥HIFN-£\§@ºû«ùªvÀø©Î¦bÀøµ{¤¤¥[¤JIFN-£\ªº¦hÓÁ{§É¸ÕÅç¡A³£Åã¥ÜIFN-£\ªº¥[¤J¡A¥i©µªø¯f±wªº½w¸Ñ´Á(¤]´N¬O¯f±¡¨ü¨ì±±¨îªº±¡§Î)1-2¦~¡C¨ä¤¤ªk°êDr. Solal-Celignyªº¸ÕÅç¡A§óÅã¥Ü¥HIFN-£\»PCHVP(¤@ºØ¤Æ¾ÇÀøªk)¨Ö¥Î18Ó¤ë¡A¥i©µªø¦s¬¡´Á¹F22Ӥ뤧¦h¡C¦]¦Ó¼Ú¬w¤Î³Ìªñªº¬ü°êÃĪ«¹«~ÀËÅ秽³£¤w®ÖãIntron A(IFN-£\ªº¤@Ó¼tµP)¥Î©óªvÀø±ß´Áªº§C´c©Ê«×«D¦óªNª÷¤ó²O¤Ú½F¡C IFN-£\¦b¹êÅé¸~½F¤§ªvÀø¤è±¡A¤]¦³¦¨¥\ªº¨Ò¤l¡C¨Ò¦p¡A¶Â¦â¯À½F¤â³N«áªº»²§UªvÀø¡A¥HIFN-£\ªvÀø¤@¦~¡A¥i©úÅã¦a¼W¥[¤F¯f±wªº¦s¬¡´Á¬ù¤@¦~¡C¦]¦Ó¦b1996¦~Àò±o¬ü°êÃĪ«¹«~ÀËÅ秽 ®Öã¥Î©ó¶Â¦â¯À½Fªº³N«áªvÀø¡C¹ï©ó®ø¤Æ¹DªºÃþÀù( Carcinoid tumor)¡AIFN-£\¤]¯à¦³®Ä§ïµ½¯f±wªº¯gª¬¡A¨Ã¨Ï³¡¥÷¯f±wªº¸~½F®ø°h¡C ¤é¥»Dr. Nishiguchi©ó1995¦~¦bLancetÂø»xªº³ø§i«ü¥X¡A¥HIFN-£\ªvÀø»´·L¨xµw¤ÆªºC«¬¨xª¢¯f±w¡A¸g¹L2-7¦~ªº°lÂÜ«á¡Aµo²{¨xÀùµo¥Íªº¤ñ¨Ò©úÅã¦a¤U°¬ù9¿¡C °Æ§@¥Î¤Î³B²z IFN-£\¤Þ°_ªº¦´Á°Æ§@¥Î¡A¥Dn¬°"Ãþ¬y¦æ©Ê·P«_¼xÔ¸s"¡C¨Ò¦p¡Gµo¿N¡Bµo§N¡B¦Ù¦×°©Àf»Äµh¡B¥¢¯v¡B¹¼¤¤£®¶¡BÅé«´î»´»P¯h²Ö¡A¥i©óª`®g«e¥ýªA¥Î¸Ñ¼öÂíµh¾¯¨Ó§ïµ½¯gª¬¡C³q±`³o¨Ç¦´Á°Æ§@¥Î¡A¥Ñ©ó¨Å麥º¥²ßºD¡A·|¦bªvÀø1-2¬P´Á¤º®ø¥¢¡C¯f±w¥i¥H¦h³Ü¤ô¡B¦h¥ð®§¡B¼ö¼Å¡B«ö¼¯¤Î°µ¤@¨ÇÅé¾Þ¨Ó©ñÃP¦Ù¦×ªºÀ£¤O¡CY¦³¹¼¤¤£®¶¡A«h¥i¤Ö¶q¦hÀ\¡B¦Y¨ÇÁ¡²ü©Î»Ä©Êªº¿}ªG¨Ó§ïµ½G¤f¡C«á´Áªº°Æ§@¥Î¡A¥Hºë¯«¼~Æ{ªº¯gª¬¤ñ¸ûȱoª`·N¡A¥²n®É¦bºÎ«eªA¥Î§Ü¼~Æ{¾¯§Y¥i§ïµ½¡C¦¹¥~¡AªvÀø´ÁÀ³nª`·N¥Õ¦å²y¼ÆªºÅܤơCY¤Ó§C¡A«h»Ý½Õ¾ã¾¯¶q¡C ¥¼¨Óªºµo®i Á`¤§¡A¤zÂZ¯À¨ã¦³§Ü¯f¬r¡B§Ü¸~½F©M½Õ¸`§K¬Ì¨t²Î¥\¯à¡C³o¨Ç¥\¯à¥Ø«e¤w¸g¦¨¥\¦a¹B¥Î©óÁ{§ÉªvÀø¤W¡C¦¹¥~¡A¥Ñ©óIFN-£\¥i½Õ¸`³\¦h°ò¦]ªºªí²{¡A§ïÅܲÓMªº¯S©Ê¡A¥¼¨Ó¥i¥H¹Á¸Õ¥HIFN-£\¨Ó¼W¶i¨ä¥LªvÀø¾¯ªºÀø®Ä¡A©Î¥H¨ä¥LªvÀø¾¯¨Ó¼W¶iIFN-£\ªº§@¥Î¡C§ÚÌ´Á«Ý¸g¥Ñ¹ï¤zÂZ¯À§@¥Î¾÷Â઺¶i¤@¨B¤F¸Ñ¡A¯àµo®i¥X§ó¦³®ÄªºIFN-£\¦X¨ÖªvÀø²Õ¦X¡A¨ÓÀ³¥Î©ó§ó¦hªºÀù¯gªvÀø¡C |
|
|
·|û¡Gchang559910142993 µoªí®É¶¡:2016/8/18 ¤W¤È 12:14:11²Ä 516 ½g¦^À³
|
¼w¤t®a±d¡G¦pªG§ùÃY¤£³Ú~§Ú´Nµ¥«Ý¨e³Ú§a¡I |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/17 ¤U¤È 04:47:25²Ä 515 ½g¦^À³
|
¤WÂd®É¡A¿ì²z¹LÃB°t°â |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/17 ¤U¤È 04:39:04²Ä 514 ½g¦^À³
|
©_©Ç¡Aªk»¡·|®É¤£¬O¥s¤j®a³£¶R²¼¡C 7¤ë¥÷«ùªÑ¡A¤jªÑªF´î¤Ö2219±i¡C ¦æ¬F°|¶}µo°òª÷¤Ö762±i¡B¶£®õ§ë¸ê¤Ö970±i¡BÄ£µØ¤½¥q¤Ö334±i¡B¨ä¥LªÑªF¡A§¡¦³«ùªÑ´î¤Öªº²{¶H¡C ¤£ª¾¬O¦óì¦]? |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/8/17 ¤U¤È 02:29:40²Ä 513 ½g¦^À³
|
³o¼ËªºªÑ»ù¨«¶ÕÁÙ¯u¿i¤H°Ú¡I |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/14 ¤U¤È 10:12:31²Ä 512 ½g¦^À³
|
¨Ï¥Î¤zÂZ¯À¥i¥H´î¤Ö¨xÅÖºû¤Æ(¨xÀù) http://www.healio.com/infectious-disease/hepatitis-c/news/in-the-journals/%7Bedb37066-5c4f-4240-bb27-a68c2fe072da%7D/arfi-elastography-predicts-fibrosis-in-patients-with-hcv-who-achieved-svr ¤fªAªºDAAÃĪ«ÁaµM«ÅºÙ¦³¹êÅç«Çªº°ªªvÀø²v¡C¯u¹êª¬ªp¨Ã«D·Q¹³¤¤ªº¦n¡C http://www.ncbi.nlm.nih.gov/pubmed/27428297 §ó¦óªp¡A¦Ü¤µ¨ÃµL³o¤@¨Ç¤p¤À¤lÃĪ«(DAA)¥i¥H§ïµ½¨xÅÖºû¤Æªº¥ô¦ó³ø¾É¡C ¦b³Ìªñ´X¦~¡A³o¤@¨Ç¤p¤À¤lÃÄ·°_¶³´é¡AP1101¥i»¡¬O³Ì·sÃĪ«¤¤ªº¥@¬É°ß¤@¡A´NÅã±oÅb¥ßÂû¸s¡C P1101³J¥Õ½è·sÃÄ¡A³Ì·s«¬¤zÂZ¯À¡A¬O§K¬ÌÀøªk¡C ¥¼¨Ó¥¦¤£ºÞ¬O³æ¿W¨Ï¥Î¡AÁÙ¬O°t¦X³o¤@¨Ç¤p¤À¤lÃÄ¡A±N·|¬O¥¼¨ÓªvÀøªº¥D¬y¡C Sovaldi ªºµo©ú¤H¤£¬Oµy¨Ó«H®§¤F¶Ü? |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/14 ¤U¤È 06:21:35²Ä 511 ½g¦^À³
|
2014¦~·s»D¤F µL²á®ø¿i®É¶¡ ¥[´î¬ÝÅo http://www.pharmaessentia.com/chinese/news_2014073101.html |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/13 ¤U¤È 08:11:34²Ä 510 ½g¦^À³
|
P1101¦Û¤v¥Í²£ ¦Û¦æ¾P°â ¤@±øÀsªº§@ªk ¤ò§Q²v·|¦³´X%©O §Ú²q40-50%¥H¤W§a |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/8/12 ¤W¤È 09:28:26²Ä 509 ½g¦^À³
|
§ë«H¤@¸ô¶R¡A¤Ñ¤Ñ¶R ¬Ý¬Ýºë´ú¡AÁö¤]°_°_¸¨¸¨¡A¦ý¤£ª¾¤£Ä±¤]¤W¥a¤¸¤F ¦nªÑ¬O¤£·|±I¹æªº ¤£ª¾¤£Ä±¤¤¡AÃĵؤ]¬On¤W¥a¤¸ªº¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/8/11 ¤U¤È 04:50:42²Ä 508 ½g¦^À³
|
¥þ±©Ê®Ú°£C¨x¡A°·«Oij»ù¤fªA·sÃÄ»¡©ú ¸ê®Æ¨Ó·½¡G¤¤¥¡°·±d«OÀI¸p §ó·s®É¶¡¡G2016/08/11 ¨xª¢¦V¨Ó¬O°ê¯f¡A¦b°ÆÁ`²Î³¯«Ø¤¯¤Î½Ã¥ÍºÖ§Q³¡ªL«µ©µ³¡ªøªº«ü¥Ü¤U¡A¬F©²±N¾ã¦X¬ÛÃö¸ê·½³W¹º°ê®a«¬C¨x¨¾ªvpµe¡F¦Ó°w¹ï¦U¬ÉÃö¤Á¢Ñ«¬¨xª¢·sÃĬO§_¯Ç¤J°·«Oµ¹¥I¡A¤¤¥¡°·«O¸p¸pªø§õ§B¼ý¤µ¤Ñªí¥Ü¡A¸g¹L¸Ó¸p»PÃļt¿n·¥Ä³»ù«á¡A¥Ø«e¤T®aÃļt¤w¦³¨â®a¦P·N¤@ÓÀøµ{°»ù¬°¤Ü¤¸U¤¸¥H¤U¡F«Ý¤E¤ë¥l¶}°·«O·|«á¡A§Y¥i¦J©w¬ÛÃö°·«O¹wºâªº¤À °t¤ÎªvÀø¹ï¶HªºÀu¥ý¶¶§Ç¡A¤À§å¯Ç¤J¦UÀøµ{¡A¹wp©ú¦~°_§Y¥i±NC¨x·sÃįǤJ°·«Oµ¹¥I¡C °·«O¸p¤µ¤ÑÁܽХxÆW¨x¯f¬ã¨s¾Ç·|²z¨Æªø²ºa«n¡B¨x¯f¨¾ªv¾Ç³N°òª÷·|°õ¦æªø·¨°ö»Ê¤ÎC¨x¯f¤ÍªLÀA°ó¥ý¥Í¡A¤@°_¥l¶}C«¬¨x¤fªA·sª¢¯Ç¤J°·«Oµ¹¥I»¡©ú·|¡C °·«O¸p«ü¥X¡A¥Ø«e°ê¤º¤Þ¶i¢Ñ¨x·sÃĪºÃļt¥]§t¦ã§Bºû¡B¥²ªv§´¡B¦N¥ß¨È¡A¨CÓÀøµ{±q¤Ê´X¸U¨ì¤W¦Ê¸U¤¸¤£µ¥¡A°·«O¸p¤é«e»P¬ÛÃöÃļt¶i¦æªì¨Bij»ù¡A¥|ºØC¨x·sÃĦ³¨âºØªvÀø°ò¦]«¬ ²Ä¤@«¬ªºÃĪ«¡A¦P·N±NÃÄ»ù°¦Ü¤@ÓÀøµ{¤G¤Q¤¸U¤¸¡A¤U©P¥| (8/18)±N°eÃĪ«¦@¦PÀÀq·|ij°Q½×¡C ¥Ñ©ó°·«OÁ`ÃB¦³¤W¡A®Ú¾Ú¦ôp¡A¦Ó¥þ°ê¢Ñ¨x±wªÌ¦h¹F55¸U¤H¡A¦]¦¹¥¼¨Ó¯Ç¤J°·«Oµ¹¥IªºªvÀø¹ï¶H¡A¤´±Nµø¯fªpªºÄY«©Ê¤Î«æ¢©Ê¦³Àu¥ý¶¶§Ç¡A¸g¹L¬ÛÃöÂå¾Ç·|©Ò´£«Øij¡A²Ä¤@Àu¥ý¶¶§Ç¬°Anti-HCV¶§©Ê¶W¹L¤»Ó¤ë¡BHCV RNA¬°¶§©Ê¡BALTȲ§±`¥B¥ý«e¨Ï¥Îªø®Ä¤zÂZ¯À¥[¹p¤Ú«ÂªLªvÀø¥¢±ÑªÌ¡C¦¹Ãþ±ø¥óªº¯f¤H¡A¤@¦~¹w¦ô¦³8,000¦Ü10,000¤H¡A²Ê¦ô¤@¦~°·«O¤ä¥X¬ù·s¥x¹ô¤Ü¤»õ¤¸¡C ¦Ü©ó³¡¤ÀÂå¬É¤H¤h¾á¤ß³oµ§ªvÀøªá¶O¥i¯à¤Þµo±ÆÀ½®ÄÀ³¡A³y¦¨°·«O°]°È§ó§Î¦Y«¡AÀ³¸Ó¨Ï¥ÎªÌ¥I¶O¡A«Øij±wªÌÀ³¦Û¦æ³¡¤Àt¾á¤¦¨¡A§õ§B¼ý¸pªøªí¥Ü¡A°·«O¸p·|¨Ì¯f¤Hªº¯fªp¤À§å¯Ç¤J¡A¦Ó¥B¦b°·«OÁ`ÃB¦~«×¹wºâ¤À°t®É¡A¤£·|±qÂå°|Á`ÃB¡B¦èÂå°ò¼hÁ`ÃB¡B¤¤ÂåÁ`ÃB¤Î¤úÂåÁ`ÃB¶µ¤U¤ä¥X¡A¦Ó¬O±qÁ`ÃBªº¨ä¥L¹wºâ¨Ó¤ä¥X¡Aµ´¹ï¤£·|µ}ÄÀ¨ìµ¹¥I´£ÂåÀø´£¨ÑªÌªºÂIÈ¡C¥t¥~¡A°·«O¸p¤]·|¦V¦æ¬F°|ª§¨ú¤ñ·Ó·R´þ¯f¡BªÍµ²®Ö¨¾ªvªº¤½°È¹wºâ¡A¤@°_§ë¤J¨xª¢¨¾ªv¡C §õ§B¼ý¸pªø¨Ãªí¥Ü¡A¥Ñ©ó°·«Oªk¨´µLÃÄ«~®tÃBt¾áªºªk·½¡A²Å¦Xµ¹¥I±ø¥óªº¯f±wµL»Ý¦³®tÃB¦Û¶Oªº¾á¼~¡C www.mohw.gov.tw/news/572256095 |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/10 ¤U¤È 03:46:31²Ä 507 ½g¦^À³
|
C¨x·sÃĶQ 2Ãļt°»ù 2016-08-10 14:22 Áp¦X±ß³ø °OªÌ§õ¾ð¤H¡þ¥x¥_³ø¾É ¥þ°ê¬ù¦³55¸U¦Ü60¸U¦WC¨x¯f±w¡AY¤£ªvÀø±N¦¨ºC©Ê¨xª¢¬Æ¦Ü¨xÀù¡A¦ýC¨x±wªÌ°ª¹F45¨ì50¸U¤H¥¼ªvÀø¡C½ÃºÖ³¡¨M±N¥xÆWC¨x¤fªA·sÃĪvÀø±N¯Ç¤J°·«O¡A¦ýÃļt¬O§_Ä@·N°»ù¦¨¬°«¤jÃöÁä¡F°·«O¸p½Ð¤T®aÃļt®ÉµªÂСA¤w¦³¨â®aÄ@·N±N¨CÓÀøµ{ªvÀø»ù®æÀ£¦Ü25¸U¤¸¡A¥xÆW±N¦¨¬°¥þ²yC¨xì¼tÃĪ«»ù®æ³Ì§Cªº°ê®a¡C ¥Ø«e¦@¦³¦ã§Bºû¡B¥²ªv§´¡B¦N¥ß¼wµ¥¤T®aÃļtC¨x¤fªA·sÃĨú±o¥xÆWÃÄÃÒ¡A¦ý§¡»Ý¦Û¶O¡A¨ä¤¤¥H¦N¥ß¼wÃÄ»ù³Ì°ª¡A¤@ÓÀøµ{»Ý140¸U¤¸¡A¦ã§Bºû¡B¥²ªv§´«h¤À§O¬°85¸U¤Î40¸U¤¸¡C ¾Ú¤F¸Ñ¡A¦ã§Bºû¡B¥²ªv§´¨â®aÃļt§¡¦P·N°»ù¦Ü25¸U¤¸¡A¦N¥ß¼w«h¦]ÃĪ«¾AÀ³¯g¸û¼s¡A¨ã¦³¿W¯S©Ê¡A¤£Ä@·N¥[¤J³o³õ°·«Oµ¹¥I¾Ô§½¡A¤´°í¦u¦Û¶O¥«³õ¡C ½ÃºÖ³¡ªøªL«µ©µ7¤ë©³«Å¥¬©ú¦~°_C¨x¤fªA·sÃįǤJ°·«O¡A¤Þ°_¨p¥ßÂåÀø°|©Ò¨ó·|¤j¤Ï¼u¡A¤W©P¥l¶}·|ijÁܱM®a¡B°·«O¸p©xû¡BÃļt¥Nªí¶}·|¡F¹ïC¨x¯Ç¤J°·«O¤@¨Æ¡AÂå°|¥Nªí¯¥Án¶©¶©¡A»{¬°¹ê¬I«á®£À£ÁY¦Ü°·«OÁ`ÃB¡Bµ}ÄÀÂIÈ¡AÅýÂå°|¬Õ¾l¤jÁY¤ô¡A®£ÅýÂåÀøÀô¹Ò§ó¦å¦½¡A©ñ¸Ü¤UӤ밷«O·|±N§ë¤Ï¹ï²¼¡C ¡u¿ú±qþ¨Ó¡H¡v¨p¥ßÂåÀø°|©Ò¨ó·|²z¨ÆªøÁªZ¦N»¡¡A¡uC¨x±wªÌ±µ¨ü¤fªA·sÃĪvÀø¡A³o·íµM¬O¦n¨Æ¡A¦ý¨S¦³¿ú¡A¦p¦ó±À°Ê¡H¡v ¥Lªí¥Ü¡A±q©ú¦~°_¡A¤@¦~30¦h»õ¤¸·R´þ¯fªvÀø¸g¶O±N¥Ñ°·«O¸pt³d¡A¥[¤WµÒ®½µu¦¬60¦h»õ¤¸¡A¨âªÌ¥[°_¨Ó°·«O¹wºâ´N¤Ö¤F¦Ê»õ¤¸¡A¦pªG¦A¥[¤WC¨x¤fªA·sÃijoÓ¡uµL©³¬}¡v¡A°·«OÂIȶե²¤j´Tµ}ÄÀ¡A¼vÅTÂå°|Àç¹B¡C ÁªZ¦Nªí¥Ü¡A¦pªG½ÃºÖ³¡°õ·N¥þÃBµ¹¥I·sÃÄ¡AÂå°|±N¤Ï¹ï¨ì©³¡A¥L«Øij±wªÌ¦Û¶O¤¦¨¡B¦Û¥I12.5¸U¤¸¡A¤~²Å¦X¨Ï¥ÎªÌ¥I¶Oì«h¡A±wªÌ¤~·|¨Ä¨Ä¦YÃÄ¡C ÁªZ¦N«ü¥X¡A¤U©P¥|±N¥l¶}²Ä¤G¦¸·|ij¡A±N´£¥X±wªÌ¦Û¶O¤¦¨ªº¶D¨D¡A¦pªG°·«O¸p¤´µLªk»¡²M·¡C¨xªvÀø¸g¶O¨Ó·½¡A¤Sn¥þÃBµ¹¥I¡A´Nºâ³¡ªø¤w¸g¹ï¥~«Å¥Ü¡A¦ýÂå°|¥Nªí¤´·|±À½¦¹¶µ´£Ä³¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/10 ¤U¤È 03:42:30²Ä 506 ½g¦^À³
|
C¨x·sÃĶQ ¥þ±§ëÃÄ¡H¤À¬qªvÀø¡H 2016-07-31 03:38 Áp¦X³ø °OªÌ³¯«BøÊ¡B¦¿¼zÖs¡þ¥x¥_³ø¾É ½ÃºÖ³¡ªøªL«µ©µ«Å¥¬©ú¦~±N¢Ñ¨x¤fªA·sÃįǤJ°·«O¡A¾Ç¬É³sÁnÆg³\¡AY°]·½¥R¨K¡A«Øij¥þ±§ëÃÄ¡AY¤£¯à¤@¦¸©Ê®Ú°£¢Ñ¨x¡AÀ³±Ä¤À¬qªvÀø¡C ¥h¦~¦Û¶O¨Ï¥Î·sÃĪv¡¢Ñ¨xªºªLÀA°óªí¥Ü¡AC¨xÃįǤJ°·«O«á¡A¥Á²³À³¥D°Ê°µ¨x¯f¿zÀË¡A¨Ã¿n·¥ªvÀø¡A¡u¤£¤î®¾±Ï¤@©R¡A§ó±Ï¤F¤@Ó®a®x¡v¡C ¯f±w®aÄݶ¾¤p©jªí¥Ü¡A¦o¶ý¶ý·íªì¦]¥Í²£®É¿é¦å¬V¯f¡A¢Ñ¨x¤fªA·sÃÄ°Ê»³¤W¦Ê¸U¤¸¡A¶ý¶ý¤£Ä@¬°¤Fªv¯fÄ묹¥þ®a¥Í¬¡«~½è¡A¤@¦A±À©µªvÀø¡Aª½¨ì¥h¦~¹Á¸Õ¤zÂZ¯ÀÀøªk¡A¥Ø«e¯f±¡±±¨î±o©y¡A¥¼¨Ó¤fªA·sÃĦpÀòµ¹¥I¡A·|Åý¥þ®a³£¨ü¯q¡C ¤¤¬ã°|¤h³¯©w«H»¡¡A¥xÆW¢Ñ¨x±wªÌ¬ù¤»¤Q¸U¤H¡A±q¤G¡³¡³¤T¦~¦Ü¤µ¥uªvÀø¤E¸U¤H¡A¬F©²¨Mij±N¢Ñ¨x·sÃįǤJ°·«O¡Aµ´¹ï¬O¤@¥ó¦n¨Æ¡A²zÀ³¥þ±§ëÃÄ¡A¦ý¢Ñ¨x·sÃÄ¡u¤Ñ»ù¡v¡A°·«OÃø¥H¤@¦¸¥þ±t¾á¡A¬F©²ÀÀ©wªvÀø¶¶§Ç¬O¥¿½Tªº¡C °ª¶¯Âå¾Ç¤j¾Çªþ³]Âå°|°Æ°|ªø²ø¸UÀsªí¥Ü¡A¢Ñ¨x¬O¥i®Úªvªº¯e¯f¡AªvÀøÃĶO¤@©w»·§C©ó¥¼¨ÓºtÅܦ¨¨xÀù©Î¨xŦ²¾´Ó©Ò»ÝªºªvÀø¶O¥Î¡A¼Ú¬ü¥ý¶i°ê®a³£»{¬°À³¥þ±ªvÀø¡C¤T¤Q¦~«e¢Ð¨x¬Ì]¬Fµ¦±À°Ê®É¡A³Q¦C¬°°ê¤º¤K¤j«ÂI¬ì§Þ¤§¤@¡A¦p¤µ¢Ñ¨x·sÃĤ]À³¥Ñ¦æ¬F°|¼h¯Å½s¦C¹wºâ¥þ±ªvÀø¡A¤£À³¥u¥Ñ°·«O©Ó¾á¡C ¨x¯f¨¾ªv¾Ç³N°òª÷·|¸³¨Æªø³\ª÷¤t»¡¡A¢Ñ¨x·sÃĤӹL©ù¶Q¡A¹wºâ¬OÓ¤j°ÝÃD¡A¡u°£«D°ê®a¤¤¤j¼Ö³z¡A§_«h«ÜÃø¥þ±ªvÀø¡v¡A¤À¶¥¬qªvÀø¤£¥¢¬OӸѨM¿ìªk¡C ¦Ü©óªvÀø¶¶§Ç¡A³¯©w«H«ü¥X¡A¢Ñ¨x¶iµ{½wºC¡A°·«OÀ³¸ÓÀu¥ýªvÀø³ÌÄY«ªÌ¡A¨Ò¦p¨xµw¤Æ¡BÄY«¨xÅÖºû¤Æµ¥¡A¨ä¾l»´¯gªÌ¡AÀ³¸Ó±Ä¨ú²{¦æªº¤zÂZ¯À¥[¤W¹p¤Ú«ÂªLªºªvÀø¡C ¥xÆW¨xŦ¬ã¨s¾Ç·|·|ªø²ºa«n»¡¡A¥xÆWªº¢Ñ¨x±wªÌ¦h¼Æ¤£ª¾¹D¤w·P¬V¡A¬F©²Yn¿zÀË¡A«Øij¥H¥|¤Q·³¨ì¤»¤Q·³±Ú¸s¬°³ÌÀu¥ý¡C |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/10 ¤U¤È 01:48:25²Ä 505 ½g¦^À³
|
·PÁ§õÁ`²Î¤jªº¤À¨É¡C 6446±¾µP¨º±ß¤p¶R¤F10ªÑIncyte(NASDAQ:INCY)¨ÓÆ[¹î¡A¹ï©ó°ê¤º·s¿³ªº·sÃĤp¼t¨Ó»¡¡AIncyte¬OÓȱoÉÃ誺¹ï¶H¡C -¦¨¥\ªº·sÃÄ -«ùÄòÂX®i·s¾AÀ³¯g -§¹¾ãªºPipeline -®ü¥~¥«³õ(Incyte¦b¬ü°ê¥H¥~)ªº°ê»Ú¤j¼t±ÂÅv -¦Û¦³¦æ¾P¹Î¶¤§G§½ Incyte¯à¦³¨º»ò°ªªº¥«È¡A¤£¥u¬O³æ¾aJakafiªº¾P°â°Ê¯à¡F±NÀ禬¦A§ë¤Jªø´Á»ùȪºµo®i¡A¬OIncyteÀò±o§ë¸ê¤H§ó°ª»{¦Pªºì¦]¡C 6446¥¼¨Ó¯à³Ð³y¦h°ªªº»ùÈ¡A¤]¨ú¨M¦b©ó6446§ë¸ê¤Hªº²´¬É¡F¦pªG¥u¬O°l¨Dµu´ÁªºEPS»P°t®§¡A§ã±þªº±N¬O¥¼¨Ó°ª«×¦¨ªøªº«´¾÷¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/9 ¤U¤È 09:20:08²Ä 504 ½g¦^À³
|
Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs • $208 million of 2016 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 46 percent growth over the same period last year • ECHO-301, the first Phase 3 trial evaluating epacadostat, now underway in combination with pembrolizumab as first-line treatment of patients with advanced or metastatic melanoma • New Phase 3 clinical data from COMFORT-I in myelofibrosis and RESPONSE-2 in polycythemia vera reinforce the leadership position of Jakafi in the treatment of patients with these myeloproliferative neoplasms (MPNs) • Ruxolitinib granted Breakthrough Therapy Designation by the FDA for the treatment of patients with acute graft-versus-host disease (GVHD) Conference Call and Webcast Scheduled Today at 10:00 a.m. ET WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 9, 2016-- Incyte Corporation (Nasdaq: INCY) today reports 2016 second-quarter financial results, including strong revenue growth driven by increased sales of Jakafi® (ruxolitinib) in the U.S. as well as continued growth in the royalties from ex-U.S. sales of Jakavi® (ruxolitinib) by Novartis. The long-term clinical profile of Jakafi was reinforced by the presentation of five-year overall survival data from the COMFORT-I trial in patients with myelofibrosis at the recent American Society of Clinical Oncology (ASCO) meeting and the successful results from the RESPONSE-2 Phase 3 trial in patients with uncontrolled polycythemia vera highlighted at the European Hematology Association (EHA) congress. Additionally, ruxolitinib has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute GVHD. Baricitinib, currently under global regulatory review for the treatment of patients with rheumatoid arthritis, may provide Incyte with a further valuable source of revenue, given the potential for milestones and royalties under the Company¡¦s license agreement with Eli Lilly and Company. The first regulatory approval for baricitinib is anticipated in the first quarter of next year. Incyte has a growing international footprint, which was accelerated by the recent ARIAD transaction in Europe, and now has a development, medical and commercial organization in Europe to complement its fully-integrated U.S. business. The expanded European team is fully operational, and will continue to grow the Iclusig® (ponatinib) brand as well as contribute to the clinical development of Incyte¡¦s portfolio of 14 product candidates. Within the R&D group, and during the second quarter of 2016, Incyte initiated the first pivotal Phase 3 trial of epacadostat, added a new clinical program with the initiation of a first-in-man trial of INCAGN1876, an anti-GITR agonist antibody, and signed a drug discovery alliance with the Moffitt Cancer Center ¡V collectively illustrating the depth and breadth of Incyte¡¦s discovery and development programs. ¡§Incyte is in an excellent position both financially and operationally as we enter the second half of the year,¡¨ stated Hervé Hoppenot, Incyte¡¦s Chief Executive Officer. ¡§Jakafi continues to grow rapidly in the U.S., and we have successfully incorporated our expanded European team. The recent initiation of the first Phase 3 trial of epacadostat was a significant milestone for Incyte, and we are preparing to launch the pivotal program for ruxolitinib in GVHD.¡¨ 2016 Second-Quarter Financial Results Revenues For the quarter ended June 30, 2016, net product revenues of Jakafi were $208 million as compared to $142 million for the same period in 2015, representing 46 percent growth. For the six months ended June 30, 2016, net product revenues of Jakafi were $391 million as compared to $258 million for the same period in 2015, representing 52 percent growth. For the quarter and six months ended June 30, 2016, net< |
|
|
·|û¡GAlan Liu10136094 µoªí®É¶¡:2016/8/9 ¤U¤È 03:45:24²Ä 503 ½g¦^À³
|
·sÃħë¸êµ¦²¤¡G©t¨àÃĽg¡]¤@¡^ tinyurl.com/z9wnprd §@ªÌ¡Gù±Óµ× | 2016 / 08 / 01 ©t¨àÃĬO«ü¶}µoµ¹¯f±w¤H¤f¤p©ó20¸U¤HªºÃĪ«¡A²Ä¤@²´¤j®a¥i¯à«Ü¯Ç´e¡A¯f±w¼Æ¨º»ò¤Ö¡A¦³¤°»ò¦n¶}µoªº¡H¶^¯}¤j®a«äºûªº¬O¡G2015¦~¥þ²y©t¨àÃÄÀ禬Á`p1020»õ¬üª÷¡A¦û¥þ²y±M§QÃÄÀ禬ªº15.5%¡Iª¾¦Wªº¥«³õ³ø§iEvaluatePharma°lÂÜ500®aÃĪ«¤½¥qªº²£«~¡A¹w´ú2020¦~¾ãÓ°ê»Ú©t¨àÃÄ¥«³õ·|¨Ó¨ì1760»õ¬üª÷ªºÀç·~ÃB¡A¦¨ªø©Ê¬O¤@¯ëÃĪ«ªº¤G¿¡A¤£®e¤pòó¡I¬õ³z¥bÃä¤ÑªºÀù¯g§K¬ÌªvÀøÃĪ«Opdivo( by BMS), Keytruda(by Merck) ©MªvÀøC¨xªºHarvoni(by Gilead)³£¬O¥Î©t¨àÃĵ¦²¤¨úÃÒªº¡A¨º»ò©t¨àÃĦ³¦ó§Q°òÅý¤jÃļt¯É¯É¸ó¤J·mÅy¡H¥xÆW¤S¦p¦óµ½¥Î©t¨àÃĵ¦²¤©O¡H¨ä¹ê¥xÆW¥Í§Þ¤½¥q¹ï©t¨àÃĨ䣯¥Í¡A¦ý´Á«Ý¥»¤å±aµ¹§ë¸ê¬É§ó²`¼hªº©t¨àÃÄ°Ó¾÷»{ÃÑ¡C ¦U°ê§¡¦³©t¨àÃĪk®× ¾Ú¦ôp¬ü°ê¦³3000¸U¤H¨ü¨î©ó7000ºØ¨u¨£©Ê¯e¯f¡A©Ò¥H¬ü°ê°ê·|©ó1983¦~³q¹L©t¨àÃĪk®×¡A¹ªÀyÃļt¶}µo¯f±w¼Æ¹L¤Öªº¨u¨£©Ê¯e¯f(rare disease)¡A¥H·ÓÅU®z¶Õ¯f±w¡C¦b©t¨àÃĪk®×¦¨¥ß¥H«e¥u¦³38Ó©t¨àÃĤW¥«¡A¤T¤Q¦~¨Ó¼úÀy«µ®Ä¡A¥[¤W°ò¦]¬ì§Þ»PÄvª§Àô¹Òªº±À°Ê¡AºI¦Ü2015¦~¬°¤î¡A¬ü°êÁ`¦@¦³511Ó©t¨àÃijQ§åã¤W¥«¡C¦Ó¤é¥»©ó1993¦~¡A¼Ú¬w©ó2000¦~¡A¤]³°Äò³q¹L©t¨àÃĪk®×¡C¨Ì¾Ú¨u¨£¯e¯f¯f±w©ó¸Ó°Ï¨C¤Q¸U¤H¤f¤¤¥X²{¾÷²v¬°4~6.5¤Hªº¤ñ¨Òpºâ¡]¦U°ê©³¼Ð¤£¦P¡A¤é¥»³ÌÃP¡^¡A¬ü°ê©t¨àÃĪùÂe¬O20¸U¤H¡A¼Ú·ù25¸U¤H¡A¤é¥»¬O5¸U¤H¡C ¬ü°ê©t¨àÃĨã¦hºØ°]°È¤Wªº¼úÀy¡G¥«³õ¿W½æ´Á¡B´îµ|©M¬ãµo¸É§U ¬ü°ê©t¨àÃĪk®×¦b¶}µoªÌªº°]°È¤Wµ¹¤©´X¶µÀu´f¡A¨ä¤¤¥H¥«³õ¿W½æ´Á³Ì¨ü«µø¡F¤@¯ëÃĪ«¶}µo°Ê»³¤Q¦h¦~¡A©¹©¹¶W¹L±M§Q«OÅ@¦~ªº17~20¦~¡A©Ò¥H¬ü°ê¹ï©t¨àÃĤW¥««áµ¹¤©¤C¦~¿W½æ´Á¡]market exclusivity¡^ªº«O»Ù¡A¼Ú¬w©M¤é¥»«h«O»Ù¤Q¦~¡C¥t¥~¦b¬ü°ê¡A©t¨àÃĶ}µo°Ó¥i´îµ|©MÀò±o¬ãµo¸É§U¡A¦b¼Ú·ù«h¦U°êµ|°È½ÆÂø¹ï¶}µoªÌ¦Ó¨¥¸ûµL´îµ|»¤¦]¡C µù¡G¬ü°ê©t¨àÃĪº¿W½æ«O»Ù¬O«ü³s¦P¸ÓÃĪºÆQÃþ©ÎàÃþ³£¤£ãÄvª§ªÌ¶i¤JÄvª§¡A¤ñ¤@¯ëÃĪ«ªº«OÅ@©Ê§ó°ª¡C ¥«³õ°Ó¾÷¡Gºë·ÇªvÀø¦³§Q©t¨àÃÄ¥«³õªºÂX¤j ¦´Á¿WÅQ¥«³õªºÃĪ«¡A¨Ò¦pªvÀø·P¬Vªº§Ü¥Í¯À¡A©Î¸Ñ°£¯gª¬°ÝÃDªº¤j©vÃĪ«¡A¨Ò¦pGÃÄ¡B¤îµhÃÄ¡B°¦åÀ£ÃÄ¡Kµ¥µ¥¡A¤w¶}µoªº®t¤£¦h¤F¡A¤jÃļt¥u¯à©¹§ó²Ó¿°¤Æªº¥«³õ°Ï¹j´M§ä¯f·½¡A¥[¤W°ò¦]¬ì§Þªºµo¹F¡A¥Ø«e«Ü¦h¥Í§Þ¤½¥q¤D´Â¼Ð¹v¯f±w¶}µoÃĪ«¡A¥ý§ä¥XP¯fì¦]¦A¹ï¯g¤UÃÄ¡A§Yºë·ÇªvÀøªººë¯«¡A©ó¬O¥«³õ²Ó¤À¤Á³Îªºµ²ªG¡A«Ü®e©ö²Å¦X¯f±w¼Æ¤p©ó20¸U¤Hªº©t¨àÃĽdÃ¥¡A¨É¨ü©t¨àÃĪk®×Àu´f¡A³o¤]¬O§Uªø©t¨àÃÄ¥«³õ³Q¹w¦ô¨â¿¦¨ªøªº¦]¯À¤§¤@¡C ©t¨àÃÄ¥«³õµ¦²¤¡G¥ý¤W¥«¡A¦AÂX¤j¾AÀ³¯g½d³ò 2014¦~³Q®Ö㪺©t¨àÃĤ¤¡A43%¨Ó¦Û©ó°ê»Ú¤jÃļt¡A¥t38%¥Ñ¤¤¤p«¬¥Í§Þ¤½¥q¶}µo¡F¤jÃļtµ½¥Î©t¨àÃĪk³W¤£¬O¬°¤F°]°È¤Wªº¼úÀy¡A¦Ó¬O¦³¨ä¥Lµ¦²¤¹B¥Î©M®É¶Õ©ÒÁͪº±À°Ê¤O¡C¤@¯ë³Ð·sÃĪ«ªºªì¨BÁ{§É¹êÅç¥Dn¥Î©óÅçÃÒªvÀø²z½×( proof of concept)¡A¥Ñ©ó·ÀI·¥°ª¡A§Y«K¬O°]¤j®ð²Êªº¤jÃļt¤]¶É¦V©ó¯à¬Ù´N¬Ù¡A¬G¥ý¥H¤p²³¥«³õÅçÃÒ²z½×¡A¥¼¨Ó¦AÂX¤j¨ì¨ä¥L¾AÀ³¯g¡A³o¦bÀùÃĪº¶}µo¤W¯S§O©úÅã¡C¦Ó³oªÑÁͶդ]¶}©lÂà¦V¤ß¦åºÞ¯e¯fªºÃĪ«¶}µo¡A¤j®a¥i¥HÄ~ÄòÆ[¹î¤§¡C ªk³W§Q°ò¡G¬Y¨Ç©t¨àÃĨã¼u©Ê®Ö¥i¾÷·| ¦Ó¨«©t¨àÃĸô®|ÁÙ¦³Ó¦n³B¬O¦b¦æ¬F¤W¸û®e©ö¹LÃö¡A¦]¬°¦³¨Ç¶W¯Å¨u¨£ªº¯e¯f¡A¯f±w¨C¤Ñ¨üW¡A¤H¹D¤WFDA·|¥[³t¨Ï¨ä¹LÃö¡A¾ÚEvaluatePharma 2015¦~¤E¤ëªº²Îp¡A¤C¦¨ªº©t¨àÃĨ«¼u©Ê³B²z¨úÃÒ¡A¤£¥²¹³¤@¯ëÃĪ««ö³¡´N¯ZºCºCÅçÃÒ¦w¥þ©Ê»P¦³®Ä©Ê¡A¾Ú³ø§i¨ä¤¤¦³¤@¥b¬O¥Hcase-by -case¹LÃöªº¡C ¤£¹L¦bÀù¯g¤W¡A©t¨àÃĨúÃÒ¾÷²v°ª©ó¤@¯ëÃĪ«ªºì¦]¬O¦]¬°ªv¯f¾÷¨î²M·¡¡A¹ï¯g¤UÃÄ¡A¦Ó¤£¬O¤H¹D©Î¹®Æ¡C ©t¨àÃĪº»ù®æ¡G°¾°ª»ù¡A¤ÞµoÄv¬Û§ë¤J ©t¨àÃĨ䣥þ¬O°ªÃÄ»ù¡A¦ý¥§¡¤ñ¤@¯ëÃĪ«°ª»ù¡CEvaluatePharma±N2014¦~©t¨àÃÄ«e¤@¦Ê¤jÁ`À禬°£¥H¯f±w¼Æ¡A±o¨ì©t¨àÃÄ¥§¡¨C¦~¨C¦ì¯f±w¥²¶·¤ä¥I111,880¬üª÷ªºÃĶO¡AµM¦ÓY¥H©t¨àÃĪº¤¤¦ì¼Æ»ù®æ§e²{ªº¸Ü¡A¬ù66,000¬üª÷¡C¦Ó«D©t¨àÃÄ«e¤@¦Ê¤jÃĪ«ªº¥§¡ÃÄ»ù¬O23,331¬üª÷¡AÃÄ»ù¤¤¦ì¼Æ¬O4775¬üª÷¡A¨â¬Û¤ñ¸û¡A©t¨àÃĪº½T°¾¦V°ªÃÄ»ù ¡C ¨º»òþ¨Ç©t¨àÃĦì©~°ª»ù©O¡H¤@¯ë»P¥Í©R§ñÃöªÌÁÙ¬O¸û®e©öÅý«OÀI¤½¥q©ÎÂå«O¦P·N¤ä¥I°ª»ù¡A¨Ò¦p¦]¥X¥Í²§±`¤Þ°_ªº¥NÁ©ʯe¯f¡A»Ýn¯S®íªº»Ã¯À¸É¥R©Î«ú§Ü¡]enzyme replacement¡^¡A§_«hµL§_¥NÁ¹ª«¤¤ªºÁÞÃþ©Î¯×ªÕ¡A³y¦¨¥Í©R¦MÀI©Î¦¨ªø¿ð½w¡A»Ã¯ÀÀøµ{¨C¦~¬ù¶·15¸U¨ì35¸U¬üª÷ÃĶO¡C ©t¨àÃĪºÁ{§É¤T´Á¶}µo¦¨¥»¸û§C¡A¨úÃҮɶ¡¸ûµu ©t¨àÃÄÃÄ»ù°¾°ª¡A¨º»ò¬ãµo¤ä¥X©O¡HEvaluatePharma¤S²Îp¡Aµo²{©t¨àÃÄÁ{§É¤T´Á¥§¡ªá¶OUS$103M¡A¦Ó¤@¯ëÃĪ«¬ùUS$193M¡AY¥[¤W¬ü°êµ|°ÈÀu´f¡A©t¨àÃÄ¥§¡¶}µo¦¨¥»¬ùUS$51M¦Ó¤w¡A¬°¤@¯ëÃĪ«ªº¥|¤À¤§¤@¡C ¦ÓÁ{§É¤T´Á¹ê験©Ò¶·nªº¯f±w¥§¡©t¨àÃĬ°761¤H¡A«D©tÃĬ°3549¤H¡]ªí¤G¡^¡A©t¨àÃÄ©Ò¶·¯f±w¬ù¤@¯ëÃĪº¤T¤À¤§¤@¡A¦b¶}µo¦¨¥»¤W©t¨àÃĤj¤j¸`¬ÙÃļtªº¤ä¥X¡C¦Ü©óÁ{§É¸ÕÅç®É¶¡¡A¦]©t¨àÃįf±w¸ûÃø§ä¡A©Ò¥HÁ{§É¤T´Á©Ò¶·ªá±¼ªº®É¶¡«h¨âªÌ®t¤£¦h¡A§¡¬ù2.88¦~¥ª¥k¡C ¦Ü©óÃĪ«±q°e¥ó®É¶¡?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/9 ¤U¤È 01:06:25²Ä 502 ½g¦^À³
|
·íªì¦VFDAª§¨ú¨ì§K¶i¦æPV¤T´ÁÁ{§Éªº¥Dn½×z¡Apk HUªºµª®×¤w¸g©I¤§±ý¥X.... Ãĵتí¥Ü¡A¥Ñ©ó¹ï·Ó²ÕÃĪ«ßm°ò(¤ë§¿)(hydroxyurea)¨ã°©Åè¬r©Ê¡A¨Ã¥i¯àPÀù¡A°ò©ó¤HÅé¸ÕÅç¹D¼w©Ê¦Ò¶q¡AFDA¦P·N³z¹L¹ê¦a¼f¬d¼Ú¬wªº¸ÕÅç¸ê®Æ¡A¥B¯à´£¨ÑÅãµÛªº¡B¤@PªºÀø®Ä¤Î¦w¥þ©Ê¼Æ¾Ú¡A¯à°÷ÃÒ¹ê³o¨Ç¼Æ¾Ú¨Ó¦ÛÄYÂÔªº¬ã¨s³]p¨Ã²Å¦XÂåÀø¤Î¬ã¨sÛ²zªº«e´£¤U¡AÃĵØÂåÃÄ¥i§Q¥Îµ¦²¤¹Ù¦ñAOPªº²Ä¤T´Á¤HÅé¸ÕÅçµ²ªG¬°¨Ì¾Ú¡A³w¦æ¦V¬ü°êFDA¾÷Ãö´£¥X¥Ó½ÐÃÄ«~¨Ï¥Î®Öã¡C |
|
|
·|û¡Gucss10142657 µoªí®É¶¡:2016/8/9 ¤U¤È 12:04:03²Ä 501 ½g¦^À³
|
§ÚÁÙ¬O°í«ùªø´Á«ù¦³ ¥Ø«eµ¥3´Á¼Æ¾Ú¤½¥¬ ÃÄ®Äpk©úÅãÀu©ó(HU/²Ä¤@½u¤ÆÀø¤è¦¡)ªº¸Ü §Ú·|¥Î¤O¦A¥[½X.µ¥«ÝªG¹êÅܤj |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/9 ¤W¤È 12:31:37²Ä 500 ½g¦^À³
|
¥xÆW¤]¥i¥@¬É«ax ®¥¶P³\²Q²b®³¨ìÁ|«¶ø¹B«ax¡C ¥H«e¥Ð®|³õ¤W³£¬O¼Ú¬ü¿ï¤â¡Aªñ´Áªº¨È¬w¤j°êµ¥¤]±U°_¡C¥xÆWÁ`¬O¯Ê¥F¨º¤@ªÑ®ð¡C ³\²Q²bªº«ax¡A¤]§i¶D¥@¬É:¥xÆW¤]¥i¥H! ·sÃĬãµo³o¤@¶ô¡A¤@ª½¬O¬ü°ê°õ¥@¬É¤û¦Õ¡A¼Ú¬w¡B¤é¥»¦³°¸¦³¨Î§@¡C ¥xÆW¦b³o¤@¶ô¦n¹³´N¸G¤@ºI¡C ¦ý¬OP1101´N¹³³\²Q²b¤@¯ë¡A¥´¯}¹L¥h°g«ä¡A¤]Á|¥X¥@¬É¤§³Ì¡C Ãĵاâ¥@¬É³Ì¦¡B³Ì¦h¤H¥Î¹Lªº§K¬ÌÀøªk-¤zÂZ¯À¡A§ï¨}¦¨"¥þ²y³Ì¨Î¤zÂZ¯À"¡C ¤é¥»¦å²G¾ÇÅv«Â¤pªQ«h¤Ò´N±NÃĵتºP1101ÅA¬°¡uªvÀø¦å²G¯f±w³Ì¦nªº²£«~¡B¥þ²y³Ì¨Î¤zÂZ¯À¡v¡C ¥@¬ÉÅv«ÂKralovics±Ð±Â«ü¥X¡A¥H°ò¦]Åé¾Ç¨¤«×¨Ó¬Ý¡A¤zÂZ¯À¬O°ß¤@¥i¥H¥h°£Àù¯g²ÓM¡]¯}Ãa©Ê²ÓM¡^ªº¯«©_ªZ¾¹¡A¥B¦b¼Ú¬w¤wÁ{§ÉÃÒ©ú°Æ§@¥Î·¥§C¡B@¨ü©Ê°ª¡A¤ñ°_¥«±¤Wªº¥ô¦óÃĪ«³£¨Î¡AKralovics±Ð±Â§óª½±µ¥H¡u¥xÆW¤zÂZ¯À¡v¡B¡u¥@¬Éªº¤¤¤ß¡vÅA¤§¡A¬ðÅãÃĵئb¦¹¤@»â°ìªº§Þ³N»â¾É¦a¦ì¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/9 ¤W¤È 12:23:06²Ä 499 ½g¦^À³
|
Sovaldi µo©ú¤H¡A¦h¦¸»PÃĵذª¼h¨£±¡A´N¥i¬Ý¥X¬Ü¨¤ http://udn.com/news/story/7485/1620846 |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/8 ¤U¤È 09:35:15²Ä 498 ½g¦^À³
|
(C¨xÃÄÄvª§¥[¼@¡I¥Í§Þ¤j¼tGilead¬å¦~«×²£«~À禬¹w¦ô) www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=%7Bff31065f-bbb7-4611-b096-c7c5e2bea3f8%7D ¨â¶g«eGileadµo¥¬²Ä¤G©u°]³ø¡AC¨x·sÃĪº¾P°â¸û¥h¦~¦P´Á°I°h¡A¯S©w¼Ú¬w¥«³õC¨xÃijø»ù¯h³n¥H¤Î¥«¦û²v¤U·Æ¡C ¼Ú¬ü¯f¤H¤]¤£¬O¤H¤H³£¦³§¹µ½ªº°Ó·~ÂåÀø«OÀI¥it¾á±o°_¤fªA·sÃÄ¡A§ó¤£¥Î»¡¨È¬w¥«³õªºt¾á¯à¤O¡C P1101ªv¡C¨xªº¼ç¤O¡A¥i¥H¬Ý¤WÂd«eªk»¡·|¼v¤ù¡AªL°êÄÁ³Õ¤h¥Î§E©ú¶©±Ð±Â¦b6/10¨È¤Ó¨xŦ¬ã¨s¾Ç·|µoªí²³ø¨Ó¸ÑÄÀªº¨º¤@¬q¡A Ó¤H»{¬°¡A´N¸gÀÙ©Ê»Pªø´Áªv¡¯à¤O¡AP1101¬O«Ü¦³¾÷·|ªº¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/8/8 ¤U¤È 04:33:02²Ä 497 ½g¦^À³
|
¬Ý¨Ó°ê¤ºªvÀøC¨xªº°·«O¨î«×ÁÙ¬O¥ý±q¤zÂZ¯À°µ°_¡C ¤½¥q³o¶ôÁÙ¬O¦³¾÷·|ªº~~~ ¦ý¤£ª¾¹DÃĵتºP1101¥i§_ªv¡C¨x¤G«¬?¤£¹³¤fªAC¨xÃĪºÁÙ¬O·|¶i®i¨ì¨xµw¤Æ©Î¨xÀùªº¡C ÁÙ¦³Ãĵتº¥Ø«eC¨x¤G«¬¦¬®×ª¬ªp¦p¦ó? C¨x©y¾¨¦ªvÀø °§C¨xµw¤Æ¤Î¨xÀù·ÀI ¤å¡þ³\ª÷¤t Q¡G³Ìªñ³ø¸ü½ÃºÖ³¡ªø»¡¡A°·«O¸p©ú¦~·|µ¹¥I¤fªAC¨xªvÀø·sÃÄ¡A¯uªº¬O¤Ó¦n¤F¡C§Úªº¥ý¥Í¬O²Ä¤@«¬C«¬¨xª¢±wªÌ¡A¥H«eÂå®vÄU¥L¥Î¤zÂZ¯ÀªvÀø¡A¦ý¥L¿ð¿ð¤£´±¡A¦]¬°Å¥»¡°Æ§@¥Î«Ü¤j¡AÁöµM²{¦b¤fªAC¨x·sÃĤw¤W¥«¡A¦ý¹ê¦b¤Ó¶Q¤F¡A§Ú̵Lªkt¾á¡A©ú¦~¯uªº´N¯à¦³°·«Oªº§K¶OC¨x·sÃÄ¥i¥Î¤F¶Ü¡H A¡GC«¬¨xª¢¦b¹L¥h¤@¡B¤G¤Q¦~¨Ó¡A³£¬O¥H¤zÂZ¯À¥[¤fªA¹p¤Ú«ÂªL¨ÓªvÀø¡A¹ï²Ä¤@«¬ªºÀø®Ä¬ù¦³60%¥ª¥k¡A²Ä¤G«¬«h¥i°ª¹F90%¥H¤W¡A¦ýªº½T¦³«Ü¤jªº°Æ§@¥Î¡AÄY«¨xµw¤Æ¤Î¥Õ¦å²y¼Æ§Cªº±wªÌ¤]¤£¾A¦X¡A¤]·|¤Þµo³h¦å°Æ§@¥Î¡C ³o¤@¡B¨â¦~¤W¥«ªº¤fªAC¨x·sÃÄ´X¥G¨S¦³¤°»òÄY«ªº°Æ§@¥Î¡A¦Ó¥B95%¥H¤W±wªÌªº¯f¬r·|§¹¥þ®ø¥¢¡A¦ý°ß¤@ªº¯ÊÂI´N¬O¤Ó¶Q¡C ¥Ñ©ó°ê¤ºC¨x±wªÌ²³¦h¡AÁöµM©ú¦~°·«O´N·|¶}©lµ¹¥I¡A¦ý¥Ñ©ó°·«O¹wºâ¦³¥i¯àµLªk¥þ±¶}©ñ¡A¤j·§·|¥ýµ¹¥I¬Y¨Ç±¡ªp¯S®íªº¯f¤Í¡]¨Ò¦p´¿¸g±µ¨ü¤zÂZ¯ÀªvÀø¥¢±Ñªº¯f¤Í¡^¡A¦ý¥Ø«eÁÙ¤£ª¾¹DÀu¥ý¶¶§Ç¬°¦ó¡C¦ý¦pªG¸gÀÙ³\¥i¡A¤S¤w¸g¦³©úÅ㪺¨xÅÖºû¤Æ©Î¨xµw¤Æ¡A©ÎC¨x¯f¬r¶q°ª¥B¨x«ü¼Æªø¦~¤@ª½©~°ª¤£¤UªÌ¡A«ØijÁÙ¬O¾¨¦·Q¿ìªk¡B¤Î¦ªvÀø¡A¥H´î¤Ö¯f±¡¶i®i¨ì¨xµw¤Æ©Î¨xÀù¡C »Ýª`·Nªº¬O¡AC¨xªvÀø¦¨¥\¥u¬OÁקK¨xŦ¦AÄ~Äò¨ü¨ìC¨x¯f¬rªº¦M®`¡A¥H§K§Î¦¨¨xµw¤Æ¡A´î¤Ö¨xÀùªºµo¥Í¦Ó¤w¡C´«¥y¸Ü»¡¡Aµo¥Í¨xÀùªº¾÷²v¤´µM¦s¦bªº¡A¥u¬Oµo¥Í¾÷²v´î¤Ö¦Ó¤w¡C ³o¬O¦]¬°ªvÀø¤§«e¡AC¨x¯f¬r¤w¸g¦b¨xŦ¶i¦æºC©Êµoª¢¡A¦Ó¨xÅÖºû¤Æ¡B¬Æ¦Ü¨xµw¤Æ¥»¨´N¬O¨xÀùªº¦MÀI¦]¤l¡A¦]¦¹§Y¨ÏªvÀø¦¨¥\¤§«á¡A¤´»Ý©w´Á°lÂÜ¡C ¡]§@ªÌ¬°¥x¤jÂå¾Ç°|¤º¬ì¦WÅA±Ð±Â¡B°]¹Îªk¤H¨x¯f¨¾ªv¾Ç³N°òª÷·|¸³¨Æªø¡^ news.ltn.com.tw/news/life/paper/1019398 |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/7 ¤U¤È 09:56:49²Ä 496 ½g¦^À³
|
±`®Ä«¬¤zÂZ¯ÀªvB¨x¡A °±ÃÄ«áÄò±±§K¬Ì; ¤fªAÃĵLªk½Õ¸`§K¬Ì¡A °±ÃÄ©ö´_µo¡C http://vector.pixnet.net/blog/post/41361547-%E9%95%B7%E6%95%88%E5%9E%8B%E5%B9%B2%E6%93%BE%E7%B4%A0%E6%B2%BBb%E8%82%9D%E3%80%80%E5%81%9C%E8%97%A5%E7%BA%8C%E6%8E%A7%E5%85%8D%E7%96%AB ¤fªA«¬³o¤@¨Ç¤p¤À¤lÃĪ«¡A °±ÃÄ«á ¥i¯à¬O²rÃz©Ê¨xª¢¡A©Î«ùÄò´c¤Æ¬°¨xÀù¡C¥¼¨ÓÃþ¦üªº³ø¾É·|¼h¥X¤£½a¡C ¶i¶¥ª©ªº§ó¯Â¡A§ó±`®Ä¡A§K¬ÌÀøªkªº¤zÂZ¯À¤~¬O³Ì¨Îªº¸Ñ¨M¤è®×¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/7 ¤U¤È 04:51:51²Ä 495 ½g¦^À³
|
ªk»¡·|¤W¡A¸â«C¬h³Õ¤h¦^µª§ë¸êªÑªFªº°ÝÃD¡G PV¥Ó½ÐÃÄÃÒ¡A¬ü°êFDA»P¼Ú·ùEMA¦ó®É·|§åã¡H ¦^µª»¡¡G¬ü°êFDA»P¼Ú·ùEMA¬O¬Û¤¬¿W¥ß¡A¤£¨ü¼vÅT¡A¦³®ÉEMA³\¥i¡AFDA¦³¥i¯à¤£¦P·N¡C¦³¦Wªº®×¨Ò¡G¨F§QÄuÁÚ¡]thalidomide¡^, EMA³\¥i¡AFDA¤£¦P·N¡C¤£¹L¡A®Ú¾ÚICHì«h¡A¨âÃ䪺¼Æ¾Ú¡A¬O¥i¥H¬Û³q°Ñ¦Ò¡C¦ÓPV¥Ó½ÐÃÄÃÒ¡A§Ú̧Ʊæ©ó2017¦~©³«e³q¹L¡C ´£¨Ñ¤@«h¤å³¹¦p¤U¡G °ê®a½Ã¥Í¬ã¨s°|¹q¤l³ø ²Ä 655 ´Á 2016-06-27 ¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^»P¼Ú¬wÃĪ«ºÞ²z§½¡]EMA¡^·sÃļf¬d¨î«×¤§®t²§¤ñ¸ûªì±´ ¤å¡G¥Í§Þ»PÃĪ«¬ã¨s©Ò®}¹Å·ì³Õ¤h«á¬ã¨sû¡B³¯¬³ªF¬ã¨sû¡n ¤µ¡]2016¡^¦~ªì¡Aªk°êÃzµo¾ú¨Ó³ÌÄY«ªºÃĪ«¸ÕÅç¨Æ¬G¡A¾ÉP1¤H¸£¦º¡B5¤H¥Í©R««¦M¡A¨ä¤¤¦³3¤H¸£³¡¨ü¨ì¥Ã¤[·l®`¡A¦¹¸ÕÅç·sÃĬO¬°¤FªvÀø±¡ºü¯¿¶Ã¡BµJ¼{¯g¥H¤Î¯«¸g°h¤Æ¯e¯f¡]ªü´þ®üÀq¯g¡^µ¥¡C ½Õ¬dµo²{¡AÁ{§É«e¸ÕÅ礤¡A´¿¦³¸ÕÅç°Êª«¦]¸£³¡¶Ë®`¦Ó¦º¤`¡AµM¦Ó¸Ó¤½¥q°ò©ó¾÷±Kµ¥¦Ò¶q¦Ó¥¼¤½¶} ¡CÁöµMªì¨B³ø§i»{¬°§@·~¬yµ{¤WÀ³µL²¨¥¢¡A¦ý¨ä¥L¿W¥ß³ø§i¤´µo²{©óÁ{§É¸ÕÅç¬yµ{»P·¾³q¤Wªº²¨¥¢¡A¾ÉP¦¹¤£¥i°f¶Ë®`ªºÂX¤jµo¥Í¡C¦]¦¹¡AY¯à§óÄYÂÔ¦a³]p¡B°õ¦æ»PºÊ·þÁ{§É«e¦w¥þ©Ê¸ÕÅç»PÁ{§É¤HÅé¸ÕÅ礧¬yµ{¡AÀ³¥iÁקK¶Ë®`ªºµo¥Í¡C ¥Ñ©ó¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]US Food and Drug Administration, FDA¡^»P¼Ú¬wÃĪ«ºÞ²z§½¡]European Medicine Agency, EMA¡^¦bªk³W¨î«×¤Wªº®t²§¡A¥i¯à³y¦¨ÃÄ®`·ÀIªº¤£¦P¡C¦b·sÃļf¬d¨î«×ªº®×¨Ò¤¤¡A¨F§QÄuÁÚ¡]thalidomide¡^´d¼@¬O³Ì¬°¤H©Òª¾ªºÃÄ®`®×¨Ò¡A¤]¶}±Ò¤F²{¥N·sÃļf¬d¨î«×ªº«äºû»P¾÷¨î¡C1960¦~¥N¡A¼Ú¬w¤Î¤é¥»µ¥¦h°ê®Ö㤧·sÃĨF§QÄuÁÚ¡A¥Dn¥Î©óµÎ½w¥¥°ü§³®W¤ÏÀ³©Ò¾ÉPªº¥¥¦R¯gª¬¡A¨Æ«á°lÂܵo²{ÃĪ«³y¦¨¤W¤d¦ì¨u¨£ªº®ü°\ªÏ·î§Î¡]phocomelia¡^·s¥Í¨à¡AÀH§Y©ó1961¦~³Q¸T¥Î]¡FÂk¥\©óFDAÄYÂÔ¤§·sÃĥӽлP®Öã¬yµ{¡A¸ÓÃĦb¬ü°ê·í®É©|¥¼Àòã¥Î©ó¥¥°ü¡A¦¹®×¨Ò»¡©ú·sÃĶi¤J¥«³õ«e¹ï©ó¨ä¦w¥þ©Ê»P¦³®Ä©Êªºµû¦ô¦P¼Ë«n¡C¸Ó¨Æ¥óµo¥Í«á¡A«P¨Ï1960¦~¥N¦Ü1970¦~¥N¦U°ê¨³³t¥ßªk³W½d¡A1962¦~FDA²v¥ýq©w¹êÃÒ¡]evidence-based¡^ªºÃÄ«~µû¦ô¾÷¨î¡A³W©wÃļt¥²¶·´£¥XÃҾڨû¡©ú¸ÓÃÄ«~¦P®É¨ã³Æ¦w¥þ©Ê»P¦³®Ä©Ê¡F¨Ã¶i¤@¨B¦a¹{¥¬¡mÀu¨}¹êÅç«Ç¾Þ§@³W½d¡]Good Laboratory Practice, GLP¡^¡n¥H½T«OÁ{§É«eÃĪ«¦w¥þ©Ê»P¬r²z¸ÕÅçì©l¼Æ¾Ú¤§¥i¾a©Ê»P§¹¾ã©Ê¡A¶i¦Ó«P¨Ï²{¤µ¥Ó½Ð·sÃÄÁ{§É¸ÕÅç¦Ü¤W¥«¤§ºÊºÞ¾÷¨î»P¨t²Îªº«Ø¥ß¡C ¥«³õªº°ê»Ú¤Æ¬O»sÃIJ£·~µo®iªºÁͶդÎÂX¤jÀò§Qªº¥²n±ø¥ó¡CÁöµMÄYÂÔªºªk³W¥i¥H«O»Ù¥Á²³¥ÎÃĦw¥þ¡A°ò©ó¦U°êÃĪ«ºÊºÞ¾÷Ãö¹ï©ó§Þ³N¸ê®Æªº»Ý¨D¤£¦P¡A²£·~¬É¶·§ë¤J§ó¦h®É¶¡¡B¸g¶O»P¤H¤O¥H²Å¦X¦U°ê¤£¦Pªk³Wªº»Ý¨D¡A¹ï©ó«æ»Ý·sÃĪvÀø¤§¯e¯f¦]ÃĪ«¤W¥«ªº©µÌX¡A¾ÉP·l®`±wªÌ¤§ªvÀøÅv¯q¡C¦]¼f¬d©µ»~¥i¯à³y¦¨ÂåÀø·ÓÅ@¦¨¥»ªº¬Û¹ï¼W¥[¡A¥HÀù¯g·ÓÅ@ªá¶O¬°¨Ò¡AÀù¯g·ÓÅ@¤§ÂåÃĪá¶O³v¦~¼Wªø¡A®Ú¾Ú²Îp¡A2009¦~¼Ú¬w°ê®a²Îp¬ù¬°510»õ¼Ú¤¸¡F¦Ó2010¦~¦b¬ü°êÀù¯g·ÓÅ@ÂåÃĶO¥Î¬ù¬°1,200»õ¬ü¤¸[8]¡A°ª©ùªº·sÃÄ»ù®æ¤]³y¦¨±wªÌªºªvÀøt¾á¡A¾ãÅ骺ÂåÀø·ÓÅ@¦¨¥»¤]´£¤É¡C¦]¦¹¡A¥þ²y¢¤Á»Ýn²Î¦X·sÃļf¬dºÊºÞÀô¹Ò¡A¨Ï·sÃļf¬dªº®Éµ{ºë²¦Ó½T¹ê¡A±Ä¦h¤¸¤Æ¼f®Ö³~®|»P¤è¦¡¡A¨Ï§ó¦h·sÃÄ¥i¥HºÉ§Ö¶i¤J¥«³õ¡A¦ý¤´»Ýn¦³®Ä³W½d»P¼sªxÀ³¥ÎªººÊºÞ¾÷¨î¡C¦³Å²©ó¦¹¡A¡u°ê»ÚÂåÃĪk³W¨ó©M·|¡]International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH¡^¡v²Õ´¦¨¥ß¡A¨ä«e¨¬°1990¦~¦¨¥ß¤§International Conference on Harmonisation¡]ICH¡^¡AFDA¤ÎEMA¬°¨ä¥Dn¦¨û¡A±q°ò¥»¬[ºc¤W¨Ó¬Ý¡AICHªº³]p¤Q¤À±µªñFDAªº¬[ºc¡C¸g¹L¤G¤Q¾l¦~§V¤O¡A¨â¤èªº·sÃļf¬dºÊºÞ¾÷ºc§¡¦³«Ü¤j¶i¨B¡A½Ñ¦pFDA»PEMAÂù¤è¤À¨É¸ê°T¡B°ê»Ú¦X§@½]¬d¡]International API Inspection Pilot Program¡^©Î·sICH²Õ´ªº¦¨¥ßµ¥¡FµM¦Ó¡AFDA»PEMA¤´¦³®t²§¡A¾ÉP¬ã¨s¸ê·½ªº®ø¯Ó¡A¥Dn¨Ó¦Û©óÃĪ«®Öã©Ò»Ýªº®É¶¡´Áµ{¡B¥ÎÃÄ«ü¥Ü¥Îµü®t²§¡B¼f¬d¬yµ{¤¤¹ï©ó½Ñ¦p±wªÌ³ø§i®ÄªG¡]patient-reported outcomes, PROs¡^¼f®Öµû¦ô¬Ýªk¤£¦P¡A¥H¤Î¼f¬dÃþ«¬¤ñ¨Ò¤£¦Pµ¥¡C¥H¤U±N¨Ì¤Wz´XÓ¤è¦V¤ÀªRFDA»PEMA¦b·sÃļf¬d¾÷¨î¤W¤§®t²§¡C ·sÃļf¬d®Éµ{¤§®t²§ ¨C¤@Ó¦¨¥\ªº·sÃÄ¡A±q¬ã¨sµo®i¦Ü¤W¥«¥§¡¬ù»Ý§ë¤J18»õ¬ü¤¸¡A¦b¦¹¤§«e¡A§ë¤Jªº¸ê·½©|µLªk¶}©lÀò§Q¡A±wªÌ¥çµLªkÀò±o·sªºªvÀø¿ï¾Ü¡A¦]¦¹¡A¯à¶V§Ö¶i¤J¥«³õ¡A·sÃĤ~¯à±o¨ì¹ê½è®Ä¯q¡C2015¦~¡A´ö´Ë¸ô³z¶°¹Î¤§°ê»Úªk³W¬ì¾Ç³Ð·s¬ã¨s¤¤¤ß¡]Centre for Innovation in Regulatory Science, CIRS¡^©Òµoªí¤§¡mR&D Briefing 57¡n³ø§i¤¤¡A¤ÀªR¤F2005¦Ü2014¦~¤§¶¡EMA»PFDA¤§·sÃħåãÁͶաC³ø§iÅã¥Ü¡A2014¦~¼f®Ö®É¶¡¤¤¦ì¼Æ¤À§O¬°418¤Ñ¡]EMA¡^¤Î343¤Ñ¡]FDA¡^¡A FDA¤§ÅܤƸûEMA¤p¡Aªñ¤T¦~¤§¼f®Ö©Ò»Ý®É¶¡¸û¬°Ã©w¡CµM¦Ó¡AEMA»PFDA©Ò»Ý®É¶¡®t²§¥Dn¨Ó¦Û©ó¨âªÌ¤§¥DºÞ¾÷Ãöªº¼f®ÖÅv¤£¦P¡AFDA¦P®Ét³d·sÃĤ§¬ì¾Çµû¦ô¤Î¥«³õ¾P°â¤§±ÂÅv³\¥i¡F¦ÓEMA¤§¬ì¾Ç±M®a©eû·|¤§¤H¥ÎÃĪ«©eû·|¡]Committee for Medicinal Products for Human Use, CHMP¡^¤§Åv¶È©ó¬ì¾Çµû¦ô¡C¨Ì¾ÚCHMP¤§µû¦ôµ²ªG¡A¦A¥ÑEMA´£¥X?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/8/7 ¤W¤È 11:19:07²Ä 494 ½g¦^À³
|
·PÁ°¶¤j¤j´£¨Ñªº¤å³¹¡C ¥t´£¨Ñ1«h¤å³¹¡G °ê®a½Ã¥Í¬ã¨s°|¹q¤l³ø²Ä 660 ´Á ·sÃĦA³Ð·s·ß¡Xº©½Í2015¦~¬ü°êFDA®Öã¤p¤À¤l·sÃÄ ¤å/¥Í§Þ»PÃĪ«¬ã¨s©ÒÁ¿³¨¹¬ã¨sû¡B§õÀRµX°Æ¬ã¨sû¡F ¼f®Õ¡G¥Í§Þ»PÃĪ«¬ã¨s©Ò³¯¬³ªF¬ã¨sû (1)DaklinzaTM (daclatasvir) Ä~2013»P2014¦~Gilead Sciences¡]GS¡^¤½¥q¤À§O±À¥XªvÀøC«¬¨xª¢ÃĪ«Sovaldi®¡]sofosbuvir¡^»PHarvoni®¡]ledipasvir/sofosbuvir¡^¡A2014¦~AbbVie¤½¥q¤]±À¥XViekira PakTM ¡]ombitasvir/ paritaprevir/ ritonavir with dasabuvir¡^½Æ¤èÃĪ«¡ABristol-Myers Squibb¡]BMS¡^¤½¥qªºDaklinzaTM¡]daclatasvir, BMS-790052 ¡^¦b¸g¾ú¤F¤@¨Çªi§é¤§«á¡A²×©ó¦b2015¦~7¤ë24¤éÀò±oU.S. FDA®Öã¦X¨ÖGS¤½¥qªºSovaldi® ¨Ï¥Î¡A¬Oº´Ú¦b¤£»Ýn»P¤zÂZ¯À©Îribavirin¦@¦P¨Ï¥Îªº±¡ªp¤U¡A¹ï§Ü²Ä3«¬C«¬¨xª¢¡]GT-3HCV¡^·P¬VªºªvÀøÃĪ«¡CDaklinzaTMªº®Öã¬O°ò©óÁ{§ÉIII´Á¡]ALLY¡V3¡^ªºµ²ªG¡A152¦ì°ò¦]«¬²Ä3«¬ªºC«¬¨xª¢±wªÌ¡]101¨Òªì¦¸ªvÀø¡A51¨Ò¦³ªvÀø¥v¡^±µ¨ü¬°´Á12¶gªºDaklinzaTM ¡]60²@§J¡^¥[Sovaldi®¡]400²@§J¡^¤è®×ªvÀø¡A³Ì²×¥H¦UªvÀø²Õ§¹¦¨ªvÀø«á24¶g®Éªº¯f¬r«ùÄò©Ê¤ÏÀ³¡]sustained virologic response, SVR¡^§@¬°ªvÀø¦¨¥\²v¤§§PÂ_¡A¦¹®É¦å²M¤¤HCV RNAÀ³§C©óÀË´ú·¥¡]<50 IU/mL¡^¡C¼Æ¾ÚÅã¥Ü¡G¨S¦³¨xµw¤Æªº±wªÌ¡A98%ªº·s±wªÌ©Î92%¦³ªvÀø¥vªº±wªÌ¡A¦b¥ÎÃÄ¥b¦~«á¦å²G¤¤´NÀË´ú¤£¨ì´Ý¯dªº¯f¬r¡F¦Ó´¿¦³¨xµw¤Æªº±wªÌ¡A58%ªº·s±wªÌ©Î69%¦³ªvÀøªº±wªÌ¡A¥ÎÃÄ¥b¦~«á¦å²G¤¤§YÀË´ú¤£¨ì´Ý¯dªº¯f¬r¡C ¥þ¥@¬É¹w¦ô¦³1,700¸U¤H¨ü¨ìC«¬¨xª¢·P¬V¡A¦Ó¦b¬ü°ê¹Ò¤º¬ù¦³270¸Uªº·P¬V¤H¤f¡Aªñ75%¬°°ò¦]«¬²Ä1«¬¡A¨ä¤¤2/3¬°°ò¦]«¬1a¡B1/3¬°°ò¦]«¬1b¡A°ò¦]«¬²Ä2«¬¦³16%¡A°ò¦]«¬²Ä3«¬¦³12%¡C¥xÆWC¨x±wªÌ¬ù¦³50¦Ü60¸U¤H¡A¥H°ò¦]«¬1b¡]66-71%¡^¡B2a¡]20%¡^©M2b¡]10%¡^¬°¥D¡CDaklinzaTM¬O¤@ºØ±j®ÄNS5A½Æ»s½Æ¦XÅé¡]replication complex¡^§í¨î¾¯¡A©ó2014¦~8¤ë¤wÀò¼Ú·ù®Öã¡A¦X¨ÖNS5B¡]RNA »E¦X酶¡]polymerase¡^¡^§í¨î¾¯ Sovaldi® ¨Ï¥Î¡A¥i¥Î©ó°ò¦]«¬²Ä1¡B2¡B3©M4«¬C«¬¨xª¢¦¨¤H±wªÌªºªvÀø¡C¥H12¶gÀøµ{¬°¨Ò¡ADaklinzaTM »ù®æ¬°63,000¬ü¤¸¡ASovaldi® ¬°84,000¬ü¤¸¡AHarvoni® ¬°95,000¬ü¤¸¡AViekira PakTM ¬°83,300¬ü¤¸¡F«OÀI¤½¥q¦ôp¥i±qÃļtÀò±o40%ªº§é¦©¡CDaklinzaTM/Sovaldi® ¬O¤@ºØ¨C¤é1¦¸¡B¤fªA¡Bªv¡²v¹F100%ªºC«¬¨xª¢Âû§À°sÀøªk¡A¬°¼sªx°ò¦]«¬C«¬¨xª¢±wªÌ´£¨Ñ¤F¤@ºØ¼ç¦bªv¡ªºªvÀø¿ï¾Ü¡A¥]¬A¤@¨ÇÃøªv©Ê¸sÅé¡A¦p¬J©¹ªvÀø¥¢±Ñªº¸sÅé¡A³o¹ïGS¤½¥q¶}µoªºHarvoni® Âû§À°sÀøªk±N§Î¦¨ª½±µ«Â¯Ù¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/6 ¤U¤È 11:48:13²Ä 493 ½g¦^À³
|
P1101 ¤~¬Oªv¨xªº³Ì²×±ÏÅ« P1101¥þ¥@¬É³Ì±`®Ä¡B°Æ§@¥Î³Ì¤Öªº¤zÂZ¯À¡A¬O³J¥Õ½è·sÃĤ]¬O§K¬ÌÀøªk¡A ®É¶¡±N·|ÃÒ©ú,§K¬ÌÀøªk¤~¬O³Ì²×¸Ñ¨M¤è®×. P1101±N¶}³Ð¤zÂZ¯ÀªvÀø¨x¯fªº¡¨¤åÃÀ´_¿³¡¨¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/6 ¤U¤È 11:38:20²Ä 492 ½g¦^À³
|
C¨x¤fªAªvÀø¨Ã«D·Q¹³¤¤ªº¦n ¤@项³Ì·sªº²Îpµ²ªG: °ò¦]²Ä¤G«¬¥Î¤fªAsofosbuvir ¡B ribavirinªvÀø®ÄªG¡A¦b¯u¹êª¬ªp¨Ã«D¦p¹êÅçµ²ªGªº¦n¡C Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials. C¨x¤j®a³£»{¬°¤p¤À¤lÃĪ«¤w¸g©Ò¦³¬ð¯}¡A¦ý¬O³o项¤j«¬12¶gsofosbuvir and ribavirinªvÀø²Îp¤W¡A µo²{¤£·|¦³SVR (ªv¡ªº«ü¼Ð)¡A¦b¦U¦¸¸sÅé«o¦³©úÅ㪺¤£¦P¡C¦]¦¹À³«·sµû¦ô¨Ï¥Î¤zÂZ¯Àµ¥µ¦²¤¡C http://www.ncbi.nlm.nih.gov/pubmed/27428297 |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/3 ¤U¤È 02:49:51²Ä 491 ½g¦^À³
|
¤A¨xÁ{§Éªv·U¡uµ¹¯f¤H¤@Ó¾÷·|¡v ¡@¡@ ºC©Ê¤A¨x¥i¥H¹ê²{Á{§Éªv·U§Yªí±§Üì¡]HBsAg¡^²M°£¡A³o¤@·§©À³vº¥³Q°ê¤º¥~¤A¨xªvÀø»â°ìªº±M®a¼s¬°±µ¨ü¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/8/3 ¤U¤È 02:43:05²Ä 490 ½g¦^À³
|
¶W´Îªº¤@«h®ø®§ |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/3 ¤W¤È 09:48:15²Ä 489 ½g¦^À³
|
¥´¥M¥u¾aªÅx¬O¤£°÷ªº ¥Ø«e³Ì·s¡B³Ì¶QªºÃij£¬O¤p¤À¤lÃÄ¡A¹B§@¾÷¨î³£¬O¤j¦P¤p²§¡AÃĬO¨C¤Ñ¦Y¡A ¦pªÅxÅF¬µ¯ë¡A¬Ý¨ì¯f¬r´N¬O¡A¸¼uºÉ¥X¡A±þµL³j¡A¯f¬r«ü¼Æ±±¨î¦b¦w¥þ«ü¼Ð¡A ´Nºâ²¬Â¡¡A½Ö±þ±o°÷§Ö¡A³o´N¬O¦nÃÄ¡C±À³¯¥X·sªº³£¬O:¡¨½ÖªºªZ¾¹§óºë·Ç±þ¦º¼Ä¤H¡¨ ¦ý¬O¦pªG¬OÁôÂæb¤U¡A¹x±j©è§Ü¯f¬r¡AÃĨSÄ~Äò¦Y¡A¤S²£¥Í§ÜÃÄ©Ê¡A ¦³®É¨Åé®z¡A¦A«×·P¬V«ç»ò¿ì¡C¥t¥~³o¤@¨Ç©Ò¿×¤p¤À¤lÃÄ¡A¹ï³Ì²×¨xÀù(µw¤Æ)¦³¦h¤ÖÀ°§U? Ãĵتº¤zÂZ¯À»P©Ò¿×·s«¬ÃĪ«§@¥Î¾÷Âà¬O§¹¥þ¤£¦Pªº¡A¥¦¬OºØ§K¬ÌÀøªk¡A¦³¦p¥þ¤è¦ìªº³¡¶¤¡C P1101¤]¦³ªÅx¡A©Î³\¨S¦³³Ì·s«¬ªÅx¨º»ò¦³®Ä²v¡A¦ý¬O¥¦¦³¦a±³¡¶¤¡A ¤]·|§ß«ù·í¦a¬F©²x¡AÅý¨Åé²£¥Í§Ü¬r§ÜÅé¡C®É¶¡·|ÃÒ©úªv¼Ð¡A¤]nªv¥»¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/3 ¤W¤È 09:33:27²Ä 488 ½g¦^À³
|
ºC©Ê¤A¨x¹ê²{¡uÁ{§Éªv·U¡v ¤W©P¡u¥@¬É¨xª¢¤é¡v¤W¡A¼sªF¬Ù§@¬°¤¤°ê¤A¨x²Ä¤@¤j¬Ù¡A¨xª¢ªvÀø¦A¦¸¦¨¬°¤½²³¸ÜÃD¡C¦b¤¤¤s¤j¾ÇªþÄݲĤTÂå°|ªº¤A¨x¬ì´¶¬¡°Ê¤¤¡A°OªÌ¤F¸Ñ¨ì¡A¤¤°ê¨xª¢¨¾ªv°òª÷·|¡B¤¤µØÂå¾Ç·|¨x¯f¾Ç¤À·|©M·P¬V¯f¾Ç¤À·|¦b¥h¦~10¤ëµo§G¤F·sª©¤¤°ê¡mºC©Ê¤A«¬¨xª¢¨¾ªv«ü«n¡n¡]²ºÙ¡m«ü«n¡n¡^¡Aº¦¸´£¥X¤A¨x¡uÁ{§Éªv·U¡v¡A©ú½T±N°±¤îªvÀø¦Zªº«ù¤[À³µª¡Bªí±§Üì®ø¥¢¨Ã¦ñ¦³¨¦¤þÂà®ò酶¡]ALT¡^´_±`©M¨xŦ²Õ´¾Çªº§ïµ½§@¬°ªvÀø¥Ø¼Ð¡A±M®aªí¥Ü¡A³o·N¨ýµÛºC©Ê¤A¨x¶i¤J¡uªv·U®É¥N¡v¡C ¡@¡@ ¤A¨xÁ{§Éªv·U¡uµ¹¯f¤H¤@Ó¾÷·|¡v ¡@¡@ ºC©Ê¤A¨x¥i¥H¹ê²{Á{§Éªv·U§Yªí±§Üì¡]HBsAg¡^²M°£¡A³o¤@·§©À³vº¥³Q°ê¤º¥~¤A¨xªvÀø»â°ìªº±M®a¼s¬°±µ¨ü¡C ¡@¡@ ¡u§Ú̹ï¤A¨xªºªvÀø¸g¾ú¤F¡y¹ï¯gªvÀø¡z¦V¡y§Ü¯f¬rªvÀø¡zªºÂàÅÜ¡A§Ü¯f¬rªvÀø¦´Á¦®¦b±N¯f¬r±±¨î¦í¡A¦Ó·sª©¡m«ü«n¡n¤¤´£¥Xªº¡yÁ{§Éªv·U¡z«h¦®¦b²M°£¯f¬r¡A¹ê²{ªv·U¡C¡v¾Ú¤¤¤s¤j¾ÇªþÄݲĤTÂå°|·P¬V¬ì¥D¥ôÂå®v®}±Ò®Ù±Ð±Â¤¶²Ð»¡¡A¡u´£¥X¡yÁ{§Éªv·U¡z·N¸q«Ü¤j¡v¡A¥H©¹±wªÌ¦³¦A¤j·NÄ@ªvÀø¤A¨x¡A§Þ³N¤ô¥¤]¹F¤£¨ì¡A¡u§ÚÌ°µÂå¥Íªº·P¨ì«Ü±{±¤¡v¡C ¡@¡@ ®}±Ð±Â»¡¡A¡uÁ{§Éªv·U¡v³Ìª½Æ[ªºªí²{´N¬O°±ßÓ¤£·|´_µo¡A¨ãÅ骺¼Ð·Ç¥]¬ADNAÂà³±¡B¤A¨x¯f¬r°±¤î½Æ»s¡BE§Üì¦å²M¾ÇÂà´«©Mªí±§ÜìÂà³±¡A¨ä¤¤³ÌÃöÁ䪺¦]¯À´N¬Oªí±§ÜìÂà³±¡C ¡@¡@ »E¤A¤G¾J¤zÂZ¯ÀªºÀ³¥Î¬O¹ê²{¤A¨xÁ{§Éªv·UªºÃöÁä¡C®}±Ð±Â¤¶²Ð¡A¦³¼Æ¾ÚÅã¥Ü¡A¸g48©Pªø®Ä¤zÂZ¯ÀªvÀø¡A60%Àu¶Õ±wªÌ¥iÀò±o¡u¤j¤T¶§¡vÂà¡u¤p¤T¶§¡v¡A10%¥ª¥k¯à§¹¥þ²M°£¯f¬r¡A¹ê²{ªv·U¡C¨Ï¥Î¤fªA®Ö苷ÃþÃĪ«ªº±wªÌ¡A¦pªG¹ê²{¤F¯f¬rÂà³±¡B¡u¤j¤T¶§¡vÂà¡u¤p¤T¶§¡v¡A¥Bªí±§Üì¤ô¥¸û§C¡A¤]¥i¥H¹Á¸Õ¤Á´«¨Ï¥Î¤zÂZ¯À¡A³¡¤À¯f¤H¥i±N¯f¬r§¹¥þ²M°£¡A¹ê²{¦w¥þ°±ßÓ¡C ¡@¡@ ¡u¦b§Ú±µÄ²ªº±wªÌ¤¤¡A¥§¡¨C¦~¦³10-20¦W±wªÌ¯à¹ê²{Á{§Éªv·U¡A±µ¨ü¤zÂZ¯ÀªvÀø¦Z³Ìªø¦³¤C¤K¦~¥¼´_µoªº¡v¡A³ÌÅý®}±Ð±Â¦L¶H²`¨èªº¬O´X¦~«e¡A¤@¦ì¦~»´¤k©Ê±wªÌ¡A¤j¾Ç貦·~¡A23·³¡AÀˬdµo²{¨¦¤þÂà®ò酶¡]ALT¡^200¦h¡A¶W¥X¥¿±`¤W5¿¡A¬°¤A¨x¤j¤T¶§¡C¦Ò¼{¨ì¸Ó±wªÌ¥H«ánµ²±B¥Í¤l¡A«Øij¦o±µ¨ü¤zÂZ¯ÀªvÀø¡A¦bªvÀø24©P¦Z¡A¡u¤j¤T¶§¡vÂà¡u¤p¤T¶§¡v¡AÄ~Äò±µ¨üªvÀø¦Zªí±§ÜìÂà³±¡A²{¦b³o¦ì±wªÌ¤w¸g°±ßÓ¥|¤¦~¡A©w´Á½Æ¬d¡A±¡ªp¨}¦n¡A¦³ªí±§ÜÅé¡BDNA³±©Ê¡B¨x¥\¯à¥¿±`¡C¤k«Ä«Ü·P¿E¡A¤w¸gµ²±B¡A·Ç³ÆÃh¥¥¤F¡C ¡@¡@ ¤zÂZ¯À¡u§Ü¯f¬r+±±¨î§K¬Ì¡v¤G®Ä¦X¤@ ¡@¡@ ¾Ú¤F¸Ñ¡AºC¤A¨x¬O¥Ñ¤A¨x¯f¬r¦bÅ餺¤£Â_½Æ»s¦Ó¤Þ°_ªºªø´Á¶i®i©Ê¡B§K¬Ì©Ê¯e¯f¡C¦]¦¹¡A¦b§Ü¯f¬r®É´£¤É¾÷Åé§K¬Ì¤O¡A¨Ï±wªÌÀò±o«ù¤[ªº§K¬Ì±±¨î¡A¬O¹ê²{Á{§Éªv·U¡B°§C¨xµw¤Æ¡B¨xÀùµo¥Í²vªºÃöÁä¡C ¡@¡@ ¥Ø«e¡A§Ü¯f¬rªvÀø¤èªk¥Dn¦³®Ö苷ÃþÃĪ«¡B¤zÂZ¯À¨â¤jÃþ¡C«eªÌ¥u¯à³æ¤@§í¨î¯f¬r¡AÀò±oE§Üì¦å²MÂà´«²v¸û§C¡AÀø®Ä¨Ì¿à©ó«ùÄòµ¹ßÓ¡A¤@¥¹°±ßÓ¡A´_µo²v°ª©ó50%¡C¦Ó¤zÂZ¯ÀªvÀø¤£¶È¥i¥H§Ü¯f¬r¡AÁÙ¯à¿Eµo¤HÅé¦Û¨§K¬Ì¤O¡A¨Ï±wªÌ¦³¸û°ª©M«ù¤[ªºE§Üì¦å²M¾ÇÂà´«¡A¹ê²{°±ßÓ¦Z«ù¤[À³µª¡A¬Æ¦Ü²M°£¯f¬r¡C ¡@¡@ ®}±Ð±Â§Î¶H¦a±N¤zÂZ¯Àªº§@¥Î¾÷¨î¤ñ§@¡u±a§L±þ¼Ä¡v¡A¯f¬r¬O¡u¼Ä¤H¡v¡A§K¬Ì¤O¬O¡u§L¤O¡v¡A®Ö苷ÃþÃĪ«¥u¯à´î¤Ö¡u¼Ä¤H¡v¡A¤zÂZ¯À¦b®ø·À¡u¼Ä¤H¡vªº¦P®ÉÁÙ¯à¼W±j¦Û¨¡u§L¤O¡v¡A¡u·íµM§ó©ö¥´³Ó¥M¡v¡C ¡@¡@ ¬°¦¹¡A®}±Ð±Â«Øij¡AºC©Ê¤A¨x±wªÌ¦b±ø¥ó¤¹³\ªº±¡ªp¤Uº¿ï¤zÂZ¯ÀªvÀøªk¡C®Ú¾Ú·sª©¡m«ü«n¡n¡AALT°ÊºA¤W¤É¥i§PÂ_ºC¤A¨xªvÀø®É¾÷¡A·íALT¤ô¥«ùÄò©Î¶¡»Ø¤É°ª¡]§Y§K¬Ì²M°£´Á¡^«K¬O³Ì¨ÎªvÀø®É¾÷¡A¦¹®É±µ¨ü¤zÂZ¯ÀªvÀø¡Aªv·Uªº§Æ±æ¤ñ¸û¤j¡C ¡@¡@ ®Ö苷Ãþ¦üª«¤£¯à»´©ö°±ßÓ¡A§_«h©ö´_µo ¡@¡@ ®}±Ð±ÂÁÙ¯S§O½Í¨ì¥H©¹ªvÀø¤¤ªº¤@Ó¸gÅç±Ð°V¡A´¿¸g¦³¤@¦ì¨k©Ê±wªÌ¡A±q17·³µo¯f¶}©l«KªA¥Î¤fªAÃħܯf¬r¡A¯f±¡¤@ª½Ã©w¡ADNA³±Âà¡Be§Üì¦å²M¾ÇÂà´«¡A³sÄò¨â¦¸¨C¥b¦~¬d¤@¦¸¤´µM¹F¼Ð¡A«ö·Ó·í®É¡m«ü«n¡n³W©w§¹¥þ¥i¥H°±ßÓ¡C25·³®É¡A¥L¬°¤F³Æ¥¥¡Aµu¼È°±ßÓ¡Aµ²ªG¤£¨ì3Ó¤ë¡A©d¤lèÃh¤W¥¥¡A¯f±¡¬ðµM´_µo¡A³Ì«áµo®i¬°««¬¤A¨x¡A¤@«×³Q°e¶iICU·m±Ï¡A²{¦bÁöµM©R¤w«O¦í¡A¦ý¨x¥\¯à¥¢¥NÀv¡A»Ýn²×¨ªvÀø¡A¤]¤£¯à´«¥Î¤zÂZ¯ÀÀøªk¡C ¡@¡@ ³o¼Ëªº®×¨Ò´£¿ô§ÚÌ¡A¤fªA§Ü¯f¬rÃĤ@¥¹¦Y¤W¡A«ÜÃø°±¤U¨Ó¡C¦pªG¯f¤H¬°¨xµw¤Æ±wªÌ¡A«h»Ý²×¨ªvÀø¡C·íµM±wªÌ¤£À³¦]¦¹®`©È¤fªAÃÄ¡A®Ö苷Ãþ¦üª«ÁÙ¬O¦³¤@©wÀu¶Õªº¡A¤ñ¦p§í¨îDNA«Ü§Ö¡A¦³«¯g·ÀI¯f¤H¤×¬°¾A©y¡A¥BªA¥Î¤è«K¡A¤£¨}¤ÏÀ³¸û»´¡F¯ÊÂI¬O¦å²M¾ÇÂà´«¤ñ¸ûºC¡AªAÃĮɶ¡ªø¡A³¡¤À±wªÌªø´ÁªAÃĦ³@ßÓ·ÀI¡C¤£¹L¡A«ö·Ó¦¹ÃþÃĪ«ªº°ò¥»Àøµ{³W«ß¡A¦b§Ú°ê¤@¯ë«Ü¤Ö§C©ó4¦~ªºªvÀø®É¶¡¡C§_«h¡A¥Ñ©ó¾d©T®É¶¡¤Óµu¡A©öµo¥Í´_µo¡C ¡@¡@ ¤zÂZ¯ÀªvÀø°Æ§@¥Î±j¡A¨Ã«D¤H¤H³£¾A¦X ¡@¡@ ¥²¶·©ú½Tªº¬O¡A»P¤fªAÃĬۤñ¡A¤zÂZ¯ÀªvÀøªkµu´Á¤º¶O¥Î¸û°ª¡A°Æ§@¥Î¤]¤ñ¸û©úÅã¡A¤£¬O©Ò¦³±wªÌ³£¾A¥Î¡C ¡@¡@ ¾Ú®}±Ð±Â¤¶²Ð¡A¨Ï¥Î¤zÂZ¯ÀªvÀøªì´Á¥i¯à·|¥X²{¬y·P¼ËÄpª¬¡A¤ñ¦pµo¿NÀYµhµ¥¡A³oºØª¬ªp¦bª`®g²Ä¤@°w®É¤×¨ä©úÅã¡AÀHµÛªvÀø¶i®i³vº¥´î»´¡CªvÀø¹Lµ{¤¤ÁÙ¥i¯à¦ñ¦³G¤f¤U°¡B®ø½G¡B²æ¾v¡B¥¢¯vµ¥Äpª¬¡A¬Æ¦Ü¾ÉP±wªÌºë¯« |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/8/1 ¤U¤È 12:15:47²Ä 487 ½g¦^À³
|
¤ÑY¦³Àº¤j¡G PV§G§½¬O¥ý¼Ú¬ü¡B«á¨È¬w¡A¨xª¢³¡¤À«h¬O¥H¨È¬w¬°¥Dn¥«³õ¡C <¤é¥»> ¥Ø«e¸ê°T¤ñ¸û©ú®Ô¡A¥i¥H°Ñ¦Ò¨â¶g«eªº·s»D¡A§Ú±À´úÀ³¸Ó¸ò¬ü°êªº¼Ò¦¡¬Û¦ü¡C -Á{§É³W¹º¡G±Ä¥Î¼Ú¬wÁ{§É¼Æ¾Ú+»Î±µ©Ê¸ÕÅç(·í¦aCRO©ÎÂå¾Ç¤¤¤ß) -«Ø¥ßKOLÁpô¡G¤pªQ«h¤Ò(¬ü°ê¬°Srdan Verstovsek) -¬ã°Q·|ij«Å¶Ç¡G2017¦~²Ä¤G©¡MPN Asia Congress¦bªF¨ÊÁ|¿ì(¥é·Ó2015¦~¬ü°êMPN & MDS Congress) <¥xÆW> ÁöµM¥xÆWMPNs¥«³õ¤£¤j¡A¦ý¤½¥qÀ³¸Ó¤£·|©¿²¤¥xÆW¯f±wªº»Ý¨D¡C -ET¤T´Á±N·|¶i¦æ¸ó°ê©ÊÁ{§É¡A¤w¥]¬A¥xÆW(¥x¡B¬ü¡B¼Ú)¡C -PV¥Ø«e¨S¦³¸ê°T¡A¥¼¨Ó¦P¼Ë¥H¼Ú¬w¼Æ¾Ú¦A¼W¥[»Î±µ©Ê¸ÕÅç¡A¬O¥i¯àªº¤è¦¡¡C -¦æ¾P³¡¤À¡A¥H¥xÆWªºMPNs¥«³õ³W¼Ò©M¦a½t©Ê¡A§Ú»{¬°Ãĵئۤv¨Ó´N¥i¥H¤F¡C <¤j³°> MPNs¥Ø«e¨S¦³¸ê°T¡AÀ³¸Ó·|¥ý¥H¨xª¢¶i¤J¤j³°¥«³õ¡C ©ú¦~¤¤¥H«e¦³¥i¯à¦V¤j³°CFDA´£¥X²Ä1¥óÁ{§É¸ÕÅç§å¤å¥Ó½Ð¡C ****¥H¤U¸`¿ý¦~³ø**** -¥»¤½¥q°£¤w©ó102¦~10¤ë¶¡³]¥ß100%«ù¦³¤§ÃĵØÂåÃÄ(»´ä)¦³¤½¥q¥HºÞ²z¥»¤½¥q¬ÛÃö±M§Q¥~¡A¥t¬°©Ý®i¤¤°ê¤j³°¥«³õ¡A¥H¨Ñ¥¼¨Ó·sÃĬãµo¤HÅéÁ{§É¸ÕÅç¥Î¡A¤]³z¹LÃĵØÂåÃĨȬw(»´ä)¦³¤½¥q¡A¦AÂà§ë¸êÃĵإͪ«¬ì§Þ(¥_¨Ê)¦³¤½¥q¡A¨Ã¤w©ó104¦~4¤ë¶¡§ë¤J¬üª÷300¤d¤¸¡C¦]¦¹¥¼¨Ó¥ç±Nµø·sÃĬãµoÁ{§É¸ÕÅç¶i«×¤Îµû¦ô¤½¥qÀç¹Bª¬ªp¡B®ü¥~¥«³õ¦æ¾P¥¬§½µ¥µ¥¦]¯À¡A¦A¼f·Vµû¦ô¬O§_¥t¦æ§ë¤JÂà§ë¸êpµe¡A¥H§@¬°Àç¹B§G§½©Ò»Ý¡C -©e°U¤¤°êCRO¥Ó½ÐÁ{§É¸ÕÅç®× --> ¿Õ«ä®æ(¥_¨Ê)ÂåÃĬì§ÞªÑ¥÷¦³¤½¥q («´¬ù°_¤é105¦~3¤ë30¤é) -¨îû¤uÅv§Q·sªÑµo¦æ¿ìªk¡G «ü¼ÐF¡G¸g¥_¨Ê®]¤½¥q¦V¤j³° CFDA ´£¥XP1101²Ä1Ó¾AÀ³¯g¤§Á{§É¸ÕÅç§å¤å¥Ó½Ð(CTA)¡C ®ÉÂI¡G¥»¨îû¤uÅv§Q·sªÑµo¦æ¤é(105¦~7¤ë4¤é)°_1¦~¤º¡A·í¥»¤½¥q¤§¤j³°®]¤½¥q¦V¤j³° CFDA´£¥XÁ{§É¸ÕÅç§å¤å¥Ó½Ð¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/1 ¤W¤È 11:03:49²Ä 486 ½g¦^À³
|
3 ¦å²G¯e¯f ¦]¬°¦å²Gµ¥¯e¯f¬OÄÝ©ó¤p²³¯e¯f¡A¥xÆW±w¯f¤H¼Æ¤£¦h¡A¦Ó¥B°·«O¤£¥i¯àµ¹¤©·¥°ªÃÄ»ù¡A¹ï¤½¥qÀ禬¦¬¯q¤£¤j¡C ¼Ú¬ü¤éµ¥¹ï©ó¦¹Ãþ¯f¦³¥ßªk¡A¦Ó¥B«OÀI¤½¥q¤£±o©Úµ´µ¹¥I¡A¼Ú¬ü¤HºØ±w¯f¼Æ¦h¡A©Ò¥H¥Ø«e¬O¥D¾Ô³õ¡C ¦b¥xÆW,¥Ø«e°£¤FET(¦å¤pªO¼W¥Í¯g)¦b¦³²Ä¤T´Á¥~¡A¥¼¨Óµøª¬ªp¡AÀ³·|¦³¿n·¥§@¬°(³o³¡¤À¥i¯à§ó°ª¬ñªº¤j¤j¤ñ¸û¤F¸Ñ)¡C ¤£¹L¤é¥»¦å²GÅv«Â¤pªQ«h¤Ò³Õ¤h¹ï³J¥Õ½è¤ßÃÄP1101±¡¦³¿WÁé¡A´£¨ì:¡¨ JakafiÄÝ©ó¤Æ¾ÇÃÄ«~(¥Ø«eªvÀø¦å²G¼W¦h¯e¯f¬O¥ÎJakafi)¡A¦Ó¤é¥»³\¦h¾Ö¦³¦å²G¼W¥Í¦³Ãö¯e¯fªº¯f±w¡A³£ÄÝ©ó¼ôÄÖ°ü¤k¡A³o¨Ç°ü¤k¤£¤Ö¤w¸g¬O§³®W¤k©Ê¡AY¥Î¤Æ¾ÇÃÄ«~®£±N·|¼vÅTL¨à°·±d¡C¡¨ http://udn.com/news/story/7254/1826893-%E8%97%A5%E8%8F%AF%E6%8E%A8%E6%96%B0%E8%97%A5-%E6%97%A5%E6%9C%89%E6%84%8F%E5%BC%95%E9%80%B2 §Æ±æ¤½¥q¯à¦h³yºÖ¥xÆW¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/1 ¤W¤È 10:26:04²Ä 485 ½g¦^À³
|
2 ¨ÅÀù ¤¤¥¡°Ó±¡ºô 2016¦~7¤ë26¤é °OªÌÁú´@´@¢A¥x¥_³ø¾É ÃĵØÂåÃÄ¡]6446¡^¤µ¤Ñ¤½§i¡A¬ãµo¤¤ªvÀø¨ÅÀù¥ÎÃĤfªAµµ§ü¾J¡]Oraxol¡^Àò¥xÆW½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p¡]TFDA¡^ã®Ö¦P·N¶i¦æÁ{§É¸ÕÅç¡C ÃĵØÃĪí¥Ü¡A±N¤À§O©ó¥x¤j¡B¥_ºa¡B¤TÁ`¡BÂù©M¡B¤¤°êªþÂå¡B¥_ÂåªþÂåµ¥Âå¾Ç¤¤¤ß±Ò°ÊÁ{§É¸ÕÅç¡K. ¥t¦]µµ§ü¾JOraxol¬°¦ÑÃÄ·s¥Îªº·s¾¯«¬¤fªA¥ÎÃÄ¡A¥i±æÁYµuÁ{§É¸ÕÅç®Éµ{¡A¥[³t·sÃĤW¥«ªº®É¶¡¡C ÃĵØÂåÃĪí¥Ü¡AOraxol¬°¦Û¬ü°ÓKinex¨ú±o¿W®a±ÂÅv¦b¥xÆW¡]¦A¶i¤j³°¡^»P·s¥[©Y¡]®¼¶iªF¨ó°ê®a¡^¨â¦a¶i¦æÁ{§É¶}µo¡C·íªì¤Þ¶iªº¥Øªº¬O¬°¥R¹ê·sÃIJ£«~½u¡A¦P®É¤]¦]¬°¸Ó¶µ²£«~¤w¦³Á{§É¼Æ¾Ú¡Aµo®i¸û¬°¦¨¼ô¡A¦³§U°§C¶}µo¦¨¥»¡BÁYµuÁ{§É¸ÕÅç®Éµ{¡A¨Ã¥[³t·sÃĤW¥«ªº®É¶¡¡C ÃĵØÂåÃÄ«ü¥X¡A¤Þ¶iªº¤fªAµµ§ü¾J¡]Oraxol¡^§t¦³HM30181A¦¨¥÷¥i¥H§í¨îP-glycoprotein¡A¤j´T´£°ª¤fªAªº§l¦¬²v¡A¦P®ÉHM30181A¤£·|³Q¸z¹D§l¦¬¥B¤£·|¿E¨ë¸zG¡A¬O¦w¥þªº¡u½á§Î¾¯¡v¡C ®Ú¾ÚOraxolªº¤G´ÁÁ{§É¸ÕÅç¸ê®ÆÅã¥Ü¡A«h¯f±w¥X²{³h¦åªº¤ñ¨Ò¶È0.9%¡A²£¥Í¤¤¼Ï¯«¸g¯kµhªº¤ñ¨Ò¤]¶È1.7%¡A°Æ§@¥Î¤j´T¤U°¡A¹ï©óÀù¯g¯f±w¨Ó»¡±N¬O¤@¤jºÖµ¡C ¦¹»Î±µ©Ê¤HÅéÁ{§É¸ÕÅçpµe¬O¥Ñ¥x¤jÂå°|Âå®v¿c«Û¦ù¡B¥_ºaÂå®v»¯¤j¤¤¡B¤TxÁ`Âå°|Âå®vÀ¹©úêP¡B¤¤°êÂåªþ³]Âå°|Âå®vªô©÷ªÚ¡A¥H¤ÎÂù©MÂå°|Âå®v»¯¯ª©É¦@¦P¥D«ù¡A¹wp©Û¦¬24¯f±w¡AY¤@¤Á¶¶§Q¡A¹wp2017¦~§¹¦¨¬ÛÃö¸ÕÅç¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/8/1 ¤W¤È 10:15:48²Ä 484 ½g¦^À³
|
Ãĵاë¤J¥xÆW¤À¤T¤j³¡¤À: 1, ªvÀøB«¬¨xª¢©MC«¬¨xª¢ªº¤HÅéÁ{§É¸ÕÅ礧¸ÕÅçÂå°| ÃĵØÂåÃĦb¥xÆW§ë¤JªºªvÀøB«¬¨xª¢©MC«¬¨xª¢ªº¤HÅéÁ{§É¸ÕÅç¡A©ó¥þ¥x16©Ò±Ð¾ÇÂå°|¶i¦æ¡A ¥Ñ³¯©w«H°|¤h¡B¹ù¹B½d°|¤h¡B³¯°öõ°|¤h»P²ø¸UÀs±Ð±Âµ¥ªñ50¦WÂå¥Í¦@¦P°Ñ»P¡C ¥x¤jÂå°| ¥x¤jÂå°|¶³ªL¤À°| ¤¤°êÂå¾Ç¤j¾Çªþ³]¾Ç°| ¥x¥_ºa¥ÁÁ`Âå°| ¥x¤¤ºa¥ÁÁ`Âå°| ¦ò±Ð·OÀÙºî¦XÂå°|¥x¥_¤À°| ¨ÈªF¬ö©ÀÂå°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|°ò¶©¤À°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|¥x¥_¤À°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|ªL¤fÁ`°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|°ª¶¯¤À°| °ª¶¯Âå¾Ç¤j¾Çªþ³]¤¤©M¬ö©ÀÂå°| °ê®õºî¦XÂå°| ¹ü¤Æ°ò·þ±ÐÂå°| ¸q¤jÂå°| ©_¬üÂå°| http://www.pharmaessentia.com/chinese/partners.html |
|
|
·|û¡G¤ÑY¦³Àº10141343 µoªí®É¶¡:2016/8/1 ¤W¤È 07:13:29²Ä 483 ½g¦^À³
|
¤pªL¤j¦ ²{¦b¤j·§ª¾¹D¼Ú¬ü§G§½¡A¨È¬w¥]¬A¤j³°¡A¤é¥»¡A»OÆW¥«³õ¦]¸Ó¤]«Ü¤j¡A³o³¡¥÷¤½¥q¦³»¡©ú¶Ü¡HÁÂÁ±z |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/7/31 ¤U¤È 09:42:28²Ä 482 ½g¦^À³
|
¤ÑY¦³Àº¤j¡G ¸É¥R¬ü°êªº¾P°â¥¬§½³¡¤À¡Aè±q¤½¥q¦~³ø¬Ý¨ìªº¡C(p.74) doc.twse.com.tw/pdf/2015_6446_20160629F11_20160731_111734.pdf (e) P1101(PV/ET)¦b¬ü°êªº¦æ¾P§G§½³W¹º ¥Ñ©ó¬ü°ê FDA ¤w¦P·N¥»¤½¥q¥¼¨Ó¥i¥H¼Ú¬w²Ä¤T´ÁÁ{§É¸ÕÅ窺¼Æ¾Ú¥Ó½ÐÃÄÃÒ¡A±©¦]²Ä¤T´ÁÁ{§É¸ÕÅç¨S¦³¦b¬ü°ê¶i¦æ¡A¬G¦æ¾P§G§½ªº²Ä¤@¨B¬O¥[±j»P KOL(Key opinion leader)ªºÁpô¡AÅý¬ü°êªº¦å²GÂå®v̹ï P1101 ¦³©Ò¤F¸Ñ¡A¬G¤½¥q¿n·¥°Ñ»P¬ü°ê¦å²G¬ÛÃö·|ij¨Ã¦b·|ij¤¤¤¶²Ð P1101¡C¦¹¥~¬°´£°ª P1101 ¦b¬ü°ê¥«³õªºª¾¦W«×¡A¤½¥q¥ç©e°U±M·~ CRO ¤½¥q³Wµe¥Ó½Ð P1101 ªº EAP(Expanded Access Program)¡A¨Ï P1101 ¦³¾÷·|¦b¬ü°ê FDA ®ÖãÃÄÃÒ¤§«e¡A¾P°âµ¹¨ä¥L³QÂå¥Í¶EÂ_¥i¨Ï¥Î P1101 ªvÀøªº¯f¤H¡C¥t¥~°£«ez¬ã°Q·|¤Î¦æ¾P¬¡°Ê¥~¡A¥Ø«e¤w¦³³\¦h°ê»ÚÃļt¿n·¥»P¥»¤½¥q¬¢½Í¦b¬ü°ê¥«³õªº¦X§@¥i¯à©Ê¡AÂǧUµ¦²¤¦X§@¹Ù¦ñ¤§¦æ¾P¸gÅç¤Î¾P°â³q¸ô¡A¼f·Vµû¦ô¿ï¾Ü³Ì¦³§Q©ó¥»¤½¥q·sÃĪø´Áµo®iªºµ¦²¤¹Ù¦ñ¡A¥H¹F¦¨¹w¦ô¾P°â¥Ø¼Ð¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/7/31 ¤U¤È 08:42:16²Ä 481 ½g¦^À³
|
2016-06-28 04:16 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É Ãĵء]6446¡^«Å¥¬¥þ±¦è¶i¡A±Ò°Ê¤¤°ê¤j³°²£«~½u¤Î¥«³õ¥¬§½¡C ÃĵØÂåÃĬQ¡]27¡^¤éªí¥Ü¡AÄ~»P¤¤°ê³»¦yCRO¤½¥q¿Õ«ä®æ¹F¦¨Á{§É¸ÕÅç¦X§@¨óij¡A ¤½¥q¥þ±±Ò°Ê¦b¤j³°¥«³õªº·sÃĶ}µoÁ{§É¸ÕÅç»P¤W¥«³W¹º¥¬§½¡C Ãĵػ¡¡A¥Ø«eÃĵإ_¨Ê¤½¥q¤w¹w³Æ°e¥æ¤¤°ê¤j³°°ê®a¹«~ÃÄ«~ºÊ·þºÞ²z§½¡]CFDA¡^ ©Ò»Ý¤§¬ÛÃö¸ê®Æ¡A¥]¬A½T»{¨ÌCFDA³W©w©Ò¥Ó³ø¸ê®Æªº§¹¾ã©Ê¡A ¦P®É¤]°w¹ï¥¼¨Óªº¥Ó³øµ{§Ç»P¤W¥«³W¹º¤@¨Ö¶i¦æ¥R¤À·Ç³Æ¡C ¦¹¥~¡AÃĵجQ¤é¤]«Å¥¬¡A¿n·¥©µÅó°ê»Ú¤H¤~¡Aªñ´ÁÁܽл´ä¤W¥«¤½¥q¨È³Õ¬ì§Þ¦@¦P³Ð¿ì¤H¥Óºû§»¡A ¾á¥ôÃĵإͪ«¬ì§Þ¡]¥_¨Ê¡^¤½¥qÁ`¸g²z¡C ÃĵØÃĪí¥Ü¡A¥Óºû§»¬O¤Ö¼Æݨã¥Íª«¬ì§Þ¤Î°Ó·~I´ºªº°ª¶¥±M·~¤H¤~¡A ¤£¦ý¨ã¦³°ò¦]¤uµ{»P³J¥Õ½èÃĪ«¬ã¨s¹O10¦~ªº¸g¾ú¡A ¤]¦b¬ü°ê±M·~³Ð·~¥þ²y±Æ¦W²Ä¤@ªº¤Ú¥¬´Ë°Ó¾Ç°|±Â¤©MBA¾Ç¦ì¡A ¨Ã´¿©ó¬ü°êª¾¦Wªº§ë¸êºÞ²z¿Ô¸ß¤½¥q±q¨ÆºÞ²z¤u§@¤¦~¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/7/31 ¤U¤È 08:07:13²Ä 480 ½g¦^À³
|
¥@½Ã²Õ´¡G¥þ²y½d³ò¤º¤¤°ê¨xª¢t¾á³Ì« 2016¦~07¤ë27¤é 10:29:27 ·sµØªÀ¤é¤º¥Ë¢¶¤ë¢±¢¶¤é¹q¡]°OªÌ±iÙç¡^¥@¬É½Ã¥Í²Õ´¤é«eµo§G¤½³øºÙ¡A¥þ²y½d³ò¤º¤¤°ê¨xª¢t¾á³Ì«¡A¥þ²y¢±¡D¢³»õºC©Ê¤A¨x±wªÌ¤¤¶W¹L¤T¤À¤§¤@¥Í¬¡¦b¤¤°ê¡C ¢¶¤ë¢±¢·¤é¬O¥@¬É¨xª¢¤é¡C¥@½Ã²Õ´¦ôp¡A·í«e¤¤°ê¦³¢¸¢¯¢¯¢¯¸UºC©Ê¤A¨x±wªÌ¡A¨ä¤¤¢±¢·¢¯¢¯¸U¤H»ÝnªvÀø¡A¢¶¢¯¢¯¸U¤H¦]ÄY«¨xŦ¯e¯f©MÀù¯gµo¯f·ÀI»Ýnºò«æªvÀø¡C¦¹¥~¡A¥þ²y¦³¢°¡D¢²¦Ü¢°¡D¢´»õ¤þ¨x±wªÌ¡A¤¤°êºC©Ê¤þ¨x±wªÌ¬ù¬°¢°¢¯¢¯¢¯¸U¤H¡A¨ä¤¤¢±¢´¢¯¸U¤H«æ»ÝªvÀø¡C ºC©Ê¨xª¢·|±a¨Ó«Ü°ªªº¨xµw¤Æ©M¨xÀù·ÀI¡A¥i¯à·|¤Þ°_¹L¦¦º¤`¡C¾Ú¦ôp¡A¤¤°ê¨C¦~¬ù¦³¢³¢¯¸U¤H¦º©ó»P¨xª¢¦³Ãöªº¨ÃµoÄp¡C¥@½Ã²Õ´¹wp¡A¦p¤£±Ä¨úºò«æ¦æ°Ê´£°ªªvÀøªº¥i¤Î©Ê¡A¢±¢¯¢°¢´¦Ü¢±¢¯¢²¢¯¦~¶¡¤¤°ê±N¦³¬ù¢°¢¯¢¯¢¯¸U¤H¦]»PºC©Ê¨xª¢¬ÛÃöªº¨xµw¤Æ©M¨xÀù¦º¤`¡A¨ä¤¤¤j³¡¤À¦º¤`®×¨Òªº¤¸¥û¬O¤A«¬¨xª¢¡C ¥@½Ã²Õ´¾nµØ¥Nªí¬I¶P¼w»¡¡A¤¤°ê¨C¢°¢²¤H¤¤´N¦³¢°¤H¬OºC©Ê¤A¨x¯f¬r©Î¤þ¨x¯f¬r·P¬VªÌ¡A¨ä¤¤¤j³¡¤À¤H¤£ª¾¹D¦Û¤vÄâ±a¯f¬r¡A¨xª¢¦¨¬°¤@ºØ¡§µLÁnªº¬Ì±¡¡¨¡C¦pªG³o¨Ç¤H¤£±µ¨üªvÀø¡A¨ä¤¤¤T¤À¤§¤@¤Hªº·P¬Vª¬ºA·|´c¤Æ¬°Àù¯gµ¥P©R¯e¯f¡C ¦ý¥@½Ã²Õ´ªí¥Ü¡A¹L¥h´X¤Q¦~¶¡¡A¤¤°ê¦b§ÜÀ»¨xª¢¤è±¤w¨ú±o¥¨¤j¶i¨B¡C¤¤°ê¤j³W¼Ò¹ê¬I¤A¨x§K¬Ì±µºØ¡A¤Ö¦~¨àµ£¸sÅ餤ºC©Ê¤A¨x¯f¬r¶Ë®`¤U°´T«×¹F¢¸¢¶¢H¡C ¥@½Ã²Õ´»¡¡A¤¤°ê¬F©²¥h¦~¦³¨â¤j¬Fµ¦°Ê¦V¡A¥]¬A¤j´T°§C¤A¨xªvÀøÃĪ«¦¨¥»¥H¤Î©Ó¿Õ´£¤É¥]¬A¤þ¨x¯f¬rªvÀøÃĪ«¦b¤ºªº·sÃĵù¥U¬yµ{®Ä²v¡A³o¤w¬°¤j½d³ò¶}®i¨xª¢ªvÀø¥´¤U°ò¦¡C¸Ó²Õ´»{¬°¡A¤¤°ê·í«eÀ³Åý§ó¦h«æ»ÝªvÀøªººC©Ê¨xª¢±wªÌÀò¨ú¦³®ÄªvÀø¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/7/30 ¤U¤È 06:53:36²Ä 479 ½g¦^À³
|
®¼Å¥¬Ý ³o¬O½×¾Â¤T׬°: 1®¼ ¦pªG¦³«ùªÑ¡A©Î¬O·Q¶R¤@¨Ç¡A·Q¦h¤F¸Ñ¡A¤~·|¶i¦¹½×¾Â¡C ÁaµM§Æ±æ¥¦¶^ªÌ¡A¤]¬O§Æ±æ³{§C¶R¶i¡A¦Ü¤Ö¹ï¦¹ªÑ²¼²¼¦³¿³½ìªÌ¡A¤~·|¶i¦¹½×¾Â¡C ¥»¤H¬O¡¨¤â¤W¦³ªÑ²¼¡AºVÆr»¡¥¦¦n¡¨¡A¼Ð·Ç¦º¦hÀY¡C 2Å¥ ¦³¥ô¦ó»¡©ú·|¡BªÑªF·|¡B¬ã°Q·|µ´¤£¯Ê®u¡C½Ð°ÝMPN Asia¦b¥x¥_¡A ¨È¤ÓC¨x·|ij¦b°ª¶¯°Ñ¥[¨S?¤WÂd«e»¡©ú·|°Ñ¥[§_?§Ú¬O¼Ð·Ç°l¬P±Ú¡C 3¬Ý ¥un·|³õµoªº¸ê®Æ¡A§Ú·|¥Î¤ß¾\Ū¡Aºô¸ô©Ò¦³«H®§¡AºÉ¤O»`¶°¡C ¨Ò¦p·s»D:¡uÂX¥RÀøµ{¤è®×¡v¡]EAP,expanded access program¡^¤è¦¡¡A ¦V¬ü°ê¹«~ÃĪ«ºÞ²z¸p¡]FDA¡^¥Ó½Ð²v¥ýµn³°¬ü°ê¡A·m¥e¥«³õ¥ý¾÷¡A¹wp¤µ¦~©³§¹¦¨¡C ¯à´£«e¥H¡u®¦·OÀøªk¡v¡]Compassionate Use¡^ªº¤è¦¡¡A´£¨Ñ±wªÌ·sªº¥ÎÃÄ¿ï¾Ü¡A ¤]Åý²£«~¯à°÷²v¥ý·m¥e¥«³õ¡A³Ð³yÂùĹ¡C©ó¬O§Ú´N§ä¨ìºô¯¸³Ì·s©x¤è¸ê°T: http://www.fda.gov/ForPatients/Other/ExpandedAccess/ucm20041768.htm ¥[»P¦LÃÒ¡A¤]ª¾¹D´N¬O¼t°Ó·Qn¦b¥¼¤W¥««e¡A¥ý¾i¯f±w¡A¤]·|¦³§ó¦h¤O¶qPush FDA¥[³t¤W¥«¡C §Ú¬O¤@Óªø´Áªº¯»µ·§ó¬O¥Î¥\ªÌ¡C ¥Ñ©óP1101¥iªvÀøªº¯f¯g¦Ü¤Ö¦³¤Q¦hºØ¡A¥Ø«e°£¤F¦b¨u¨£¦å²G¯e¯fPV¡A ³ÌªñªºET¡A¥¼¨Ó±NÂX¤j¥Î©óªvÀøºC©Ê°©Åè©Ê¥Õ¦å¯f¡Bìµo©Ê°©ÅèÅÖºû¤Æ¯g¤§¥~¡A Àù¯g¦X¨Ö§K¬ÌÀøªk¡A¤ÎB«¬»PC«¬¨xª¢ªº·sÃĶ}µo¡C ³o¬O¤@¶¡¬ì¾Ç®a·í®a§@¥D¡A¬ì¾Ç¾É¦Vªº¤½¥q¡A³o¸s³Ì³»¦yªºªº¬ì¾Ç®a¥¿µo´§³Ì¤jªº¯à¶q¡A ¡§Ãĵء¨µS¦p¤@¥»ºë±m¸U¤Àªº®Ñ¡A§Ú¦Û»{¥\¤O¥u¦³¨â¦¨¡A¶Ô¯à¸É©å¡A§Ú·|ºÉ¤O²r°l¡C |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/7/29 ¤U¤È 06:25:21²Ä 478 ½g¦^À³
|
³o´X¤Ñ«ùÄò¦V¤U¬~ ~ §A(©p)©È¤F¶Ü? ©~µM«e´X¤ÑÁÙ¦³ªO¤Í¥HªÑ»ùº¦¶^¨Ó§P©w6446¬O¤£¬OÄꤽ¥q¡AÅý¤H¬Ý¤F´N·Q¯º... «¢~«¢~«¢ |
|
|
·|û¡G¤ÑY¦³Àº10141343 µoªí®É¶¡:2016/7/29 ¤U¤È 12:22:24²Ä 477 ½g¦^À³
|
youtu.be/USdu8DS4-9k ¤WÂd«eªk»¡¯uºë±m ´£¿ô¤j®a¶R²¼^_^¡A@¤H´M¨ý ÁÂÁ¤pªL¤jÁ¿¸Ñ |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/7/29 ¤W¤È 10:42:58²Ä 476 ½g¦^À³
|
¤ÑY¦³Àº¤j¡G °£¤F¤½¥q¸gÀç¹Î¶¤¡AÀ³¸Ó¨S¦³¤Hª¾¹D¦b¼Ú¬w½T¤Áªº±ÂÅv±ø¥ó¡AÃĵةMAOP OrphanÀ³¦³NDAµLªk¤½¶}¡C ¥Ñ©óAOP Orphanºâ¬O±NP1101±a¶i¦å²G¨u¨£¯e¯fªº¶Q¤H¡A¥B¬°¦´Á±ÂÅv¡A¨Ã¥ÑAOP Orphan¥X¸ê¼Ú¬wÁ{§É¶O¥Î©Ó¾á¥¢±Ñ·ÀI¡A ¦]¦¹Ó¤H±À´ú¡AÀ³¸Ó¬O¨S¦³«e´Á±ÂÅvª÷©M¨½µ{ª÷¡F¦Ü©ó¾P°âÅv§Qª÷¡A¥Ø«e´¶¹M¹w´ú¬O20%~25%¡C ¬ü°ê©M¤é¥»³¡¤À¡Aµø¥¼¨Ó»P·í¦a¦æ¾P¹Ù¦ñ¦X§@ªº¼Ò¦¡¡AÃĵإi¥H¨É¦³¤j³¡¤ÀªºÅv§Q¡C |
|
|
·|û¡G¤p¤p§L10139501 µoªí®É¶¡:2016/7/29 ¤W¤È 10:01:54²Ä 475 ½g¦^À³
|
°O±oµL¤j¦b¥t¤@©«¤¤´¿¸g´£¥Xªi®ö²z½×¡A Ó¤H¦bªÑ®ü¤G¤Q´X¦~¹ïªi®ö²z½×¤]²¤¦³¬ã¨s¡A ´¿´£¿ô¦b±¾µP¤é³sÄò¤T¤é»ù¶qIÂ÷¡A ±¾µP¤é±N¬OC¬q¤U¶^ªiªº¶}©l¡A ªGµM¦b¤»¤ë¤G¤Q¤@¤é¨£°ªÂI233, ¦p¥H¶Àª÷¤Á³Î²vpºâ¡A233¡Ñ(1-0.191)=189, ¦¹»ù¦ì¦b7¤ë7¤é¤w²{¡A 쥻¹wp¥i¥H¥´W©³«e¤éW©³¤w¯}¡A²{¦b¤w§Î¦¨MÀY, ³Ì¦n§Ö³t¯¸¤W30¤é§¡½u(190ªº¦ì¸m)¡A §_«hD¬q¤U¶^ªi±NµLªkÁקK, §Þ³N¤ÀªRÁöµM¬O¨Æ«á½×¡A¦ý¤]¦³¥¦¥iÅçÃÒ¤§³B¡C °¶¤j¤j¦ü¥G«Ü¤F¸ÑÃĵØÂåÃĪº±¡§Î¡A ¸Ü»¡¤T±ø§Þ³N½u¤ñ¤£¤W¤@±ø¤º½u¡A Áٽඤj¤j¦h¦h¶}ÄÀ¤½¥q°ò¥»±¡A ³yºÖ§Ú̳o¨Ç¤p´²¤á¡C |
|
|
·|û¡G°¶¤j¤j10136951 µoªí®É¶¡:2016/7/28 ¤U¤È 11:23:52²Ä 474 ½g¦^À³
|
¿ú¦³¦n¿ì¨Æ ET¡B¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¦PÄݨu¨£¦å²G¯e¯f¡AP¯f¾÷¨î¬Û¦P¡A¥BÃĵØÂåÃĦb¼Ú¬w¶i¦æªºPV²Ä¤@´Á¡B²Ä¤G´Á¡BÁ{§É¸ÕÅçµ²ªG¨}¦n¡A²Ä¤T´Á¤]°µ§¹¡A¥¿¾ã²z¸ê®Æ¥Ó½ÐÃÄÃÒ¤¤¡B¦]¦¹FDAÅýÃĵإi¥Hª½±µ¥Ó½Ð¶i¤JÁ{§É²Ä¤T´Á¡C ¥Ø«e¬ü°êªºET¯f±w¬ù¦³15¸U¤H¡A¯f±w¼Æ¬ù»PPV¬Û·í¡A¦Xpªñ30¸U¤H¡Aªk¤H¦ôp¬ü°êªºET»PPVÃĪ«¥«³õ³W¼Ò¦Xp¥i¯à¤W¬Ý¦Ê»õ¬ü¤¸¡C ¬ü°ê°µ¹êÅç¬O«Üªá¤j¿úªº¡A³Ìªñ¤½¥q¤j¤J±b¡A¦³¿ú´N¦n¿ì¨Æ¡A¦~©³«eÀ³·|´£¥XET¤T´Á¥Ó½Ð http://www.gbimonthly.com/2016/03/%E7%8D%B2fda%E6%AD%A3%E9%9D%A2%E5%9B%9E%E6%87%89%EF%BC%8C%E8%97%A5%E8%8F%AF%E9%86%AB%E8%97%A5et%E6%96%B0%E8%97%A5%E5%8F%96%E5%BE%97%E9%87%8D%E5%A4%A7%E7%AA%81%E7%A0%B4/ |
|
|
·|û¡G¤ÑY¦³Àº10141343 µoªí®É¶¡:2016/7/28 ¤U¤È 09:23:24²Ä 473 ½g¦^À³
|
½Ð°ÝÃĵØÃľP°â¦p¦ó§G§½¡A¦³±ÂÅvª÷¶Ü¡HÁÂÁ |
|
|
·|û¡G¤pªL10142678 µoªí®É¶¡:2016/7/28 ¤U¤È 08:16:46²Ä 472 ½g¦^À³
|
·Æ½ü¤j¡A ì¨Ó¦p¦¹¡A¥Ø«e©|µLFDA®Ö¥iªºETÀøªk¡A¨º³o¼Ëªºµ¦²¤§Ú´N¯à²z¸Ñ¤F¡C ·PÁ±zªº¦^ÂÐ! |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/7/28 ¤U¤È 06:52:38²Ä 471 ½g¦^À³
|
¦^¤pªL¤j°ÝÃD¡G Why 2nd-line not 1st-line: (§Ú°Ý¹L¦¹°ÝÃD¡^ Ans: ¥Î2½uÁ{§É¸ûµu¶}µo®É¶¡ªºÀu¶Õ·m¥ý¾÷, ¤S¦]¬°ET¥Ø«eµL¤@½u¥ÎÃÄ, 1101 ¤@¥¹®Ö¥i¬°2½u¥ÎÃÄ, ¤£¥u¦³¾÷·|¨ú±o¸û°ªÃÄ»ù, ¤S·|³Q·í¤@½u¥ÎÃĨϥÎ. ET/CML PIII: Ans: n°µÓ§OªºPIII trial. |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/7/28 ¤U¤È 06:28:53²Ä 470 ½g¦^À³
|
ÃĵØÃÄ6446¡A¥~¸ê¤£½æ¶W¡An«ùÄò¶R¶W¡A¤~¦³¾÷·|¯Ç¤JMSCI¦¨¥÷ªÑ¡C ¥»¤é¥~¸ê¤w¤p¶R26±i¡A¥t§ë«H¶R¶W123±i¡C¤´n«ùÄòÆ[¹î¡A¥~¸ê»P§ë«H¬O§_Ä~Äò¶R¶W¡C ÃĵØÃÄ¡A¥[ªo¡C |
|
|
|